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Abstract
The pregnane X receptor (PXR) is regarded as the master regulator o f the mammalian 
xenobiotic response. It has evolved the ability to respond to a variety o f chemically 
unrelated endogenous and exogenous compounds, and regulate a large repertoire of 
genes involved in their uptake, metabolism and excretion, such as the cytochrome P450 
(CYP) 3A gene family. Early studies on the regulation o f CYP3A genes highlighted 
species-specific differences in response to various xenobiotics; upon discovery o f PXR, 
it was hypothesised that the species origin o f the receptor dictates the species-specific 
pattern o f CYP3 A inducibility. The aims o f this study were two-fold; first, to determine 
the molecular mechanisms underlying the regulation o f the PXR genes in humans, 
primates and rodents; and second, to determine potential differences in the ligand 
binding domain o f PXRs from diverse species, in order to assess their impacts on the 
species differences of response to changes in chemical flux.
Using in vitro reporter gene assays, it was demonstrated that human and rat PXR 
proximal promoters contain regions o f positive and negative regulation, suggesting 
complex mechanisms of regulation in both species. Further analysis, demonstrated that 
basal expression is regulated by hepatocyte nuclear factors (HNF) 3p and 4a in an 
identical manner. Exposing the cell lines to various chemicals identified that species- 
specific PXR gene activation is dependent on the nature of the PXR promoter, the 
abundance/ratio and ligand affinity o f ligand-activated transcription factors within the 
host cell. I have also demonstrated that the glucocorticoid receptor (GRa) mediates an 
increase in human PXR gene expression following treatment with clotrimazole; the 
same transcription factor also appears to regulate the rat PXR gene. Hence, 
clotrimazole-mediated GRa induction o f PXR genes appears to be a cross-species event.
In silica analysis of PXR ligand binding domains fiom diverse species identified that a 
species-specific activation profile may be attributed to both the spatial geometry of the 
ligand binding pocket and the amino acid residues lining the walls o f the pocket. Taken 
together, I conclude that species differences in response to changes in the chemical flux 
are determined by PXR at both the genomic level and proteomic level.
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1. Introduction
1.1 Regulation of homeostasis upon chemical exposure
1.1.1 Introduction
Individuals are exposed to numerous foreign chemicals (xenobiotics) everyday, both 
deliberately (e.g. therapeutic medicines) and accidentally (e.g. environmental 
contaminants); consequently, the body must be vigilant to the level of xenobiotic 
exposure as well as to fluctuating levels o f endogenous (endobiotic) chemicals, in order 
to maintain noimal cellular function and prevent toxicity (Plant 2003). The precise 
regulation of specialist proteins within the body controlling the absorption, distribution, 
metabolism and excretion (ADME) of both endo- and xenobiotics, ensures that 
homeostasis is maintained. The major features o f ADME processes will be examined 
below, with the specific role o f the pregnane X receptor (PXR; NR 112) in regulating 
these processes discussed in subsequent sections.
1.1.2 Absorption
Absorption is defined as the passage of a dmg from its site o f administration into the 
plasma. It is, therefore, important for all routes o f administration, except intravenous 
injection. Xenobiotics can thereby reach the bloodstream via three routes o f absolution; 
though the skin, lung or intestine. The latter is the most common due to increased 
compliance o f therapeutics taken via the oral route and the exposure o f individuals to 
chemicals within the diet; however to enter the body via any o f these routes, the 
chemical must first cross a cell membrane to enter the plasma. This can be achieved via 
passive diffusion, facilitated diffusion or active transport (Plant 2003).
1.1.3 Distribution
Once absorbed into the bloodstream, a chemical will be carried around the blood system 
and hence, can be distributed to most organs. Differences in blood flow to each organ 
result in unequal distribution around the body, whereby the most perfused organs 
receive the largest percentage o f any chemical entering the body. One such organ is the 
liver, which represents the major site of metabolism in the body and the highest 
concentration of enzymes for endo- and xenobiotic metabolism (Yamazaki et al. 1996). 
Extrahepatic metabolism also occurs but to a lesser degree in the mucosa o f the 
gastrointestinal tract, in the kidney and in the lung (Kiishna and Klotz 1994). Uptake of 
most compounds is mediated by transporter proteins that are embedded in the 
membrane of cells o f the different organs; examples of which include members of the 
organic anion transporter protein (OATP) family, which transport organic anions into 
across the cell membrane (Hsiang et al. 1999) and members o f the organic cation 
transporter (OCT) family, which conversely transport cations into cells (Nagel et al. 
1997). Among these, OATP2, whose expression is confined to the liver, mediates the 
transport o f endobiotics such as bile acids, and xenobiotics such as pravastatin (Hsiang 
et al. 1999) and OCTl, also expressed in the liver but also in the kidney and small 
intestine, is responsible for the transport of small cations such as choline and 
monoamine neurotransmitters (Nagel et al. 1997). The expression o f these transporters 
is conh'olled by regulatory proteins, and the pregnane X receptor has been identified as 
a key regulator of these genes (Guo et al. 2002; Staudinger et al. 2003; Anapolsky et al. 
2006). This step in the passage o f a chemical through the body needs to be considered 
as a key process in maintaining cellular homeostasis; therefore it is imperative that the 
molecular mechanisms governing the regulation of transporter proteins are fully 
understood.
1.1.4 Metabolism
Drug metabolism is divided into two phases: phase I metabolism, which ‘functionalises’ 
the chemical entity by uncovering or adding a chemically reactive group, and phase II, 
which increase the polarity o f the metabolites, facilitating their excretion and hence 
inactivation (Gibson and Skett 2001). Phase I is not a prerequisite for phase II reactions,
with chemicals that already possess chemically reactive groups being able to process 
directly to phase II enzyme-mediated conjugation. An example of this would be 
paracetamol, which at therapeutic doses is cleared from the body via direct phase II 
enzyme-mediated conjugation o f glucoronide or sulphate onto an existing hydroxyl 
group. This is a very efficient system of detoxification resulting in rapid removal of 
potentially harmful chemicals from the body. However, it should be noted that 
metabolism xenobiotics can bioactivate inert compounds producing reactive 
intermediates. These can cause toxic effects such as mutagenesis, carcinogenesis and 
cell death if  not further detoxified (Gibson and Skett 2001). Once again paracetamol is 
a good example o f such a balance. As noted above, at therapeutic concentrations, 
metabolism is mainly via direct conjugation to glucoronide or sulphate. However, a 
small percentage o f paracetamol will undergo phase I enzyme-mediated activation of 
NAPQI, followed by subsequent phase II enzyme-mediated conjugation and 
elimination. Under situations o f increased paracetamol exposure (e.g. overdose) or 
CYP2E1 enzyme induction (e.g. concomitant exposure to alcohol) results in the 
increased production of the reactive metabolite NAPQI, and this can result in gross 
hepatotoxicity.
1.1.4.1 Phase I
Phase I metabolism, also termed the functionalisation reactions, is preparatory for the 
chemical entity to enter phase II metabolism; they can detoxify, although they are more 
usually associated with bioactivation o f chemicals. By means o f oxidation, reduction, 
hydrolysis and hydration reactions, they increase the chemical reactivity and prepare 
substrates for phase II metabolism. O f these types o f reaction, oxidation reactions are 
the most prominent, with the majority catalysed by the cytochrome P450 enzymes.
Cytochrome P450 is a superfamily o f haem-containing enzymes which have existed for 
over 3.5 billion years and have been identified in a wide variety o f species, from 
animals and plants to fungi and bacteria (Nelson et al. 1996). Initially required for the 
biosynthesis of steroids, evolutionary development o f the digestive tract resulted in an 
extension o f P450 function to include the metabolism of xenobiotics such as therapeutic
drugs, environmental chemicals, carcinogens and dietary constituents, as well as the 
catabolism and anabolism o f endogenous compounds, including fatty acids, steroids and 
bile acids (Gonzalez et al. 1993). In higher animals, the number of expressed P450s is 
in the range o f 50 to 80, with 57 P450s and 33 pseudogenes known in the human 
genome (Nebert and Russell 2002), reflecting the ability of this family has for the 
metabolism o f a vast number o f different chemical structures. The cytochiome P450 
(CYP) enzymes are divided into sub-families according to amino acid sequence 
similarity, each with differing substrate specificities, as presented in table 1.1.
The CY Pl, 2 and 3 sub-families are considered to be most important phase I drug 
metabolising enzymes with respect to xenobiotics, accounting for 70 % of the total 
hepatic content (Wrighton and Stevens 1992). O f these, the CYP3A sub-family may be 
regarded as the most important, due to both the abundance o f CYP3A4 in the liver 
(30 % of total CYPs) and small intestine, and the ability to metabolise 60 % of 
pharmaceutical drugs in use today (Cholerton et al. 1992). A central regulator of the 
CYP3A sub-family is the nuclear receptor pregnane X receptor (PXR), an orphan 
nuclear receptor which is activated efficiently by both endogenous steroid compounds 
and diverse clinical dmgs (Bertilsson et al. 1998). This nuclear receptor has also been 
identified as regulating the expression o f other phase I metabolising enzymes including 
CYP2B6 (Goodwin et al. 2001), CYP2B10 (Maglich et al. 2002), CYP2C8 (Gerbal- 
Chaloin et al. 2001) and CYP2C9 (Chen et al. 2004). However, the repertoire of target 
genes of PXR is not just limited to drug metabolising enzymes; it also regulates 
enzymes involved in endobiotic metabolism, such as CYP7A1, a cholesterol 7a- 
hydroxylase responsible for the synthesis o f the bile acid, lithocholic acid (Staudinger et 
al. 2001) and CYP24, a 24-hydroxylase and major catabolic enzyme o f vitamin D 
(Pascussi et al. 2005).
Table 1.1: Example substrates and functions of human CYP genes
P450 family Substrates and functions
CYP 1-3 Foreign chemicals, arachidonic acid, eicosanoids
CYP4 Fatty acids, arachidonic acid, eicosanoids
CYP5 Thromboxane A 2  synthase
CYP7 Cholesterol, bile acid synthesis
CYP8 Prostacyclin synthase, bile acid synthesis
CYP 11 Steroidogenesis
CYP 17 Steroid 17a-hydroxyIase, 17/20-lyase
CYP 19 Aromatase to form oestrogen
CYP20 Unloiown
CYP21 Steroid 21-hydroxylase
CYP24 Vitamin D 3  24-hydroxylase
CYP26 Retinoic acid hydroxylation
CYP27 Bile acid biosynthesis, vitamin D 3  hydroxylations
CYP39 24-hydroxy cholesterol 7 a-hy droxylase
CYP46 Cholesterol 24-hydroxylase
CYP51 Lanosterol 14a-desmethy lase
(Adapted from Nebert and Russell 2002)
The combined metabolic versatility o f the phase I drug metabolising enzymes coupled 
with the activation o f CYP gene expression by a diverse set o f chemicals constitutes the 
molecular basis for many drug-drug interactions. The large spectrum o f substrates that 
these enzymes can recognise means that a CYP3A4 inducing compound, which may not 
necessary be a substrate for the enzyme, is potentially capable o f increasing the 
metabolism and clearance of any coadministered drug. Examples o f such cases are well 
documented for the antidepressant St. John’s Wort and macrolide antibiotic rifampicin, 
as highlighted in table 1.2.
Table 1.2: Established drug-drug and drug-herb interactions between CYP3A 
metabolised chemicals
CYP3A substrate CYP3A inducer Potential effect o f interaction
Retonavir 
Cyclosporin A  
Theophylline 
Warfarin 
Acetaminophen
Rifampicin 
Rifampicin 
St. John’s Wort 
St. John’s Wort 
Troglitazone
Loss o f antiviral activity 
Organ graft rejection 
Loss o f bronchodilator activity 
Reduced anticoagulant activity 
Hepatotoxixity
(Adapted from Plant and Gibson 2003)
Interactions can also occur through competition of substrates for the active site, usually 
resulting in the inhibition o f the rate o f metabolism of one or both chemicals, such as 
the inhibition of CYP3A4 by bergamottin, a constituent of giapeffuit juice. This 
interaction is exemplified when coadministering a CYP3A4-metabolised drug such as 
the cholesterol-lowering drug simvastatin. Decreased metabolic clearance o f the drug 
results in increased serum concentration and ultimately skeletal muscle toxicity (Lilja et 
al. 1998).
1.1.4.2 Phase II
In the second phase o f drug metabolism, also termed the conjugation reactions, 
chemicals are further modified by the addition of large complex chemical structures 
(conjugates) generally leading to water-soluble product which can be excreted in bile or 
urine (Gibson and Skett 2001). Several different enzyme families are involved in phase 
II metabolism, each of which catalyses the addition of a different conjugate onto the 
substrate; however, the majority o f reactions are catalysed by one o f three families, 
namely glucuronidation, glutathione conjugation and sulphation. The nuclear receptor 
PXR is involved in the regulation o f a number of phase II enzymes, including 
glucocuronosyl-transferases (Xie et al. 2003), glutathione S-transferases (Falkner et al. 
2001) and sulphotransferases (Sonoda et al. 2002). Coordinate regulation o f phase I and 
phase II drug metabolising enzymes by PXR ensures that the reactive intermediates by 
phase I metabolism can be rapidly removed and subsequently excreted from the body.
1.1.5 Excretion
The main routes o f excretion are the liver and kidneys (Ayrton and Morgan 2001). As 
both o f these routes are water-based the requirement for metabolism can be seen, as 
hydrophobic chemicals (ideal for passive absorption) can be converted into more 
hydrophilic metabolites that will be efficiently excreted. Active transport o f hydrophilic 
products o f metabolism is mediated by protein transporters found in the liver and 
kidneys, whose role is to enhance biliary and renal excretion into faeces and urine 
respectively (Plant 2003). Members o f the ATP-binding cassette family o f transporters 
are the main transport proteins involved in the removal o f toxic metabolites, which can 
be divided into four sub-families, multidrug resistance proteins (MDR), multidrug 
related proteins (MRP), breast cancer resistance protein (BCRP) and the bile salt export 
pumps (BSEP) (Albermann et al. 2005; Eloranta and Kullak-Ublick 2005). PXR has 
been identified to be a key regulator o f some these transporters; for example, expression 
o f M DRl is regulated by PXR (Geick et al. 2001; Synold et al. 2001), as well as MRP2 
(Kast et al. 2002), plus recent evidence suggests that PXR also participates in the 
regulation o f BCRP mRNA transcription (Albermann et al. 2005). This regulation adds 
another level o f regulation mediated by this receptor, and suggests that drug metabolism 
and excretion are coordinately regulated. This ensures for rapid and efficient clearance 
o f a chemical from the body; however, an increase in dmg transporter expression has 
the potential to cause resistance and ultimately poor bioavailability o f some dmgs.
Taken collectively, it can be seen that PXR is integral in maintaining cellular 
homeostasis; playing a key role in coordinating the absorption, distribution, metabolism 
and excretion o f endogenous and exogenous compounds. The ability to regulate genes 
o f such differing functions highlights PXR as the subject for further research. 
Investigation into the regulation o f the receptor is o f utmost importance and will allow 
for a better understanding of the species differences that exist in response to changes in 
the chemical flux through the body.
1.2 Cytochrome P450 3A sub-family
Cytochrome P450 enzymes play a vital role in the body to maintain homeostasis; as 
discussed previously, human CYP3A is involved in the metabolism o f approximately 
60 % of drugs in current clinical usage, as well as a variety of endogenous compounds 
(Cholerton et al. 1992), and may therefore be regarded as the most important phase I 
metabolising enzyme sub-family. The CYP3A sub-family has been the thoroughly 
investigated in mammals; in addition, the presence o f CYP3A-like enzymes in non­
mammalian vertebrates, including fish, amphibians, reptiles and birds has also been 
confirmed (reviewed by McArthur et al. 2003). At present, 65 different CYP3A genes 
in 32 species have been completely or partially characterised at the level o f the gene, 
cDNA or protein, as presented in table 1.3. When comparing the amino acid sequences 
o f the CYP3A enzymes, a high degree o f similarity is evident (at least 70 % similarity, 
which is required for inclusion of enzymes into a sub-family), indicating that there has 
been significant conservation o f protein structure throughout evolution, both inter- and 
intra-species, which suggests the possibility that CYP3A genes diverged from a 
primitive CYP3A gene in the process o f higher animal evolution, but also reflects the 
pivotal role these enzymes play in the metabolism of exogenous chemical and 
endogenous compounds. The human and rat CYP3A families however, have been the 
focus o f the most intense research over the past 25 years; work, which has identified 
both similarities and differences in the expression and regulation of these gene families.
Table 1.3: List of all known CYP3A forms in each species
Species CYP3A forms identifîed
Human CYP3A4, CYP3A5, CYP3A7, CYP3A43
Cynomolgus monkey CYP3A8
Rhesus monlcey CYP3A64, CYP3A66
Chimpanzee CYP3A67
Marmoset CYP3A21
Dog CYP3A12
Pig CYP3A22, CYP3A29,
Cow CYP3A28, CYP3A74, CYP3A75, CYP3A76
Sheep CYP3A24
Goat CYP3A19
Rat CYP3A1/23, CYP3A2, CYP3A9, CYP3A18, CYP3A62
Mouse C yp3all, Cyp3al6, Cyp3a25, Cyp3a41, Cyp3a44
Hamster CYP3A10, CYP3A31
Guinea pig CYP3A14, CYP3A15, CYP3A17
Kangaroo CYP3A70
Koala CYP3A78
Minke whale CYP3A32, CYP3A72
Dali’s porpoise CYP3A33
Stellar sealion CYP3A34
Spotted seal CYP3A35
Ribbon seal CYP3A36
Rainbow trout CYP3A27, CYP3A45
Teleost CYP3A30
Zebrafish CYP3A65
Pufferfish CYP3A47, CYP3A48, CYP3A49
Medeka fish CYP3A38, CYP3A40
Large mouth bass CYP3A68, CYP3A69
Mediterranean sea bass CYP3A79
Alligator CYP3A77
Ball/Royal python CYP3A42
Chicken CYP3A37
Turkey CYP3A80
Adapted from http://drnelson.utmem.edu/CytochromeP450.html
1.2.1 Human CYP3A forms
Four CYP3A genes have been described in human, CYP3A4, CYP3A5, CYP3A7 and 
CYP3A43 (Nelson et al. 1996; Domanski et al. 2001), which are all localised in a 
cluster on chromosome 7 (Spurr et al. 1989). Each gene has a well-conserved exon- 
intron structure, consisting o f 13 exons and approximately 25 kbp in length (Hashimoto 
et al. 1993). The CYP3A enzymes are the major cytochrome P450s in human liver at 
all stages of development, with CYP3A7 dominating in foetal liver and CYP3A4 in 
adult liver (Schuetz et al. 1994). CYP3A5 appears to be expressed in kidney and 
intestine and shows a polymorphic expression in liver (Jounaidi et al. 1996), with only 
approximately 25 % of individuals expressing significant levels. CYP3A43 is the most 
recently discovered member o f the human CYP3A sub-family, but is generally 
expressed at low levels; highest expression is detected in liver, kidney, pancreas and 
prostate (Domanski et al. 2001), but even within the liver, expression is only 
approximately 0.1 % and 2 % o f CYP3A4 and CYP3A5 expression, respectively 
(Westlind et al. 2001). In addition, changes to important active site amino acid residues 
in CYP3A43 results in a protein with low metabolic activity towards the classical 
CYP3A substrate testosterone (Domanski et al. 2001). Taken together, the low 
expression of and low activity o f CYP3A43 suggest that its biological input into human 
CYP3A activity is probably negligible.
1.2.2 Rat CYP3A forms
The rat CYP3A sub-family was originally thought to contain six genes, CYP3A1, 
CYP3A2, CYP3A9, CYP3A18, CYP3A23 and CYP3A62 (Nelson et al. 1996; 
Matsubara et al. 2004), which are thought to be clustered on chromosome 6 (Simmons 
et al. 1985). CYP3A23 was, however, identified to be the same form as CYP3A1 by 
analysis of the CYP3A1 gene (Nagata et al. 1999), and as a result, CYP3A1 has since 
been assigned the name CYP3A23. With the exception of CYP3A62, these CYP3A 
forms are predominantly expressed in rat liver in a sex-dependent manner. For 
example, CYP3A2 and CYP3A18 are male-specific forms, whereas CYP3A9 is a 
female-dominant form (Matsubara et al. 2004). Expression of CYP3A2 and CYP3A23 
appear to be restricted to the liver, whereas CYP3A9 is detectable in stomach, brain and
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lung, and CYP3A18 is expressed in lung, kidney and spleen. The most recently 
characterised form, CYP3A62 appears to be the major CYP3A enzyme expressed in the 
gastrointestinal tract (Matsubara et al. 2004).
1.2.3 Regulation of CYP3A gene expression
The regulation o f the CYP3A sub-family is multi-factorial process, within a system 
responsive to both exogenous chemicals and endogenous compounds that act as 
inducers and inhibitors. Investigations into the role o f nuclear receptors have identified 
mechanisms o f regulatoiy control, which most commonly occurs at the transcriptional 
level, through altered levels o f activation of CYP3A gene expression. It should be 
noted however, that both post-transcriptional and post-translational effects have been 
demonstrated to be a factor in the expression o f CYP3A proteins, including mRNA 
stability, enhanced rate o f mRNA translation and increased protein stabilisation 
(Hostetler et al. 1989; Eliasson et al. 1994).
1.2.3.1 Inducers of CYP3A expression
The first CYP3A inducer identified was pregnenolone 16a-carbonitrile (PCN) (Lu et al.
1972), which provided the means for the purification and characterisation of the first 
CYP3A sub-family member P 4 5 0 p c n  (later renamed CYP3A23). PCN was also central 
in the subsequent demonstration that this enzyme was readily distinguishable from other 
forms of cytochrome P450 in rat liver (Elshourbagy and Guzelian 1980). Since its 
identification as an inducer, much work has been done to understand PCN-mediated |
induction o f CYP3A, and also to identify other inducers o f this class of P450 enzyme.
Indeed, the administration o f synthetic and endogenous steroid hormones to rats 
identified that dexamethasone was a more efficacious inducer of de novo CYP3A23 
protein synthesis than PCN itself (Heuman et al. 1982). Given that PCN is an 
antiglucocorticoid, the obseiwation that both it and glucocorticoids were CYP3A23 
inducers appeared contradictory; this led to the hypothesis that the induction of 
CYP3A23 by glucocorticoids was mediated by a mechanism distinct from that o f the 
classical glucocorticoid receptor (GR) pathway (Schuetz and Guzelian 1984).
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Other studies identified that the macrolide antibiotics, especially troleandomycin and 
phénobarbital are potent inducers o f CYP3A, not only in rats, but also in other rodent 
species (Wrighton et al. 1985). The subsequent enzyme characterisation in human liver, 
also identified these compounds as inducers o f CYP3A4 protein and mRNA, both in 
vivo and in vitro in human hepatocytes (Watkins et al. 1985; Schuetz et al. 1993). Since 
these studies were conducted, more efficacious CYP3A inducers have been described. 
Several of these plus other classical CYP3A inducers are listed in table 1.4, which 
highlights one of the most intriguing facets o f the CYP3A sub-family, which is, the 
ability of stmcturally unrelated chemicals to stimulate transcription of these genes.
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Table 1.4: Examples of xenobiotic inducers of CYP3A
Xenobiotic class Inducer References
Antibiotics Erythromycin
Rifampicin
Troleandomycin
(Sonderfan et al. 1987)
(Lange et al. 1984; Wrighton et al. 1985; Schuetz et al. 
1993; Barwick et al. 1996)
(Watkins et al. 1985; Wrighton et al. 1985; Fabre et al. 
1988; Schuetz et al. 1993)
Anticonvulsants Carbamazepine
Phénobarbital
Phenytoin
(Kerr et al. 1994; Tomlinson et al. 1996)
(Heuman et al. 1982; Watkins et al, 1985; Schuetz et al. 
1993; Larsen et al. 1994; Kocarek et al. 1995) 
(Tomlinson et al. 1996)
Antidepressants Hyperforin (Moore et al. 2000a)
Antiulcer drugs Lansoprazole
Omeprazole
Pantoprazole
(Curi-Pedrosa et al. 1994) 
(Curi-Pedrosa et al. 1994) 
(Masubuchi etal. 1997)
Antiretroviral drugs Efavirenz
Nevirapine
Ritonavir
Tipranavir
(Mouly et al. 2002) 
(Riska et al. 1999) 
(Hsu etal. 1997) 
(Boffito et al. 2006)
Statins Lovastatin
Mevastatin
Pravastatin
Simvastatin
(Schuetz et al. 1993; Kocarek et al. 1995) 
(Raucy et al. 2002)
(Karayalcin etal. 1991)
(Horsmans et al, 1993)
Antifungals Clotrimazole (Hostetler et al. 1989; Ogg et al. 1999)
Steroids Dexamethasone
Mifepristone
PCN
(Heuman et al. 1982; Schuetz et al. 1984; Wrighton et al. 
1985; Barwick et al. 1996)
(Williams etal. 1997)
(Schuetz et al. 1984; Watkins et al. 1985; Barwick et al. 
1996)
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1.2.3.2 Species differences in induction
There are marked species differences in response to CYP3A inducers, as best 
exemplified by rifampicin and PCN in figure 1.1. Rifampicin bas been identified as one 
o f die most efficacious inducers o f CYP3A4 expression and activity, but bas no effect 
on its ortbologue CYP3A23 in vivo or in vitro. This is not a buman-specific effect 
however, as rifampicin is also a potent inducer of CYP3A6 in rabbits (Wrighton et al. 
1985; Kocarek et al. 1995). In contrast, PCN induces CYP3A23 but fails to induce 
CYP3A6 in rabbits (Wrighton et al. 1985; Kocarek et al. 1995). CYP3A4 may be 
induced by PCN, which has been reported following obseiwations in human 
hepatocytes, but to a much lower extent than observed with CYP3A23 (Kocarek et al. 
1995; Barwick et al. 1996). These findings led to the speculation that there may be two 
human populations, one responsive to PCN, and the other non-responsive to PCN as an 
inducer; and that such heterogeneity o f inductive response was most probably due to 
differences in the formation o f liver transcription factors and the availability of the 
nuclear receptors that regulate CYP3A23 expression.
Figure 1.1; Species differences in CYP3A induction 
(Adapted from Kocarek et al. 1995)
n.d. not determined HUMAN
Hyperforin
Clotrimazole Spironolactone 
Cyproterone , acetate /
TAo y
Rifampicin
/  RU486 \
Phénobarbital)Dexamethasone
n.d. PCN
n.d.RABBIT RAT
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Species differences were examined by a trans-gene transfer study (Barwick et al. 1996). 
The 5’-flanking regions, or proximal promoters of CYP3A2, CYP3A4, CYP3A5, 
CYP3A6, CYP3A7 and CYP3A23 were inserted upstream of a chloramphenicol 
acetyltransferase (CAT) reporter gene, and transiently expressed in primary hepatocyte 
cultures. When transfected into rat hepatocytes, dexamethasone and PCN, but not 
rifampicin increased the CAT activity o f all the CYP3A reporter genes; however, in 
primary cultures of rabbit hepatocytes, rifampicin and dexamethasone, but not PCN 
transactivated the CYP3A reporter constructs. It was concluded that the failure o f PCN 
to induce liver CYP3A in rabbits and in some humans is more likely due to a deficiency 
of cellular factors in rat hepatocytes, i.e. present in the rat, but absent in the rabbit liver 
cells. Conversely, rat hepatocyte lacks essential factors which permit rabbit liver cells to 
respond to rifampicin, i.e. present in the rabbit, but absent in the rat liver cells. This 
indicated that in addition to gene stmcture, host cellular environment dictates the 
species differences of CYP3A inducibility.
These data suggest that the interspecies differences in induction may be at the 
transcriptional level, which indicate that there are different regulatory mechanisms 
between species. Thus, extensive analyses o f these species-dependent regulatory 
aspects are required to enable effective data extrapolation from animal models to 
humans.
1.2.4 CYP3A nucleotide sequence analysis
The cloning and characterisation o f CYP3A promoters and subsequent identification of 
regulatory elements and transcription factors/ nuclear receptors that interact with these 
promoter sequences to control CYP3A expression have helped in providing a rationale 
for the observed species differences. The nucleotide sequences o f the 5’ regulatory 
regions o f all CYP3A genes for rat, mouse and human are loiown from the genome 
sequencing projects completed on these species. O f these regulatory regions, several 
have been examined in detail, as will be discussed below; in contiast, some (i.e. 
CYP3A9, 3A18 and 3A62 and 3A43) have been studied in little detail to date.
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1.2.4.1 CYP3A1 promoter
Burger et al. (1992) analysed 1.5 kb o f the 5’ flanking region o f the rat CYP3A1 gene. 
A 164 bp fragment (-220 to -56 bp) was identified and found to confer dose-dependent 
responsiveness to dexamethasone and PCN independent of its orientation when linked 
to a heterologous thymidine kinase promoter and CAT reporter gene (Burger et al.
1992). This fragment did not contain a classical glucocorticoid response element 
(GRE), but instead motifs similar to ORE consensus half palindrome sequences (Burger 
et al. 1992). These findings were in agreement with earlier reports (Schuetz and 
Guzelian 1984; Schuetz et al. 1984) and indicated that CYP3A1 induction involves 
either a classical GR interacting directly or indirectly with altered GREs or, a GR-like 
receptor with altered DNA binding characteristics, initially ternied the PCN receptor. 
The PCN receptor has subsequently been identified as the pregnane X receptor, as will 
be discussed in further detail section 1.3.
Examination of a 165 bp fragment, approximately 200 bp upstream from the 
transcriptional start site of CYP3A1 revealed further details o f the potential modes of 
regulation within this region (Quattrochi et al. 1995). It was demonstrated that the 
region contained two protected regions, FPl (-135 to -117 bp) and FP2 (-108 to -85 bp), 
indicative o f DNA: protein interaction sites. However, only fragments containing the 
FPl segment, independent o f orientation, were responsive to dexamethasone and PCN, 
at a similar magnitude to the endogenous hepatic levels of CYP3A1 transcriptional 
activation (Quattrochi et al. 1995). Close examination of the FPl segment revealed a 
palindromic sequence (underlined) ATGAACTTCAT that overlaps one o f two direct 
repeats o f ATGAACT separated by two nucleotides (Quattrochi et al. 1995). A 6 bp 
portion of these 7 bp repeat sequences TGAACT, on the opposite strand (AGTTCA), is 
a DNA motif, known as a DR3, which represents a high affinity binding site for the 
N RII family o f nuclear receptors, which includes the peroxisome proliferator activated 
receptors, retinoic acid receptors and PXR (Quattrochi et al. 1995).
A third protected site region was identified in the 5’ flanking region o f CYP3A1 
between -164 and -145 bp, termed 6PB-C, which contained a 3 ’ half-site sequence 
AGGTCA (Ogino et al. 1999). FP2/6PB-A was shown to be HNF4a binding site
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required for basal transactivation of CYP3A1 (Ogino et al. 1999). Consistent with 
previous findings, FPl/6pB-B was shown to contain a DR3 motif.
1.2.4.2 CYP3A23 prom oter
Huss et al. (1996) examined the regulation of CYP3A23 by dexamethasone using a 
reporter gene construct, whereby the 5’ flanking region was cloned upstream of the 
luciferase reporter gene. DNase I footprinting identified thiee protected sites within the 
region o f -167 to -60 bp (Huss et al. 1996), Site A (-110 to -91 bp) shared over 80 % 
identity with a HNF4 consensus element, which had been shown to be present on other 
CYP genes (Chen et al. 1994; Huss et al. 1996). Sites B (-136 to -118 bp) and C (-169 
to -144 bp) mediated dexamethasone responsiveness in a cooperative fashion; however, 
neither o f these sites contained a consensus glucocorticoid response element, and all 
three sites were shown to be crucial for the full glucocorticoid responsiveness o f 
CYP3A23 (Huss et al. 1996; Huss and Kasper 1998).
Site B (also Imown as DexRE-2) comprised an ATGAACT direct repeat separated by 
three nucleotides (DR3 motif); a motif previously identified in the CYP3A1 proximal 
promoter sequence, and known to be a binding site for PXR/RXRa heterodimers and 
COUPTF homodimers (Huss and Kasper 1998; Kliewer et al. 1998). Site C (also 
known as DexRE-1) comprised o f AGGTCA which could be viewed either as an 
imperfect direct repeat with a four nucleotide spacer (DR4) or an everted repeat with a 
six nucleotide spacer (ER6) (Huss et al. 1996). The ER6 in site C is imperfect due to a 
single mismatch in the upstream hexamer, suggesting that PXR/RXRa binding to this 
site is too weak to directly mediate ligand activation (Huss and Kasper 2000). The 
finding that COUPTF homodimers are capable o f binding to site C in addition to site B 
(Huss and Kasper 1998) suggests that glucocorticoid inducibility o f CYP3A1/23 is 
complex and involves multiple factors.
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1.2.4.3 Summary of rat CYP3A promoters
The rat CYP3A promoters comprise o f  thr ee major sites involved in CYP3A regulation 
(Quattrochi et al. 1995; Huss et al. 1996; Ogino et al. 1999). Site A (FP2/6pB-A; -110 
to -91 bp) binds HNF4, which exclusively regulates basal CYP3A expression and is 
required for maximal responsiveness to dexamethasone (Huss and Kasper 1998). Site B 
FP1/6PB-B/ DexRE-2; -136 to -118 bp) contains a perfect DR3 motif, to which 
PXR/RXRa heterodimers and COUPTF homodimers compete for binding (Huss and 
Kasper 1998; Kliewer et al. 1998). Site C (6PB-C/ DexRE-1; -169 to 144 bp) contains 
an imperfect ER6 motif, although the proteins that bind to this site have yet to be fully 
identified (Huss and Kasper 1998).
1.2.4.4 CYP3A4 promoter
Sequencing and analysis o f the 5’ flanking region o f CYP3A4 revealed a promoter 
containing both a basic transcription element (BTE) and a TATA box (Hashimoto et al. 
1993). There are also putative binding sites o f transcriptional regulatory factors such as 
octamer-binding protein (Octl), CCA AT-binding protein (CPI), activator protein 3 
(AP3), estrogen receptor (ER), progesterone/glucocorticoid receptor (PR/GR), 
hepatocyte nuclear factors (HNF)4 and HNF5 and p53 (Hashimoto et al. 1993). The 
functionality of the putative glucocorticoid receptor binding site (GR) has since been 
confiimed (El-Sankary et al. 2000).
To investigate the regulatory elements responsible for the transcription of CYP3A4, 
deletion mutants o f the promoter region were linked to CAT reporter genes. Transient 
expression assay in HepG2 cells revealed that nucleotides -362 to -94 bp of the 
CYP3A4 gene possess promoter activity in response to inducers (Hashimoto et al.
1993). Baiwick et al. (1996) located a single copy of ATGAACT located at -171 bp 
within this region which corresponded to a DR3 half-site in the CYP3A1/23 5’ flanking 
region. It also contains a second hexamer (AGGTCA, which is associated with group II 
orphan receptor binding) located six nucleotides downstream of the DR3 half-site 
(Barwick et al. 1996). Together these half- sites constitute an everted repeat ER6 motif, 
which PXR/RXRa heterodimers are known to bind (Bertilsson et al. 1998).
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There are two cw-acting elements in the region -2900 to -445 bp which appear to 
repress tianscription, and another element between -445 and -254 bp, which is required 
for efficient transcriptional activity in HepG2 cells. The latter region contains both the 
P450NF-specific element (NFSE) and the CAAT motif, known to be an important ex ­
acting element for the enhancement o f transcription. The NFSE is a characteristic 
sequence o f the CYP3A4 promoter; however, it has no known regulatory function 
(Hashimoto et al. 1993). When the same deletion mutants were transfected into human 
amnion (FL) cells, no significant enhancement enhancer activities of CYP3A4 were 
observed (Hashimoto et al. 1993), further emphasising the importance o f liver-specific 
factors in the regulation o f CYP3A4 gene transcription.
Rodriguez-Antona et al. (2003) identified three functional binding sites for 
CCAAT/enhancer binding protein-a (C/EBPa) at -1668 to -1659 bp, -1402 to -1393 bp 
and -130 to -121 bp that are involved in the constitutive transcription o f CYP3A4. 
C/EBPa-mediated transactivation of CYP3A4 was synergistically activated in hepatic 
cells by HNF3y, which binds distally at -1730 to -1718 bp and facilitates C/EBPa action 
by modification o f the chromatin structure of CYP3A4 promoter (Rodriguez-Antona et 
al. 2003). Other members o f the C/EBP family have been identified to be involved in 
the regulation o f CYP3A4 transcription; a distal enhancer site at -5950 to -5663 bp has 
been reported by Martinez-Jimenez et al. (2005), where C/EBPp-LAP binds and 
activates transcription, whereas the truncated form, C/EBPp-LIP, antagonises LAP 
activity and causes gene repression (Martinez-Jimenez et al. 2005).
The activity o f the CYP3A4 proximal promoter is further augmented by a distal 
enhancer module (termed XREM) in the CYP3A4 promoter, located at -7836 to -7607 
bp relative to the transcription start site (Goodwin et al. 1999). DNase I footprinting 
analysis o f this promoter region revealed four protected sites on the sense strand, termed 
FPl (-7811 to -7777 bp), FP2 (-7763 to -7740 bp), FP3 (-7738 to -7717 bp) and FP4 
(-7698 to -7682 bp), which cooperate with the cx-acting elements o f the CYP3A4 
proximal promoter and confer maximal responsiveness to rifampicin. FPl contains 
overlapping recognition sequences for RORal and COUPTF/HNF4, whereas FP2 
shows significant homology to a C/EBPa motif; however, their roles have still to be
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elucidated. FP3 contained an imperfect DR3 m otif and the FP4 domain overlapped an 
ER6-like element. In addition, a third putative nuclear receptor-binding motif, located at 
-7290 to -7270 bp appeared to be critical for maximal xenobiotic responsiveness, 
although itself was only capable o f weakly binding PXR/RXRa heterodimers (Goodwin 
etal. 1999).
A second enhancer was identified in the distal promoter of CYP3A4 at -1140 to -1050 
bp, designated the constitutive liver enhancer module of CYP3A4 (CLEM4) 
(Matsumura et al. 2004). Transfection o f HepG2 cells with successive deletions o f the 
5’ flanking region o f CYP3A4 linked to luciferase reporter genes identified several 
putative binding sites for liver-emiched and ubiquitously-expressed transcription factors 
within the 900 bp region o f gene promoter, including HNFl and HNF4. Examination of 
the functional significance o f these sites revealed the particular importance o f the HNF4 
binding site within the region for the hepatic CYP3A4 constitutive expression, whereby 
site-directed mutagenesis resulted in a 44 % reduction in enhancer activity. Moreover, 
screening for genetic polymorphisms within CLEM4 identified a novel variant, TGT 
insertion, whose allele frequency was 3.1 %, which resulted in a 36 % reduction of the 
enhancer activity (Matsumura et al. 2004). The significance o f discovering an active 
HNF4 site within an enhancer o f CYP3A4 is supported by the identification o f a 
functional HNF4 site within the XREM that is involved in the induction o f gene 
transcription through the cooperative interaction with the adjacent PXR sites (Tirona et 
al. 2003).
1.2.4.5 Summary of the human CYP3A4 promoter
The CYP3A4 promoter comprises o f two major sites which are involved in the 
induction of CYP3A expression in response to dexamethasone and rifampicin (Barwick 
et al. 1996; Goodwin et al. 1999). An ER6 motif located 165 bp upstream o f the 
transcription start site binds PXR/RXRa heterodimers. This is the minimal promoter 
required to elicit a response to rifampicin; although in vivo reporter gene studies suggest 
that it functions poorly on its own (Robertson et al. 2003); hence, maximal xenobiotic 
responsiveness is achieved through a cooperative interaction with the ER6 and DR3
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elements o f the distal enhancer (XREM) located at -7836 to -7607 bp. Several sites 
have been identified which are involved with constitutive CYP3A4 expression 
(Rodriguez-Antona et al. 2003; Matsumura et al. 2004; Martinez-Jimenez et al. 2005), 
including three C/EBPa sites within the proximal promoter and C/EBPp and HNF4 sites 
in the distal promoter. PXR, however, is still regarded as the central regulator of 
CYP3A gene expression.
1.3 Factors involved in the regulation of CYP3A and other ADME genes
CYP3A genes are part o f a complex network o f proteins responsible for the 
maintenance of homeostasis, which includes other cytochrome P450s, phase II drug- 
metabolising enzymes and membrane transporters. Transcription factors are essential 
for the precise control o f CYP3A gene expression, and as we have seen for PXR, their 
regulatory role extends to other ADME genes, thereby illustrating their importance in 
mediating the response to changes in chemical flux through the body. The liver 
represents the major site o f dmg metabolism; hence, it is of no surprise that liver- 
enriched factors (LETFs) are involved the regulation o f CYP gene expression and 
activity; the significance o f these factors will be discussed in section 1.3.1. Nuclear 
hormone receptors such as PXR are regarded as the body’s metabolic sensors, which 
detect changes in the level of endo- and xenobiotics and then respond by altering the 
expression of ADME genes. Several other nuclear receptors are also involved in the 
regulation o f genes for different metabolic pathways; these are collectively refened to 
as ligand-activated transcription factors (LATFs). The roles of these factors will be 
discussed in section 1.3.2.
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1.3.1 Liver enriched transcription factors
Several families of liver enriched transcription factors are responsible for governing the 
transcription of CYP genes (Gonzalez and Lee 1996). These families, characterised by 
structurally related DNA binding domains, include the hepatocyte nuclear factor 
(HNF)l, HNF3 and HNF4, although the latter is a member of the nuclear receptor 
superfamily, and the CCAAT/enhancer binding protein (C/EBP) and the albumin D-site 
binding protein (DBP) (Cereghini 1996). LETFs are not known to be under the control 
o f endogenous ligands and thus play a role in the constitutive and tissue-specific 
expression of many hepatic genes (Akiyama and Gonzalez 2003).
1.3.1.1 Hepatocyte nuclear factor 1
HNFl a  is expressed in the liver, kidney, intestine, stomach and pancreas (Cereghini 
1996). It is involved in regulating transcription of more than 30 different hepatic genes 
including liver fatty acid binding protein, glucose-6-phosphatase transporter, albumin, 
and clotting factors (Cereghini 1996; Akiyama and Gonzalez 2003). HNFl a  has been 
shown to serve as positive regulator of a number o f CYP such as CYP1A2 and 
CYP2E1; it also acts in down-regulating the expression of CYP4A1, CYP7A1 and 
CYP27 enzymes, thereby suggesting a role for HNFl a  in the regulation of fatty acid 
metabolism and bile acid synthesis (Cheung et al. 2003). HNFl a  mutations are the 
most common cause of maturity-onset diabetes of the young (Bingham et al. 2001), 
whereby patients with HNFl a  deficiency suffer from high levels o f fatty acids and 
exhibit a marked hypersensitivity to antidiabetic drugs (Chiang et al. 1996), which in 
part, can be explained by the involvement HNFl a  in the regulation of the genes 
highlighted above. In summary, HNFl a  has a critical role in the regulation of specific 
CYPs and hence, may have an influence on drug metabolism, carcinogenesis, as well as 
fatty acid and bile acid metabolism.
1.3.1.2 Hepatocyte nuclear factor 3
Three distinct members o f HNF3 (HNF3a, -3(3 and -3y) have been identified so far in 
mammals (ICaestner et al. 1994). The HNF3 genes are closely related to the Drosophila
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melanogaster gene forkhead, which is essential for the proper formation of the foregut 
and hindgut during fly development. Therefore, it has been suggested that the HNF3 
genes would function in an orthologous manner during mammalian liver and gut 
development. This hypothesis is supported by the obseiwation that the HNF3 genes are 
expressed veiy early during embryonic endoderm formation, from which liver and gut 
are derived (reviewed by Kaestner et al. 1998). The HNF3 isoforms share 93 % amino 
acid identity within their DNA binding domains, and are capable o f binding to the same 
response element in the regulatory region of target genes (Cereghini 1996). HNF3 
binding sites have been discovered in more than 100 genes that are expressed in the 
liver, pancreas, intestine and lung, as well as during early embryogenesis, including the 
transthyretin, tyrosine aminotransferase, aldolase B and albumin genes (Vallet et al. 
1995; Cereghini 1996). HNF3a and HNF3p proteins appear to promote activation o f 
liver-specific genes by directly altering chromatin structure (McPherson et al. 1993); 
HNF3 proteins bind to DNA on the nucleosome core and displace the linker histone, 
which is responsible for maintaining the DNA in a tianscriptionally-inactive state. 
Thus, the net result o f HNF3 binding to gene promoters might be to de-compact 
chromatin and facilitate binding o f other transcription factors.
HNF3 has been shown to regulate basal expression o f CYP3A4, in which HNF3y has a 
synergistic effect on C/EBPa-mediated increase in CYP3A4 mRNA, which is facilitated 
by modification o f the promoter chromatin structure (Rodriguez-Antona et al. 2003). 
Similarly, the mutation o f  a C/EBPa/HNF3 binding within the CYP3A4 proximal 
promoter disrupted the induction of CYP3A4 by glucocorticoids (El-Sankary et al.
2002). Interestingly, dexamethasone has been reported to increase the expression of 
HNF3P mRNA in rats (Imae et al. 2000), suggesting that glucocorticoids affect hepatic 
gene transcription by direct and indirect mechanisms. By comparison, disruption of a 
second HNF3 binding site within the proximal CYP3A4 promoter, resulted in decreased 
activation by phénobarbital and clotrimazole and an increased response to metyrapone 
(Bombail et al. 2004), thus illustrating the complexity of CYP3A4 regulation by HNF3. 
Taken together, these data highlight the important role that HNF3 proteins play in 
mediating both basal and xenobiotic-induced CYP3 A4 gene expression.
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1.3.1.3 Hepatocyte nuclear factor 4 (NR2A1)
HNF4a is a highly conserved member o f the nuclear receptor superfamily that is 
expressed in liver, kidney, intestine, stomach and pancreas (Cereghini 1996; Drewes et 
al. 1996). HNF4a is classified as an ‘orphan’ receptor since an endogenous or 
exogenous ligand for this receptor has yet to be identified, though it has been reported 
that long-chain fatty acids directly modulate its transcriptional by way o f their acyl-coA 
thioesters binding to the ligand binding domain (Hertz et al. 1998). HNF4a is 
indispensable for the constitutive expression of several key hepatic genes encoding 
enzymes involved in fatty acid and cholesterol metabolism and lipid transport (Hayhurst 
et al. 2001); it plays a significant role in the constitutive expression o f some CYP genes. 
Analysis of promoter and enhancer sequences o f CYP genes has shown the existence of 
putative binding sites for HNF4a and several studies have identified that this factor 
plays a positive role in the regulation o f rat CYP3A (Huss and Kasper 1998; Ogino et 
al. 1999), mouse CYP2A4 (Yokomori et al. 1997) and rabbit CYP2C1/2 (Chen et al.
1994). Furthermore, a recent study using cultuied human hepatocytes transfected with 
the adenoviral vector expressing HNF4a antisense RNA, revealed a significant down- 
regulation o f the genes encoding CYP3A4, CYP3A5 and CYP2B6 (Jover et al. 2001). 
A molecular mechanism for the induction o f CYP3A4 was provided by the 
identification of a putative binding site for HNF4a within the CYP3A4 distal promoter, 
where HNF4a increased PXR-mediated transactivation of CYP3A4 in the absence and 
presence of PXR ligand (Tirona et al. 2003). Subsequent analysis of the 5’ flanking 
region of the mouse PXR gene identified a putative binding site for HNF4a that was 
required for activation of the promoter in foetal muiine hepatocytes (Kamiya et al.
2003). Taken together, these data show that HNF4a is involved in the regulation of 
CYP genes in multiple species, by directly binding to their promoters and also 
indirectly, through the control o f nuclear receptor expression.
1.3.1.4 CCAAT enhancer binding protein
CCAAT enhancer binding proteins (C/EBPs) encompass a family o f six transcription 
factors with stmctural as well as functional homologies that are highly expressed in 
several tissues including liver, lung, intestine and adipose (Lekstrom-Himes and
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Xanthopoulos 1998). Members are designated C/EBPa, -p, -y, -6, - e , and -Ç, and are all 
believed to bind to CCAAT sequences in promoters and enhancer elements, with the 
exception o f C/EBP^ (CHOP), which is not believed to bind DNA (Antonson and 
Xanthopoulos 1995). Collectively, they interact with each other and other LETFs to 
regulate transcription of genes involved in the cellular differentiation o f hematopoietic 
cells, adipocytes and hepatocytes (Lekstrom-Himes and Xanthopoulos 1998). They are 
also involved in the regulation o f some CYP genes. The mRNA levels of CYP2B6, 
CYP2C9 and CYP2D6 for example, were increased following over-expression of 
C/EBPa in HepG2 cells (Jover et al. 1998). Similarly, both C/EBPa and C/EBP5 have 
been reported to transactivate the rat CYP2B1 promoter in the lung epithelial cell line 
A549 (Cassel et al. 2000), suggesting a role for these transcription factors in the 
regulation o f the CYP2 family. In addition, as discussed earlier, several putative binding 
sites for C/EBPa/ HNF3 within the CYP3A4 promoter conferred basal expression as 
well as modulating the xenobiotic response of this gene (El-Sankary et al. 2002; 
Rodriguez-Antona et al. 2003; Bombail et al. 2004). Genes encoding C/EBPa have been 
cloned from several species and they show a high degree of evolutionary conservation 
(Antonson and Xanthopoulos 1995), suggesting that it has a critical function in hepatic 
expression gene expression.
1.3.2 Ligand-activated transcription factors
In order to maintain homeostasis upon toxic insult or to changes in levels o f endogenous 
chemicals, the body needs to respond quickly. This is achieved through altering the 
expression o f CYP3A and other ADME genes, whereby the increased production of 
proteins that facilitate the removal o f the specific chemical is followed by a return to 
normal once the stimulus has been eliminated. The transcriptional activation of these 
genes is controlled by a group o f nuclear receptors known as ligand activated 
transcription factors (LATFs), which upon chemical ligand binding modulate the 
expression of ADME genes.
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1.3.2.1 Structure of LATFs
Ligand activated transcription factors are composed of five independent but interacting 
functional modules. These are the modulator domain, the DNA-binding domain (DBD), 
the hinge region and the ligand-binding domain (LED). For some nuclear receptors, the 
sequence of the protein extends beyond the LBD at the carboxy-terminal end, but no 
specific role has been assigned to these additional amino acids where present (Giguere 
1999). Figure 1.2 shows the typical structure of a nuclear receptor.
Figure 1.2: Schematic representation of a typical nuclear receptor 
(Adapted from Giguere 1999)
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Nuclear receptors may be divided into six regions based on structure and function similarities (denoted A, 
B, C, D, E and F). The modulator domain contains a transcriptional activation function (AF-1) and 
interacts with some cofactors. The DBD functions to recognise DNA response elements within promoters 
o f  target genes; it contains two zinc finger modules and a carboxy-terminal extension. The LBD functions 
to recognise ligands; it also contains dimérisation interface and a second transcriptional activation 
function (AF-2), which interacts with coactivators. The DBD and LBD are connected a hinge region, 
which contains a CoR box.
The DBD of nuclear receptors spans a core o f 66 residues that forms a highly conserved 
domain encompassing two zinc finger modules followed by a carboxy-terminal 
extension (CTE). The core domain is conserved across all members of the receptor 
family and contains two a-helices, one of which engages with the major groove of DNA 
to make specific contacts with the bases of the half-site (Luisi et al. 1991). In addition, 
the CTE plays duel roles in providing both protein-DNA and protein-protein interfaces 
with the h a lf  site and the receptor dimérisation partner, respectively (Mangelsdorf and 
Evans 1995). The hinge region o f nuclear receptors is variable in both length and 
primary sequence, and as the name suggests, it serves as a hinge between the DBD and 
LBD, and may act as a docking site for corepressor proteins (Chen and Evans 1995).
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The LBD is a multifunctional domain that mediates ligand binding, dimérisation, 
interaction with heat shock proteins, nuclear localisation, and transactivation functions 
(Giguere 1999). It is composed o f twelve a-helices arranged in three layers, which 
results in the ligand-binding pocket being buried within the core o f the LBD (Watkins et 
al. 2001). Ligand binding induces a conformational change in the LBD allowing 
coactivators to bind to the activation function-2 (AF-2) a-helix localised at the carboxy- 
terminal end of the LBD (Giguere 1999). Generally, upon ligand binding, the 
cytoplasmic receptor translocates to the nucleus, forms an association with a 
dimérisation partner, and activates transcription, as illustrated in figure 1.3. However, 
although this model is valid for some nuclear receptors; other receptors in the absence 
of ligand are constitutively active or act as strong repressors o f gene expression. 
Furthermore, there is increasing evidence that nuclear receptors exist in pools within 
both the nucleus and cytoplasm, with binding of (ant)agonist changing the ratio of these 
pools.
Figure 1.3: Diagram showing a simplified mechanism of action of LATF-mediated 
up-regulation of gene transcription
Ligand
^Nucleu
Cytoplasm
Ligand molecule enters the cell associates with the nuclear receptor (NR) ligand binding domain. The 
activated receptor translocates to the nucleus as a dimer with its partner (e.g. 9-cis retinoic acid receptor). 
The complex then binds to a response element (RE) within the target gene promoter and transactivates 
gene expression through recruitment o f the transcriptional machinery.
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1.3.2.2 Role of nuclear receptor coregulators in transcriptional regulation
Nuclear receptor coregulators are coactivators and corepressor proteins that are required 
by nuclear receptors for efficient transcriptional regulation. In this context, coactivators 
are defined as molecules that interact with nuclear receptors and enhance their 
transactivation. Analogously, corepressors are factors that interact with nuclear 
receptors and lower the transcription rate of their target genes (McKenna et al. 1999).
Coactivators represent a diverse group o f proteins that serve to enhance transcription 
primarily by binding to the ligand activated nuclear receptor. Most coactivators possess 
one or more NR boxes -short motifs represented by the amino acid sequence LXXLL, 
which contacts the AF-2 helix of the LBD; coactivator interaction can also occur with 
activation function (AF-1) at the amino- terminal of the receptor (Heery et al. 1997). 
Coactivators are diverse in both structure and function; however, for many coactivators, 
a shared characteristic is their enzymatic activities that promote transcription. For 
instance, many coactivators, such the steroid receptor coactivator 1 (SRC-1) and other 
members o f the p i60 family, possess histone acetyltransferase (HAT) activity, which is 
critically important for activation (Spencer et al. 1997). Chiomosomal DNA is tightly 
wrapped around nucleosomal units composed o f core histones; whereby, the acétylation 
o f lysine tails on histones ‘opens up’ this chromatin structure, and relieves 
transcriptional repression by allowing transcription factors access to response elements 
(Wolffe 1997).
SRC-1 has been shown to bind and activate the transcriptional activity of mouse 
(Kliewer et al. 1998) and human PXR (Lehmann et al. 1998). Upon activation o f PXR, 
SRC-1 binds to the receptor and interacts with other histone acetyltransferase (HAT) 
complexes such as CBP (CREB-binding protein)/p300, (Watkins et al. 2003a), which 
also functions in recruiting RNA polymerase II complexes to the promoter (Glass and 
Rosenfeld 2000). The interaction o f SRC-1 and PXR is both ligand-dependent 
(Lehmann et al. 1998) and dose-dependent (Masuyama et al. 2000), thereby suggesting 
that coactivators are in part, critical in determining the extent o f PXR-mediated 
transactivation o f target gene expression.
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In the unliganded state however, DNA-bound nuclear receptors are actively repressing 
transcription o f target genes. Repression is mediated by the recruitment corepressor 
proteins that are recruited to the LBD AF-2 helix of the receptor, o f which there are two 
major types: the nuclear corepressor (NCoR) and the silencing mediator for retinoid and 
thyroid receptors (SMRT) (Chen and Evans 1995; Horlein et al. 1995). The 
transcriptional functions o f NCoR and SMRT are the opposite of coactivators; although, 
the corepressors themselves do not possess enzyme activity, they do recruit multiple 
histone deacetylases (HDAC) to the target gene (Heinzel et al. 1997), thereby reversing 
the effects of histone acétylation described earlier and leading to a compact, repressed 
state o f chromatin. NCoR and SMRT have also been reported to interact with general 
transcription factors (reviewed by Hu and Lazar 2000), suggesting a possible 
mechanism of repression through direct interactions with the basal transcription 
machineiy.
SMRT has been reported to interact with to the LBD of unliganded PXR, in which 
cotransfection of SMRT inhibited not only basal but also rifampicin-induced 
transcriptional activity of PXR on the CYP3A4 promoter through a specific SMRT- 
PXR interaction (Takeshita et al. 2002). Conversely, ketoconazole inhibited 
corticosterone-induced PXR-mediated transcription on the CYP3A4 promoter through 
direct dissociation o f PXR with SRC-1 (Takeshita et al. 2002). Likewise, unliganded 
PXR was shown to interact with SMRT; this interaction was reversed by the 
chemotherapeutic agent, paclitaxel, but not by docetaxel, a closely related antineoplastic 
agent, indicating that the restricted ability o f docetaxel to activate PXR is closely related 
to its inability to displace corepressors (Synold et al. 2001). However, both these 
compounds were able to promote an interaction with PXR and coactivators, suggesting 
that the induction o f ADME genes expression upon chemical exposure is dependent on 
the chemical’s ability of both, displacing corepressors, and also o f recruiting 
coactivators to the nuclear receptor LBD.
In summary, it can be presumed that the relative balance of the interaction of PXR with 
SRC-1 and SMRT may well determine the activity of this receptor towards its target 
genes (Takeshita et al. 2002). However, it is anticipated that the PXR coactivator
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complex is comprised o f many more components than just SRC-1 and SMRT, which 
collectively function to dynamically modulate PXR target gene transactivation (Han et 
al. 2006).
1.3.2.3 Glucocorticoid receptor (NR3C1)
The glucocorticoid receptor alpha (GRa) is ubiquitously expressed throughout the body. 
In its inactive state, GRa is sequestered to the cytoplasm; binding o f glucocorticoid 
promotes dissociation from the heat shock protein 90 (Hsp90) complex, and subsequent 
translocation to the nucleus (Pratt 1993).
However, the role o f GRa in the regulation of CYP3A gene regulation is not yet fully 
resolved. Although putative glucocorticoid response elements have been identified in 
the 5 ’ flanldng regions o f human and rat CYP3A genes (Burger et al. 1992; Hashimoto 
et al. 1993), a direct interaction o f GRa with the promoters has never been reported. 
However, several lines of evidence suggest that GRa is involved in the induction of 
these genes. For example, the induction of endogenous CYP3A4 in cultured 
hepatocytes is potentiated by pre-treatment o f cells with dexamethasone (Pascussi et al. 
2000a); similarly, the induction o f a CYP3A4 gene reporter by glucocorticoids is 
increased in the presence of cotransfected GRa (El-Sankary et al. 2000).
However, using GRa-deficient mice, it was proposed that GRa was not an absolute 
requirement for the induction of CYP3A by glucocorticoids (Schuetz et al. 2000). 
Furthermore, reports that PCN antagonised dexamethasone-induction o f the classical 
glucocorticoid-responsive gene, tyrosine aminotransferase, whereas the combined 
administration o f dexamethasone and PCN enhanced the induction of CYP3A23, led to 
the suggestion that the induction o f CYP3A was via a mechanism distinct from the 
classical GR-mediated pathway (Schuetz and Guzelian 1984). The mediator o f this 
pathway was later identified as another LATF, the pregnane X receptor (Bertilsson et al. 
1998; Kliewer et al. 1998).
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The glucocorticoid receptor indirectly regulates the transcriptional activation o f CYP3 A 
genes. For instance, under physiological conditions, dexamethasone acts through the 
classical glucocorticoid receptor pathway to induce transcription of PXR, RXRa and 
CAR genes, which then potentiate the induction of their target genes, including 
CYP3A4, CYP2B6 and CYP2C9 target genes (Pascussi et al. 2000a; Pascussi et al. 
2000b; Gerbal-Chaloin et al. 2002; Wang et al. 2003). In summary, the involvement of 
GRa in CYP3A induction is at least partially due to its regulation o f other nuclear 
receptors, most notably PXR.
1.3.2.4 Constitutive androstane receptor (NR1I3)
The orphan constitutive androstane receptor (CAR) was isolated through screening o f a 
cDNA libraiy with a nuclear receptor DBD-based oligonucleotide as a probe (Baes et 
al. 1994). The name CAR was originally defined as constitutively activated receptor, 
because it forms a heterodimer with RXRa that binds to retinoic acid response elements 
and transactivates target genes in the absence o f ligand (Baes et al. 1994). CAR is 
predominantly expressed in the liver and intestine (Baes et al. 1994). Two androstane 
metabolites, androstanol and androstenol, were identified as endogenous CAR ligands. 
However, instead o f activating CAR, both ligands act as antagonists by dissociating 
CAR from its coactivator and inhibiting transactivation of CAR (Forman et al. 1998). 
Thus, CAR is also referred to as constitutive androstane receptor.
CAR is located in the cytoplasm and translocates to the nucleus upon activation 
(Kawamoto et al. 1999). The nuclear receptor is sequestered in the cytoplasm through 
complex formation with the cytoplasmic CAR retention protein (CCRP) and Hsp90 
(Kobayashi et al. 2003). In contrast to PXR, CAR activation can occur via two different 
routes; either by ‘classical’ direct activation, as with the pesticide contaminant 1,4- 
bis[2-(3,5 dichloropyridyloxy)]benzene (TCPOBOP), or indirectly, as with the 
prototypic CAR activator phénobarbital (Kawamoto et al. 1999; Moore et al. 2000b; 
Tzameli et al. 2000). Unlike TCPOBOP, phénobarbital does not bind directly to CAR, 
but it activates nuclear translocation o f the receptor through a phosphoiylation cascade 
(Yoshinari et al. 2003). In addition, CAR is activated by dieldrin, phenytoin and
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chloipromazine (Wei et al. 2002; Wang et al. 2004), as well as by endogenous 
compounds such as bilirubin, 5p-pregnane-3,20-dione and 17p-estradiol (Moore et al. 
2000b; Huang et al. 2003; Makinen et al. 2003).
Human and mouse PXR share only 72 % amino acid identity in their ligand binding 
domains (Choi et al. 1997) and demonstrate marked differences in their responsiveness 
to ligands. For example, clotrimazole is an efficacious deactivator o f human CAR but 
has little or no activity on mouse CAR (Moore et al. 2000b). Conversely, TCPOBOP, 
chlorpromazine, and 17p-estradiol are potent activators of mouse CAR but lack any 
activity on human CAR (reviewed by Jyrkkarinne et al. 2005). The divergence in 
amino acid sequence between human and mouse orthologs most certainly contributes to 
differences in CAR-meditated gene regulation, and subsequently the species-specific 
induction profiles CYP2B and CYP3A enzymes.
CAR mediates xenobiotic induction o f CYP2B genes by binding to two imperfect DR4 
motifs within a conserved phénobarbital responsive element module (PBREM) 
(Honkakoski et al. 1998; Kawamoto et al. 1999; Wei et al. 2000). CAR has also been 
shown to transactivate the PXR-responsive ER6 m otif within the promoter o f CYP3A 
genes (Sueyoshi et al. 1999; Xie et al. 2000a; Burk et al. 2004). However, several 
groups have demonstrated that PXR can bind to the PBREM DR4 elements and regulate 
CYP2B genes (Xie et al. 2000a; Goodwin et al. 2001; Smirlis et al. 2001), thereby 
illustrating the significant overlap in PXR and CAR target genes. Furthermore, recent 
studies indicate that the overlap in target genes extends to the regulation of phase II 
drug-metabolising enzymes and drug transporters (Maglich et al. 2002; Staudinger et al.
2003). In addition to recognising each other’s response elements, CAR and PXR have 
been shown to share some common ligands. Both phénobarbital and clotrimazole are 
ligands for CAR and PXR (Moore et al. 2000b), indicating that these nuclear receptors 
have the potential to cross-regulate gene expression by two independent mechanisms 
(Pascussi et al. 2003).
It has been suggested that CAR and PXR evolved from the same ancestral gene CXR 
(chicken xenobiotic receptor), and have then diverged duiing species evolution from
32
bird to man with the conservation of signalling pathways mediated by these xenobiotic- 
sensing receptors (Handschin et al. 2004). Such conservation highlights the important 
role that these nuclear receptors play in protecting organisms against potentially harmful 
chemicals.
Taken together, these findings illustrate the complexity of the xenobiotic response and 
the transcriptional regulation o f ADME genes.
1.3.2.5 Pregnane X receptor (NR1I2)
The pregnane X receptor (PXR) also referred to as the steroid and xenobiotic receptor 
(SXR) and pregnane-activated receptor (PAR) was cloned from a mouse liver cDNA 
library searched for sequences showing high identity with the ligand binding domains 
(LED) of a number o f nuclear receptors, and found to be efficaciously activated by 
naturally occurring pregnanes (Blumberg et al. 1998; Kliewer et al. 1998). The PXR 
has been subsequently identified in a range o f mammalian species including human, 
rhesus monlcey, rat and rabbit (Bertilsson et al. 1998; Zhang et al. 1999; Savas et al. 
2000; Moore et al. 2002), and most recently in the non-mammalian vertebrate teleost 
fish Fugu rubripes (pufferfish) (Maglich et al. 2003). The nuclear receptor is 
predominantly expressed in the liver and intestine, which parallels the expression o f its 
target genes, such as the CYP3A sub-family members and multidmg resistance proteins 
(Bertilsson et al. 1998; Lehmann et al. 1998; Geick et al. 2001).
However, a study has recently expanded the number o f human tissues expressing PXR 
to include stomach, brain, adrenal gland and bone marrow (Lamba et al. 2004). In 
contrast to the liver and small intestine, CYP3A expression is considered to be relatively 
low, suggesting that PXR is involved in biochemical pathways which do not involve 
CYP3A. Within discrete regions o f the brain for instance, PXR activation by 
neurosteroids may serve to modulate the neurosteroid pathway, involved in learning, 
memory, anxiety and depression (Lamba et al. 2004). It could also function to protect 
against neurotoxin insult, through activation o f CYP3A4 and M DRl (Lamba et al.
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2004). Collectively, these data highlight the importance o f PXR and its role in 
mediating metabolic pathways in different organs o f the body.
PXR has been shown to be maintained in the cytoplasm in the absence of ligand, 
thi’ough complex formation with the cytoplasmic constitutive active/ androstane 
receptor retention protein (CCRP) and Hsp90 (Squires et al. 2004). Removal of CCRP 
through treatment o f HepG2 cells with siRNA, attenuated the response of a reporter 
assay for PXR activity following exposure to rifampicin and PCN, demonstrating that 
CCRP plays a key role in activation o f both human and mouse PXRs (Squires et al.
2004). In contrast to these findings, unliganded PXR has been shown to be directly 
interacting with the silencing mediator for retinoid and thyroid hormone receptors 
(SMRT) (Johnson et al. 2006), a nuclear receptor corepressor protein that is 
concentrated in discrete nuclear foci when expressed in cultured cells (Park et al. 1999). 
A second study has also shown that PXR is predominantly localised in the nucleus o f 
COS-1 and HepG2 cells, both in the absence and presence o f rifampicin, where it binds 
to condensed chromosomes during mitosis (Saradhi et al. 2005). These findings suggest 
that PXR is continuously shuttling between the cytoplasmic and nuclear compartments, 
a characteristic previously observed for other nuclear hormone receptors (Maruvada et 
al. 2003).
1.3.2.5.1 Target genes for PXR
PXR regulates the transcription o f approximately 40 genes whose products control the 
metabolism and excretion o f both endo- and xenobiotics. PXR was originally shown to 
regulate the expression o f the CYP3A gene family and has since been dubbed the 
master regulator of CYP3A4 transcription (Bertilsson et al. 1998). Gel mobility shift 
assays confirmed that PXR binds to an ER6 motif within the CYP3A4 proximal 
promoter, as a heterodimer with 9-cis retinoic acid receptor (RXR) (Bertilsson et al. 
1998; Kliewer et al. 1998; Lehmann et al. 1998). In addition, it was demonstrated that 
PXR/RXRa heterodimers bind to an imperfect DR3 and ER6 motifs within the distal 
xenobiotic enhancer module (XREM), located approximately 8 kb upstream of the 
transcription start site (Goodwin et al. 1999), whereby maximal induction is achieved
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through the cooperative binding o f PXR at both the proximal and distal response 
elements (Goodwin et al. 1999).
In addition to the CYP3 A gene family, PXR has been reported to be a regulator o f other 
phase I metabolism enzymes, as well as phase II metabolism enzymes and membrane 
transporters. Table 1.5 shows the targets o f PXR in humans. The finding that PXR, 
which was more commonly associated with xenobiotic metabolism, could be activated 
by certain bile acids, such as the highly toxic lithocholic acid (LCA) (Staudinger et al. 
2001; Xie et al. 2001), led to the recognition that PXR is an important regulator 
endogenous metabolism, including bile acid homeostasis.
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PXR serves as a physiological sensor o f LCA and in doing so, protects against liver 
toxicity by coordinately regulating gene expression so as to reduce its concentration. 
Once activated by the ligand LCA, the receptor inhibits the expression o f CYP7A1, an 
enzyme responsible for bile acid synthesis, and simultaneously induces the expression 
of OATP2 and CYP3A genes, which promote their hepatic uptake and hydroxylation 
(Staudinger et al. 2001; Xie et al. 2001). The subsequent excretion of bile acid 
metabolites is mediated by M D Rl, which is also a PXR target gene (Geick et al. 2001). 
The small heterodimer partner-1 (SH Pl) gene has recently been reported as a primary 
PXR target gene, suggesting an alternative or additional pathway, in which PXR, by 
sensing elevated bile acid concentrations, increases SHPl protein levels. This protein 
then directly represses CYP7A1 expression (Frank et al. 2005). A previous report 
(Ourlin et al. 2003) however, identified that increasing bile acid concentrations resulted 
in the inhibition o f CYP3A-mediated bile acid biosynthesis through the inhibition o f 
PXR transcriptional activity by SHPl. Such observations reveal a tightly controlled 
regulatory cascade for both the maintenance o f bile acid production and detoxification 
in the liver, wherein PXR plays an integral role as a sensor for endogenous bile acids, 
and in monitoring changes in homeostasis.
PXR has been reported to be implicated in the regulation of CYP24 expression, the 
major enzyme responsible for the biological catabolism of vitamin D hormone, found 
primarily in the kidney (Pascussi et al. 2005; Zhou et al. 2006). Pascussi et al. identified 
that osteomalacia, a metabolic bone disease characterised by a defect of bone 
mineralisation caused by vitamin D deficiency, is the result of activation of PXR by 
drugs such as rifampicin, phénobarbital and carbamazepine. Whereby, activated PXR 
directly binds to and transactivates the two proximal vitamin D-responsive elements 
present in the CYP24 promoter, resulting in the up-regulation o f CYP24 and an 
acceleration o f vitamin D catabolism (Pascussi et al. 2005). These findings are 
however, brought into question by Zhou et al., who report that activation o f PXR neither 
transactivates the CYP24 promoter nor induces CYP24 expression. Instead, PXR plays 
a dual role in mediating drug-induced osteomalacia, whereby the receptor up-regulates 
CYP3A4-mediated hydroxylation o f vitamin D whilst indirectly inhibiting CYP24 
expression. Inhibition is achieved by restricting the vitamin D receptor (VDR) fi*om
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activating the promoter through competition o f nuclear receptor coactivators shared by 
PXR and VDR (Zhou et al. 2006). Taken together, these findings highlight PXR as an 
important factor in vitamin D and bone homeostasis, in addition to xenobiotic 
homeostasis and cholesterol and bile acid detoxification.
PXR not only regulates the expression o f enzymes and membrane transporters, but may 
be involved in the regulation of other receptors, such as the AhR receptor (Maglich et 
al. 2002), thereby providing an indirect role o f PXR in the metabolism o f polycyclic 
aromatic hydrocarbons and polychlorinated biphenyls. In addition, the search for other 
PXR target genes using an information theoiy-based model, identified an active 
PXR/RXR binding site was upstream of the CASP 10 gene which may act as an 
enhancer element (Vyhlidal et al. 2004).
In summary, the growing list o f genes regulated by PXR is testament to the complexity 
o f the body in responding to fluctuating chemical levels and maintaining homeostasis. 
However, the pathways affected by PXR-mediated transcription, may extend beyond 
drug biotransformation and transport to include apoptosis, signal transduction and cell- 
cycle control, thus raising the potential for PXRs broader physiological function.
1.3.2.5.2 Activation by ligands
Historically, compounds that activate nuclear receptors have been identified in cell- 
based reporter assays in which an expression plasmid containing the receptor of interest 
is cotransfected into cells with a relevant reporter gene plasmid (Evans 1988). The 
receptor expression plasmid can encode either the full-length receptor or a chimera 
between the LED of the receptor and the DBD of another protein such as the yeast 
transcription factor GAL4. In the absence o f its cognate response elements, PXR 
activators were initially delineated using a chimeric system in which the mouse PXR 
LED was fused to the GAL4 DBD. Expression vectors containing the chimeras were 
transiently transfected into CV-1 cells together with a reporter plasmid containing five 
copies o f a GAL4 DNA binding site upstream of the chloramphenicol acetyltransferase 
(CAT) reporter, thereby identifying activators of mouse PXR (Kliewer et al. 1998).
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Following the identification of the PXR response elements within the CYP3A4 
promoter (Hashimoto et al. 1993; Barwick et al. 1996; Goodwin et al. 1999), a cell- 
based PXR reporter gene assay has been established to screen CYP3A4 inducers, 
whereby a receptor expression plasmid containing full-length PXR is cotransfected with 
a reporter plasmid containing the enhancer and promoter of CYP3A4 driving luciferase 
expression (Moore et al. 2000b). The number o f chemicals that are reported to activate 
PXR has grown rapidly and have mostly been identified using the latter type o f assay. 
Table 1.6 shows a selection o f activators for PXR including drugs, endogenous 
compounds and environmental chemicals. These chemicals have differing affinities for 
PXR and possess varying CYP3A4-inductive abilities. For instance, clotrimazole and 
rifampicin have been shown to be strong activators whereas dexamethasone and 
paclitaxel are weak activators of CYP3A4 (Luo et al. 2002).
Ligand activation o f PXR may even be exploited to treat human diseases. For example, 
the catatoxic steroid PCN affords protection against bile acid-induced toxicity through 
the activation o f PXR, which may have implications in the treatment o f human 
cholestatic liver disease (Staudinger et al. 2001). Similarly, rifampicin and the herbal 
PXR agonist St. John’s Wort, both PXR agonists, have been used to treat cholestasis, 
although the mechanism by which they exert their effects is not well understood 
(reviewed by Kliewer and Willson 2002).
PXR was originally shown to regulate CYP3A genes, but now it is known that this 
receptor regulates an entire program of genes in the liver and intestine that are involved 
in the metabolism and elimination o f potentially toxic chemicals from the body. 
Importantly, PXR is activated by a remarkably diverse set of chemicals, including both 
xenobiotics and endogenous compounds such as bile acids and steroids. Thus, in 
contrast to almost all other nuclear receptors, which are specialised to recognise a 
discrete range o f ligands, PXR has evolved to function as a broad substrate chemical 
sensor.
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Table 1.6: Ligands that activate PXR and their functions
Drug Function Reference
Pregnanes, pregnenolone Natural steroid (Kliewer et al. 1998)
Progesterone, 17p-estradiol Natural steroid (Bertilsson et al. 1998)
Dexamethasone Synthetic steroid (Kliewer et al. 1998)
PCN Antiglucocorticoid (Kliewer et al. 1998)
Mifepristone (RU486) Antiprogesterone/ antiglucocorticoid (Lehmann et al. 1998)
Dehydroepiandrosterone Neurosteroid (Ripp et al. 2002)
Rifampicin Antibiotic (Bertilsson et al. 1998)
T roleandomycin Macrolide antibiotic (Luo et al. 2002)
Clotrimazole Antifungal (Lehmann et al. 1998)
Phénobarbital Anticonvulsant (Lehmann et al. 1998)
Phenytoin, carbamazepine Anticonvulsant (Luo et al. 2002)
Cyproterone acetate Antiandrogen (Schuetz et al. 1998)
Spironolactone Diuretic (Schuetz et al. 1998)
Tamoxifen Anticancer drug (Desai et al. 2002)
Paclitaxel Anticancer drug (Synold et al. 2001)
Cyclophosphamide Anticancer drug (Lindley et al. 2002)
Ritonavir HIV protease inhibitor (Dussault et al. 2001)
Glutethimide Sedative (Handschin et al. 2001)
Hyperforin Antidepressant (Moore et al. 2000a)
Forskolin Vasodilator (Ding and Staudinger 2005)
Guggulsterone Hypolipidaemic (Brobst et al. 2004)
SR12813 Cholesterol-lowering drug (Jones et al. 2000)
Lovastatin Cholesterol-lowering drug (Lehmann et al, 1998)
Lithocholic acid Fat emulsifier (Staudinger et al. 2001)
Nifedipine Calcium channel blocker (Bertilsson et al. 1998)
Troglitazone Antidiabetic (Jones et al. 2000)
Nicotine Tobacco constituent (Lamba et al. 2004)
Phthalate esters Plasticisers (Hurst and Waxman 2004)
Polychlorinated biphenyls Environmental toxicant (Schuetz et al. 1998)
DTT, lindane Organochlorine pesticide (Lemaire et al. 2004)
Nonylphenol, bisphenol A Endocrine disruptor (Masuyama et al. 2000)
Vitamin E Antioxidant (Landes et al. 2003)
Vitamin K2 Bone mineralisation (Tabb et al. 2003)
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Although PXR functions to regulate the detoxification of xenobiotics by responding to a 
large range of chemicals and inducing a battery o f genes involved in their metabolism 
and excretion, its activation also represents the basis for many drug-dmg interactions 
which can lead to the loss o f therapeutic effect or an increase in toxicity. An example of 
the latter is seen with the coadministration o f PCN and paracetamol. Under normal 
conditions, paracetamol is mainly cleaved via several routes, including CYP3A 
metabolism to form a highly reactive NAPQI intermediate, which is then cleaved by 
GST in phase II metabolism. However, if  CYP3A is up-regulated (by for example, 
PCN-activated PXR) and GST is depleted (through excessive paracetamol intake), 
NAPQI accumulation occurs and centrilobular hepatotoxicity ensues (Guo et al. 2004).
The identification of the active ingredient in the antidepressant herbal St. John’s Wort as 
a PXR activator exemplifies the prototypical herb-drug interaction paradigm (Moore et 
al. 2000a). Hyperforin induces the expression o f the CYP3A4 enzyme via PXR, and 
increases the metabolism o f coadministered medications that are CYP3A4 substrates, 
such as oral contraceptives, immunosuppressive agents and HIV protease inhibitors, 
leading to a loss of therapeutic effect, often with life-threatening circumstances (Moore 
et al. 2000a). Two other herbal remedies that induce herb-drug interactions have been 
identified. The fat-loss agent forskolin and the cholesterol-lowering treatment 
guggulsterone both function as agonists for PXR and induce CYP3A, and are therefore 
likely to confer similar effects to hyperforin when coadministered with other 
medications (Brobst et al. 2004; Ding and Staudinger 2005).
CYP3A4 is involved in the metabolism o f over 50 % of all prescription drugs (Kliewer
2003). Thus, drugs that activate PXR have the potential to reduce the clinical efficacy 
o f more than one half o f all other drugs that are coadministered. As exemplified above, 
this is often a problem in the current era o f polypharmacy, in which patients are often 
taking multiple medications.
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1.3.2.5.3 Species differences in ligand activation
There are marked differences in the induction of rat CYP3A23, rabbit CYP3A6 and 
their human orthologue CYP3A4 by xenobiotics. For example, rifampicin causes a 
large induction o f human and rabbit CYP3A compared to rat CYP3A23, where the 
response is weak. The opposite situation is observed with PCN, a strong inducer of 
CYP3A23 but not o f CYP3A4 and CYP3A6 (Kocarek et al. 1995; Barwick et al. 1996) 
These effects were cell line-specific, which led to the conclusion that an endogenous 
cellular factor was mediating these responses (Barwick et al. 1996). Additional studies 
revealed striking differences in the activation profiles of PXR across species. Whereas 
PCN was an effective activator of mouse and rat PXR, it had much less activity on the 
rabbit and human receptors. Conversely, rifampicin activated human and rabbit PXR 
but had virtually no activity on the mouse and rat receptors (Lehmann et al. 1998; Jones 
et al. 2000; Savas et al. 2000). Table 1.7 shows further examples o f compounds which 
are capable o f activating PXR in a species-specific manner. Taken together, these data 
provided strong pharmacological evidence that PXR serves as a key regulator of 
CYP3A gene expression and that the species origin o f PXR dictates the CYP3A 
induction profile.
To examine the significance of PXR in xenoregulation in vivo, transgenic mice have 
been developed (Xie et al. 2000b). The expression of human PXR in mouse liver 
resulted in rodent-specific CYP3A induction by PCN, mediated by the wild type mouse 
PXR, plus human-specific induction by rifampicin. Targeted disruption o f the mouse 
PXR gene eliminated the induction by PCN; however, in the presence of rifampicin, 
CYP3A induction was as before. Transgenic mice expressing a constitutively active 
human PXR were shown to develop a sustained human CYP3A induction profile, 
resulting in enhanced protection against challenges o f xenobiotic toxicants (Xie et al. 
2000b).
At present, animal models are highly unreliable predictors of the human xenobiotic 
response underlying diug-dmg interactions, because o f the species differences in 
xenobiotic response. Thus, the creation of “humanised” rodent models is o f great
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significance to the pharmaceutical industry, thereby allowing for more accurate drug 
and toxicity screening and ultimately the development o f safer drugs.
Table 1.7: Species differences in PXR activation
Xenobiotic Human Rabbit Rat Mouse References
5(3 pregnane-3,20-dione ++ + 4 .4. 44- (Jones et al. 2000; Savas et al. 2000)
Dexamethasone - ++ 4- 4- (Jones et al. 2000)
PCN - - 44- 4-4- (Jones et al. 2000; Savas et al. 2000)
Mifepristone (RU486) + - 4- 4-4- (Savas et al. 1999)
Rifampicin ++ - - (Savas et al. 1999; Jones et al. 2000)
Clotrimazole -H- + - - (Savas et al. 1999; Jones et al. 2000)
Phénobarbital ++• + - - (Jones et al. 2000)
Cyproterone acetate - 44- 4-4- -f- (Jones et al. 2000)
Spironolactone - 4- 4- 4- (Jones et al. 2000)
SR12813 -H- 4- - - (Jones et al. 2000)
Lovastatin + n.d. n.d. - (Lehmann et al. 1998)
Nifedipine ++ n.d. n.d. 4-4- (Bertilsson et al. 1998; Xie et al.
2000b)
Troglitazone + 4- - - (Jones et al. 2000)
++ Strong activator; + moderate activator; - weak/non activator; n.d. not determined
Activation profiles were generated by transient cotransfection o f  the PXR with various CYP3A response 
elements. Because different reporter constructs and cell lines were used in these assays, information 
listed in the table should not be considered quantitative.
The phenomenon that PXRs from different species respond to distinct sets of 
compounds, has been termed ‘directed promiscuity’, to reflect the fact that each species’ 
PXR is promiscuous only in a specific subset o f xenobiotic and endogenous compounds 
(Watkins et al. 2001). The first steps to understanding the molecular basis of ‘directed 
promiscuity’ were taken by the alignment and comparison o f PXR amino acid 
sequences from human and rodent species. Greater insight was later achieved through 
the generation of crystal structures o f the human PXR LED, and the characterisation of 
mutant receptors o f human and mouse PXR.
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1.3.2.5.4 Structural features of PXR
Cloning and characterisation o f PXR from human, rabbit, rat and mouse have shown 
that there is 92 to 96 % sequence identity in the DNA binding domain (DBD) regions. 
However, as shown in table 1.8 (adapted from Moore et al. 2002), the LBDs of PXRs 
are much less identical and with the exception o f rhesus monkey PXR, share only 50 to 
87 % amino acid identity (Bertilsson et al. 1998; Blumberg et al. 1998; Lehmann et al. 
1998; Jones et al. 2000; Moore et al. 2002).
Table 1.8: Percent amino acid sequence identity of PXR LBD between species
1 11 s Q 1 1 1 1
*** 96 87 83 82 76 77 52 Human
89 83 83 77 78 52 Monkey
*** 84 83 76 78 51 Pig
78 75 76 50 Dog
78 79 51 Rabbit
*** 97 53 Rat
53 Mouse
*** Fish
The degree of divergence o f PXR LBD is veiy unusual in the nuclear receptor 
superfamily, in which orthologues typically share > 90 % sequence identity, a feature 
that reflects the markedly different activation profiles in response to xenobiotics. By 
comparison, the DBD o f PXR is highly conseiwed between species. Located within the 
DBD is the NLS (nuclear localisation signal), which together with the XRS 
(xenochemical response element) and AF2 domain both located in the LBD of PXR are 
required for the nuclear translocation of mouse PXR (Squires et al. 2004). Human PXR 
requires only the NLS for nuclear translocation, whereby the bipartite sequence o f basic 
amino acids is specifically recognised by cargoes of importin a, which facilitate 
transport across the nuclear pore complex (Kawana et al. 2003). The requirement o f the 
NLS for both human and mouse PXR translocation and the relatively similar DBDs are
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consistent with the notion that PXR orthologues can bind to PXR response elements of 
different species.
Specific amino acid substitutions within the LBD may be responsible for the species 
differences in PXR activation profiles. For example, rat PXR had nine amino acid 
substitutions compared with the mouse PXR in the LBD, which are likely to be 
responsible for the lower responsiveness of rats to rifampicin (Zhang et al. 1999). 
Indeed, the substitution of key amino acids at the entry of the ligand binding cavity in 
rat PXR was able to produce responsiveness to rifampicin. In particular, residue 305 in 
rat PXR seems to be the key amino acid residue that modulates receptor activation by 
large molecules such as rifampicin, paclitaxel and hyperforin (Tirona et al. 2004; 
Chrencik et al. 2005; Song et al. 2005).
Using crystal structures of the human PXR LBD in the absence and presence of ligands, 
it has been possible to speculate on the ability of PXR to be activated by a wide-range 
o f ligands. Essentially, the LBD contains three novel features that play a significant 
role in the binding promiscuity and function o f the receptor (Watkins et al. 2002). 
Firstly, a mobile hydrophobic loop lies adjacent to the ligand binding pocket, which 
provides molecular ‘slack’ for enlargement o f the pocket upon binding large ligands 
such as rifampicin (Watkins et al. 2001). Thus, this region allows the ligand binding 
pocket o f PXR to expand and contract, facilitating the binding o f both large and small 
compounds. A second novel feature o f the PXR structure that may impact on its 
promiscuity is the presence o f two additional (3-sheets, which together with the three 
other p-sheets form one wall o f the ligand binding pocket (Watkins et al. 2001). The 
extended p-sheet is unique to PXR and serves to expand the size of the binding pocket 
to facilitate the promiscuous interaction with ligands. The third novel feature of PXR is 
its large, hydrophobic ligand binding pocket, which is conferred by the presence of 
multiple polar residues in the LBD. These polar residues not only create allow PXR to 
form hydrogen bonds and hydrophobic interactions with ligands o f varying size, shape 
and chemical structure, but also confer the specificity between human and rodent 
ligands. For example, mutation o f four polar residues in the LBD pocket of mouse PXR 
to those seen in human PXR LBD resulted in activation o f the mouse PXR by the
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human-specific ligand rifampicin (Watkins et al. 2001). Mutation o f a large polar 
residue within the human PXR LBD to a smaller hydrophobic residue present at the 
corresponding position in mouse PXR conferred an improved binding to the rodent- 
specific ligand PCN. This suggests that the type o f bond formed within the LBD pocket 
is an important factor in determining the activation profile o f the receptor, whereby a 
hydrophobic interaction may be more favourable for PCN binding in close proximity to 
this residue (Ostberg et al. 2002).
The ability of PXRs from diverse species to respond to different sets o f compounds 
almost certainly signifies the different evolutionary pressures placed on species to 
recognise and respond efficiently to xenobiotic stresses particularly to their 
environments. The differing activation profiles of rifampicin for example, suggest that 
the rabbit diet may contain compounds similar to rifampicin in shape or chemical 
nature, but the human diet may contain less of these compounds and, by extension, the 
diets o f mice and rats contain little o f these compounds (Chrencik et al. 2005). 
Alternatively, the species-specific PXR activation profiles may be driven by differences 
in the production of endogenous chemicals such as and bile acids (Krasowski et al. 
2005).
Taken together, the species-specific expression o f downstream target genes is ultimately 
driven by the directed promiscuity o f PXR.
1.3.2.5.5 Transcriptional activation
The expression of PXR itself, like its target genes is drastically altered by certain 
xenobiotics as well as certain physiological conditions. For instance the levels o f PXR 
mRNA are rapidly decreased in rats treated with the endotoxin lipopolysaccharide 
(Fang et al. 2004). With human hepatocytes, pro-inflammatory cytokine interleukin-6 
has been shown to markedly reduce the levels of PXR mRNA, which in turn, reduced 
the induction of PXR-regulated genes such as CYP3A4 (Pascussi et al. 2000c). A 
potential mechanism is suggested from the observation that PXR gene expression is 
down-regulated by the over expression of PXR protein in a human hepatoma cell line.
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which shows that PXR, or endogenous ligands for the receptor, are capable of 
repressing its own expression (Aouabdi et al. 2006)
In contrast to suppression, several chemicals have been shown to markedly increase 
PXR expression. In primary human hepatocytes, for example, dexamethasone increases 
the mRNA for both PXR and RXRa (Pascussi et al. 2000a), The increase in expression 
o f these two receptors was shown to be mediated by the glucocorticoid, as the induction 
was abolished by the glucocorticoid antagonist RU486 (Pascussi et al. 2000a). In 
addition, treatment with actinomycin D, an inhibitor o f transcription, did not influence 
the decay o f PXR mRNA in response to dexamethasone. Moreover, pre-treatment with 
the protein synthesis inhibitor, cycloheximide, did not affect the increase in PXR 
mRNA, demonstrating that dexamethasone does not affect degradation of PXR mRNA, 
and that the increase in PXR mRNA in response to dexamethasone is not through 
mRNA stabilisation. These observations led to the conclusion that PXR is regulated at 
the transcriptional level, in part by GRa (Pascussi et al. 2000a).
Further examples in rodents have been reported; in mice treated with the 
antiglucocorticoid PCN, for example, the level o f PXR was significantly increased 
(Maglich et al. 2002). Similarly in rats, PXR mRNA levels were markedly increased 
following treatment with a variety o f chemicals including two non-CYP3A inducers, 
isoniazid and perfluorodecanoic acid (PFDA) (Zhang et al. 1999). Interestingly 
however, rat hepatocytes treated with the peroxisome proliferators, clofibrate and 
PFDA, both markedly increased PXR mRNA and protein levels. Treatment of rat 
hepatocytes with actinomycin D and puromycin, which selectively inhibit mRNA 
synthesis and protein translation, respectively, resulted in the abolition of PXR 
expression, demonstrating that the level o f PXR is not increased through increasing 
protein stability (Ma et al. 2005). Interestingly, neither clofibrate nor PFDA are PXR 
ligands, but are PPARa ligands, providing additional complexity on the regulated 
expression of drug-metabolising enzymes. These data together with the finding that not 
all PXR activators (e.g. Troleandomycin) are capable o f increasing the mRNA levels of 
PXR, suggest a novel mechanism for drug-dmg interactions through the synergistic 
effects on CYP3A induction (Zhang et al. 1999).
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1.3.2.5.6 Splice variants of PXR
Alternative mRNAs for nuclear receptors arise by a combination o f alternative promoter 
usage and exon splicing, with the latter occurring at greater frequency. Splice variants 
can differ in their pattern of expression, gene targets, biological functions, DNA- 
binding, intracellular binding interactions with other proteins, and subcellular 
localisation (Keightley 1998); thus creating additional layers of signalling complexity 
for the expression of downstream target genes.
Human PXR has four isoforms o f its mRNA, namely PAR-2 (Bertilsson et al. 1998), 
PXR.2 (Dotzlaw et al. 1999) and PXR.3 (Lamba et al. 2004) together with wild type 
PXR.1 (Blumberg et al. 1998; Lehmann et al. 1998). The PAR-2 splice variant contains 
39 extra amino acids at the N-terminus due to an alternatively spliced first exon 
(Bertilsson et al. 1998), whereas the PXR.2 splice variant is characterised by an in­
frame deletion of 111 nucleotides from exon 5, resulting in the deletion of 37 amino 
acids from the LBD (Dotzlaw et al. 1999). PXR.3 is the product o f a second splicing 
event in exon 5, whereby the deletion o f 123 nucleotides results in the expression of a 
truncated protein lacking 41 amino acids from the LBD. PXR.3 is identical to the only 
splice variant identified in the original cloning of mouse PXR (Kliewer et al. 1998), 
indicating a conservation across species. Furthermore, when the nucleotide sequences 
encoding exon 5 of PXR LBDs from diverse species were aligned, it was evident that 
the cryptic ‘AG’ splice sites that generate PXR.2 and PXR.3 in human were 
evolutionally conserved in monkey, rabbit, rat and mouse (Lamba et al. 2004). 
Although PXR.1 is the predominantly expressed transcript in human liver (97 %), the 
high evolutionary conservation o f PXR.2 and PXR.3 splice sites implies some essential 
function for these alternative mRNAs. By comparison, a fifth transcript has been 
characterised that has a deletion o f 71 bp from the 3’ end o f exon 2 (Lamba et al. 2004), 
which results in the formation o f a truncated protein with 106 amino acids, and 
consequently is not thought to be biologically viable.
Currently, only the single transcript o f rat PXR mRNA has been identified (Zhang et al. 
1999); however, the advancement o f the rodent genome project does not preclude the 
identification o f alternative mRNA splice variants.
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1.3.2.5.7 Human PXR promoter analysis
Recent studies o f the promoter region have provided novel mechanistic insights into the 
ti'anscriptional regulation of human PXR (Aouabdi et al. 2006; Kurose et al. 2006). 
Several putative DNA/protein interaction sites were identified within the PXR proximal 
promoter, for both auxiliary/tissue-specific transcription factors such as HNF3(3, 
HNF4a, C/EBPa and Spl, and a large number of ligand activated transcription factors, 
including VDR, GRa, PR and PPARa. It was demonstrated that PPARa mediates it 
activation o f PXR gene expression via the PPRE located -1346 bp upstream of the 
putative transcription start site (Aouabdi et al. 2006). The minimal essential region for 
promoter activity was mapped to a 160 bp region upstream of the transcription start site, 
an area that also showed nuclear protein binding (Kurose et al. 2006). Gel mobility 
shift assays identified thi*ee sites which corresponded to two putative HNF3p binding 
sites and possibly an Octl binding site or a GRE. Comparison o f the nucleotide 
sequence around these sites with those o f rat and mouse showed that the 160 bp region 
was relatively conserved among the species (Kurose et al. 2006), suggesting that these 
sites are evolutionally important for PXR basal expression across species.
1.3.3 Summary
The pregnane X receptor is central in the regulation and maintenance of cellular 
homeostasis. In response to fluctuating chemical levels, the orphan nuclear receptor is 
capable o f binding a broad range o f endogenous and xenobiotic compounds, and then 
activating the transcription of a large and expanding repertoire of target genes, including 
phase I (e.g. CYP3A) and phase II (e.g. UGTl A) drag metabolising enzymes as well as 
those encoding drug transporters. As a result, PXR is regarded as the major metabolite 
sensor and the master regulator o f the xenobiotic response.
There are significant differences in the CYP3A activation profiles between human and 
rodents. These differences can be accounted for in part, by the directed promiscuity of 
PXR towards ligands. However, it is becoming increasingly apparent that the expression 
of PXR itself is controlled by other LATFs and LETFs, thereby illustrating a complex
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regulatory network, in which PXR induction is a contributory factor to the observed 
species differences in CYP3A activation.
Extrapolating data from animal models has proven unreasonable due to the species 
differences outlined herein. Therefore, an understanding of the cross-species similarities 
and differences that exist in the transcriptional regulation of PXR^ and the impact upon 
CYP3 A activation, will not only aid in the prediction o f the human response to chemical 
exposure, but also be o f great importance in the development of novel therapeutic 
agents.
1.3.4 Aims of the study
This study will highlight the similarities and differences in the molecular mechanism of 
PXR gene expression and regulation between humans, primates and rodents in order to 
address the hypothesis that the species differences in response to changes in the 
chemical flux through the body are determined, at least in part, by the regulation of 
PXR and its interaction with other nuclear receptors.
I will achieve this by:
• In silico examination of PXR ligand binding domains from diverse species, to
investigate potential mechanisms for the observed differences in activation of
PXR by ligands;
• In vitro analysis o f PXR transcript levels in response to PXR ligands;
• In silico analysis o f PXR proximal promoters from diverse species, to identify
putative binding sites for potential regulatory factors and investigate differences 
in regulation;
• In vitro analysis to determine differences in the functionality o f putative binding 
sites in response to PXR ligands using reporter gene assays and mutagenesis 
techniques.
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2: Materials and methods
2.1 Materials
2.1.1 Chemicals and plasticware
Specialised reagents and materials used throughout the study and their respective 
supplier are shown in table 2.1. All other chemicals were purchased from Sigma 
Aldrich (St. Louis, MO, USA) and o f molecular grade standard.
2.1.2 Plasmids
SEA? Basic plasmid was purchased from BD Biosciences (Franklin Lakes, NJ, USA). 
The SEAP hPXR proximal promoter reporter constructs were previously cloned within 
the laboratoiy by Dr Sihem Aouabdi. The hepatocyte nuclear factor (HNF) 3p was a 
gift from Dr Hung Fan (University o f California, Irvine, USA), and HNF4a was a gift 
from Dr Richard B. Kim (Vanderbilt University, Tennessee, USA). The vitamin D 
receptor (VDR), peroxisome proliferator activated receptor alpha (PPARa) and 
glucocorticoid receptor alpha (GRa) were a gift from Dr J. Tugwood (Astrazeneca, 
Macclesfield, UK). Retinoid X receptor alpha (RXRa) was a gift from Professor P. 
Chambon (INSERM, Strasbourg, France). Maps o f all these plasmids are shown in 
section 9.1.
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Table 2.1: Suppliers of reagents and items used in this study
Reagent Supplier
Human and rat genomic DNA  
Chimpanzee genomic DNA  
Human total RNA 
DNA modifying enzymes 
RNA modifying enzymes 
DNA oligomers and probes 
Germany)
Agarose
Bacterial agar, phosphate buffered saline (PBS) tablets, 
tiyptone, yeast extract
Vented tissue flasks, 6-well plates, 96-well plates 
Disposable pipette tips
DMEM, DMEM/F12 (1:1), foetal bovine serum, penicillin, 
streptomycin, gentamycin, non essential amino acids, 
trypsin-EDTA
DNA purification (gel extraction, plasmid mini and maxi preps), 
RNA purification
TOP 10 E.Coli competent bacterial cells 
Fugene 6 
Transfast 
96-well optiplate 
USA)
Aurora alkaline phosphatase chemiluminescent reporter gene 
assay kit
Ribogreen RNA quantification kit 
96-well optical reaction plate, optical adhesive cover
}
Promega (Madison, WI, USA) 
Biochain (Hayward, CA, USA) 
Stratagene (La Jolla, CA, USA) 
Promega (Madison, WI, USA) 
Invitrogen (Carlsbad, CA, USA) 
MWG Biotech (Ebersberg,
Promega (Madison, WI, USA) 
Oxoid (Basingstoke, UK)
Nalge Nunc (Roskilde, Denmark) 
Alpha Laboratories (Eastleigh, UK)
Invitrogen (Carlsbad, CA, USA)
Qiagen (Epsom, UK)
Invitrogen (Carlsbad, CA, USA) 
Roche (Basel, Switzerland) 
Promega (Madison, CA, USA) 
Perkin Elmer (Wellesley, CA,
MP Biomedicals (Irvine, CA, USA)
Invitrogen (Carlsbad, CA, USA) 
ABgene (Epsom, UK)
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2.2 Methods
2.2.1 Polymerase chain reaction
2.2.1.1 Proximal promoter sequence identification
The complete mRNA sequences of human, chimpanzee and rat PXR were aligned 
against their respective genomes using BLAST (Basic Local Alignment Search Tool) 
algorithm; http://www.ncbi.nlm.nih.gov/BLAST (Altschul et al. 1990), which identified 
genomic DNA contigs that corresponded to the exons o f the respective PXR genes. The 
accession numbers used, contigs identified and chromosomal location are shown in 
table 2.2. The nucleotide start position along the chromosome of the exonl contig was 
used as reference to select the 1.5 kb upstream, which is the genomic equivalent to 
position 1 on the mRNA and is the gene promoter region.
Table 2.2: PXR accession numbers used to identify proximal promoters
Species mRNA accession number Contig accession number Chromosomal location
Human NM_003889 NT_005612 3
Chimpanzee AF_454671 NW_104931 3
Rat NM 052980 NW 047356 11
2.2.1.2 Primer design
The sequences for the 1.5 kb proximal promoter regions of chimpanzee PXR (cPXR) 
and rat PXR (rPXR) were obtained from the NCBI GenBank Database website, as 
described in section 2.2.1.1 and imported into the primer design programme Vector NTI 
4.0 (Invitrogen, Carlsbad, CA, USA). The parameters for primer design were set at 
product length 1500-1600 bp, percentage GC o f 45-55 % and primer length 20-30 bp. 
The primers identified are shown in table 2.3, which were supplied lyophilised; upon 
delivery, primers were resuspended in nuclease-ffee water to a stock concentration of 
100 pmol/pl, and stored at -20 °C. A working concentration o f 50 pmol/pl was 
achieved by mixing the sense and antisense primers at a ratio o f 1:1. The working 
primer stock was also stored at -20 °C.
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Table 2.3: Primer sequences used for PCR amplification of PXRs
Target Sense/Antisense Amplicon (bp) T„. CC) Sequence
cPXR
Sense
Antisense
1513
1513
47.5
48.9
5 ’-GTCTGGGAG AATTACC AACC-3 ’ 
5 ’-CAGCTTTCTTTGGGTCTCAC-3 '
rPXR
Sense 
Anti sense
1503
1503
50.1
49.4
5 ’-ACCTTTCTTCCCCTACGTTG-3 ’
5 ’-GGGCGCAGAAACTATACTTG-3 ’
2.2.1.3 Polymerase chain reaction
PCR reactions were initially optimised using Taq Polymerase, due to its low cost and 
high tolerance to varying primer annealing temperatures. For cloning procedures, PCR 
was carried out using Pjx Polymerase, as this has a much higher fidelity, eliminating 
PCR-derived artefacts in the final clone. The volumes used for the Taq polymerase 
PCR reactions are indicated in table 2.4. Rat and chimpanzee genomic DNAs were 
supplied at concentrations o f 285 ng/pl and 610 ng/ pi, respectively.
For amplification of the rPXR 1.5 kb proximal promoter region, the annealing 
temperature was adjusted to find the optimal temperature for both sets o f primers using 
a 12-point gradient from 45 to 65 °C. The polymerase chain reactions were performed 
in a PTC-200 DNA Engine (Bio-Rad, Hercules, CA, USA). Cycle parameters for rat 
PXR amplification are given in table 2.6. PCR products were visualised by separation 
in a 1 % agarose gel containing ethidium bromide as describe in section 2.2.1.4. Once 
initial amplification parameters had been identified using Taq polymerase, PCR was 
performed using Pfx polymerase under the same condition with reaction volumes as 
listed in table 2.5. The cPXR 1.5 kb proximal promoter region was amplified using Taq 
polymerase under the same reaction conditions as those listed in table 2.6, except for an 
annealing temperature o f 57 °C.
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Table 2.4: Volumes used for Taq polymerase for PCR
Reagent Volume (pi) Worldng concentration
Taq polymerase (5 U/pl) 1 0.2 U/pl
Primers 1 (of 1:1 primer pair mix) 2 pmoL/pl
dNTPs (10 mM) 0.5 0.2 mM
Buffer (1 OX) 2.5 IX
MgCb (25 mM) 1.5 1.5 mM
DNA 200 ng 8 ng/pl
Nuclease-free water Make up reaction volume to 25 pi
Table 2.5: Volumes used for Ppc polymerase PCR
Reagent Volume (pi) W orking concentration
Pfx DNA polymerase (2.5 U/pl) 1 0.05 U/pl
Primers 1 (of 1:1 primer pair mix) 1 pmol/pl
dNTPs (10 mM) 1.5 0.3 mM
Buffer (1 OX) 5 IX
MgS0 4  (50 mM) 1 1 mM
DNA 200 ng 8 ng/pl
Nuclease-free water Make up reaction volume to 50 pi
Table 2.6: Cycle parameters for Pfx polymerase PCR amplification of rat PXR
Temperature (®C) Time (secs) Cycles
94 300 1
94 15 35
60 30 35
68 60 35
72 600 1
2.2.1.4 Agarose gel electrophoresis
Standard 1 % (w/v) agarose gels were prepared in IX TAB (0.04 M Tris acetate, 0.01 M 
EDTA pH 8.3) containing 0.5 pg/ml ethidium bromide. Samples were mixed with 5X 
loading dye (50 % glycerol and 1 % w/v Orange G dye) and then loaded onto the gel 
alongside an appropriate molecular weight marker. The gel was run at 4-5 volts/cm at
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room temperature until sufficient separation had been achieved, and then bands were 
visualised under UV illumination. Photographic records were taken using the Gene 
Genius Bio Imaging System, controlled by GeneSnap version 4.01 software (Syngene). 
UV visualisation will result in damaged DNA due to formation of thymine dimmers, 
and hence reduced cloning efficiencies; therefore, all samples requiring gel purification 
prior to cloning were separated on agarose containing 10 mg/ml crystal violet instead of 
ethidium bromide, as this can be visualised under normal light.
2.2.1.5 DNA purification from agarose gels
DNA from the band corresponding to the correct size was gel purified using a QIAGEN 
QIAquick Gel Extraction Kit, according to the manufacturer’s instmctions. Briefly, the 
band was cut from gel with a scalpel, and heated at 50 °C in buffer QG, (solubilisation 
buffer, contains guanidine thiocyanate a powerful protein dénaturant) to melt the gel. 
This solution contains a pH indicator to allow optimum binding (pH 5). The pH needs 
to be less than 7.5 and is characterised by a yellow colour. This solution was then 
passed through an affinity column with a silica membrane. DNA binds to the silica 
membrane in the presence o f high salt. Traces o f agarose were removed by another 
wash with buffer QG and centrifugation. Salts were removed by washing with buffer PE 
containing ethanol, and purified DNA was eluted under basic conditions and low salt 
concentrations using 50jiil H2O.
2.2.1.6 DNA quantification
DNA was quantified using a Nanodrop ND-1000 spectrophotometer (Nanodrop 
Technologies, USA) An absorbance value o f 1 at 260 nm coiTelates to 50 pg/ml o f 
double stranded DNA or 40 pg/ml single stranded RNA. The spectrophotometer also 
provided an estimate of the purity o f DNA or RNA with respect to contaminants that 
absorb in the UV, such as proteins or buffer components. This estimate is in the form o f 
the ratio between the absorbance readings at 260 nm and 280 nm (A260 / A280), with an 
acceptable ratio being in the range 1.8 to 2.0.
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2.2.1.7 Phenol chloroform extraction and ethanol precipitation
DNA was diluted to a volume o f 100 pi using IX TE buffer and then phenol-chloroform 
extraction was performed to remove contaminant (e.g. DNA modifying enzymes, salt). 
One volume of phenol chloroform (1:1 v/v) was added and the solution was mixed by 
vortexing for one minute. The phases were then separated by centrifugation at 
15,700 xg for 5 minutes and the aqueous layer removed to a fresh tube. The DNA was 
ethanol concentrated by the addition of three volumes o f absolute ethanol (stored at -20 
°C), 0,1 volume 3 M sodium acetate, and 1 pi tRNA (10 mg/ml). The DNA was 
centrifuged for 15 minutes at 15,700 xg; the ethanol decanted, and then centrifuged for a 
further 5 minutes at 15,700 xg. The remaining ethanol was aspirated from the DNA 
pellet which was allowed to air dry for 10 minutes at room temperature, before 
resuspension in 10 pi TE buffer. DNA was stored at -20 °C until required.
2.2.2 Cloning
2.2.2.1 Ligation
As successful cloning requires a molar excess of insert DNA to vector DNA, the 
relative concentrations o f each was determined prior to cloning. One microlitre of 
purified insert DNA together with 1 pi vector DNA were separated on a 1 % agarose gel 
to estimate the ratio o f their concentrations. The volumes used for ligation are shown in 
table 2.7, producing a ligation mixture with vector-insert ratios o f approximately 1:3. 
These ligations were incubated at 16 °C overnight.
Table 2.7: Volumes used for ligation into SEAP Basic vector
Reagent PXR (pi) Negative control (pi)
Linearised vector 
DNA insert
I OX ligation buffer (with ATP) 
T4 DNA ligase (3U/pI)
Sterile water
IX
3X
1
0.5
Make up reaction volume to 10 pi
IX
0
1
0.5
Make up reaction volume to 10 pi
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2.2.1.2 Transformation into bacteria
Cloned were transformed into competent TOP 10 E.Coli using the Invitrogen One Shot 
Transformation Kit, as instructed by the manufacturer’s technical manual. A 50 pi 
Aliquot of cells was thawed on ice, and 2 pi o f the ligation reaction or unligated, but 
digested, plasmid (as a negative control) were added to the cells and incubated on ice 
for 30 minutes. This was then heat shocked for 45 seconds at 42 °C, and allowed to 
recover on ice for 2 minutes. Next, 250 pi LB-Broth (5 g o f tryptone, 2.5 g yeast 
extract, 5 g NaCl, in 500 ml o f water) were added and incubated with shaking (225 rpm) 
at 37 °C for 1 hour. The transformed cells were then spread out onto an LB-Agar (as 
LB-Broth but with 7.5 g o f Agar added) plate containing 50 pg/ml and incubated at 
37 °C overnight.
2.1.2.3 Rapid screening of recombinant plasmids
Overnight colonies for LB-Agar plates were picked off and cultured in 5 ml LB-Broth 
containing ampicillin (50 pg/ml) at 37 °C overnight with shaking. Rapid screening of 
colonies was carried out using phenol-chloroform lysis. Sixty microlitres o f culture 
medium was vortexed with an equal volume of phenol chloroform (1:1 v/v) together 
with 10 pi loading dye; this was vortexed briefly and centrifuged at 15,700 xg for one 
minute, to separate the phase containing proteins (bottom) from the phase containing 
nucleic acids (top). Twenty microlitres of the top phase was separated by 
electrophoresis on a 1 % agarose gel, and the presence o f an insert confirmed by 
comparison to blanlc vector DNA marker.
2.2.2.4 Minipreparation of plasmids
High quality DNA preparations were performed using the QIAGEN Miniprep Kit; an 
affinity column system, based on alkaline lysis o f bacterial cells followed by adsorption 
o f DNA onto silica in the presence o f high salt. The protocol was followed as detailed in 
the manufacturer’s technical manual. Briefly, after overnight culture of the required 
plasmid in LB-broth (37 °C with shaking), 2 ml o f culture was centrifuged and the pellet 
resuspended in 250 pi o f lysis buffer PI. 250 pi o f buffer P2 were added and mixed by
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inversion 8 times until the solution became clear and viscous. After addition of 350 pi 
o f buffer P3 a white, fluffy precipitate formed containing genomic DNA, proteins and 
cellular debris. The tube was centrifuged for 10 minutes at 16,060 xg and the 
supernatant containing the plasmid DNA was transferred to a QIAprep column and 
centrifijged for a further 1 minute at 16,060 xg. The flow-through volume was 
discarded and the column was washed with 500 pi o f buffer PB which removes trace 
nuclease activity from the sample. The column was then washed with 750 pi buffer PE; 
after 1 minute incubation, the column was centrifuged for 1 minute twice to remove any 
residual ethanol. Thirty to 50 pi buffer EB (10 mM Tris Cl, pH 8.5) was applied to the 
column, placed in a clean tube, and centrifuged for 1 minute at 10,000 xg. The yield was 
increased by leaving the column incubating for at least 1 minute at room temperature 
prior to the elution step
2.2.2.S Endofree maxipreparation
Transfection experiments demand larger quantities of DNA, which are free of 
endotoxins as this may reduce transfection efficiency, and hence endofree DNA 
maxipreparation is required. One hundred microlitres o f overnight culture of the 
required plasmid in LB-broth was used to inoculate 250 ml o f LB-Broth containing 50 
pg/ml ampicillin, and left in shaker at 37 °C overnight. The culture was centrifuged at 
6000 xg at 4 °C for 15 minutes, and then lysed with buffer PI (as part o f the kit). Buffer 
P2 was added (10 ml) and was mixed gently by inversion and left for 5 minutes at room 
temperature. Chilled buffer P3 was added, and the mixture poured into a QIAfilter 
Cartridge, and left for 10 minutes. The lysate was filtered into a 50 ml tube, and the 
bacterial endotoxins were removed by adding 2.5 ml of buffer ER added and incubated 
on ice for a further 45 minutes. After equilibrating the QIAGEN-tip with 10 ml o f buffer 
QBT, the lysate was applied and allowed to enter by gravity flow. The column was 
washed with 2x 30 ml of buffer QC. The DNA was eluted with 15 ml o f buffer QN and 
precipitated with 10.5 ml o f isopropanol and centrifuged after mixing at 15,000 xg at 4 
”C for 30 minutes. The supernatant was removed carefiilly and pellet was washed with 5 
ml o f endotoxin-free, room temperature 70% ethanol, and centrifuged at 15,000 xg for 
10 minutes. The pellet was dried and redissolved in 500 pi endotoxin-free buffer TE.
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2.2.2.6 Diagnostic restriction digest
The integrity of the plasmids and the size o f the insert were confimied by double 
digestion; the screening was performed by choosing one enzyme cutting within the 
insert at the 5’ or 3’ edge o f the insert (rPXR: Acc65I; cPXR: Hindlll) and the other 
cutting within the body o of the SEAP vector (Xbal). Restiiction digests were perfoimed 
on empty vectors as a negative control. DNA was digested for one hour in the 
appropriate buffer and at the right temperature (37 °C unless otherwise stated); 
however, if  the two enzymes were not 100 % efficient in the same buffer, the digestion 
time was extended. The volumes used and enzymes selected are shown in table 2.8.
Table 2.8: Volumes used for diagnostic digest
Component Volume (pi)
DNA 2
Acc65I / Hindlll 1
Xbal 1
Buffer 2
Water Make up reaction volume to 20 pi
2.2.3 DNA sequencing
All inserts were confiimed by DNA sequencing. The sequencing method used was the 
“Termination reaction”, with the primers used being the 5’ and 3’ multiple cloning site 
SEAP primers. The SEAP 5’ primer sequence was CTAGCAAAATAGGCTGTCCC; 
the 3 ’ primer sequence was CCTCGGCTGCCTCGCGGTTCC. Plasmids were 
sequenced from 250 ng DNA per reaction using a CEQ 2000XL DNA system 
(Beckman Coulter) by Dr K. Plant. Four different fluorescent dye labels were 
incorporated into extended DNA products using 3’ dye-labelled dideoxynucleotide 
triphosphates, products separated by capillary electrophoresis and detected by 
fluorescence emission. Sequence identity to the target sequence was then confinned by 
interrogating the chimpanzee and rat genomes using the BLAST algorithm 
(www.ncbi.nlm.nih.gov/BLAST).
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2.2.4 Cell based techniques
2.2.4.1 Culture conditions
2.2.4.1.1 Huh? cell culture
The human hepatoma cell line Huh? (a gift from Dr Steve Hood, GlaxoSmithKline UK) 
was cultured in 15 ml Dubelcco’s modified Eagle medium (DMEM; with phenol red 
and L-Glutamine) supplemented with 10 %(v/v) foetal bovine serum, 1 % (v/v) non- 
essential amino acids, 100 U/ml penicillin and 100 pg/ml streptomycin.
2.2.4.1.2 FaO cell culture
The rat hepatoma cell line FaO (ECACC No. 89042701, Porton Down, UK) was 
cultured in Dulbecco's Modified Eagle Medium: F-12 Nutrient Mixture (D-MEM/F-12 
1:1 Mixture; with phenol red, L-glutamine and 15 mM HEPES) supplemented with 
10 % (v/v) foetal bovine serum, 1 % (v/v) non-essential amino acids and 100 pg/ml 
gentamycin.
2.2.4.2 Charcoal treatment of foetal bovine serum
Foetal bovine serum (FBS) was pre-tieated with dextran coated charcoal (DCC) to 
remove steroid and hormonal contaminants, which otherwise could affect the 
assessment o f induction of the PXR gene. Briefly, 500 mg activated charcoal and 
50 mg dextran T70 were added to 500 ml FBS and the mixture stirred for 30 minutes. 
The charcoal was pelleted by centrifugation at 1,500 xg for 15 minutes, after which the 
supernatant was passed through a 0.45 pm filter to remove any remaining particles. To 
ensure cell culture sterility, the resultant DCC-treated serum was filter sterilised under 
vacuum through a 0.22 pm filter.
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2.2.4.3 General cell maintenance
Cells were standardly cultured in 75 cm^ vented flasks in 5 % CO2 at 37 °C, and 
passaged every four days, or when they reached about 80 % confluency. The medium 
was removed by aspiration and the cells were washed with 10 ml PBS, before addition 
o f 2 ml trypsin-EDTA. The flask was rocked gently and then incubated at 37 °C until 
the cells had detached from the flask surface and formed single-cell groupings. The 
protease activity was inhibited by the addition o f 6 ml of medium. The cell suspension 
was divided into 4 flasks and fresh medium added to a volume of 15 ml.
2.2.4.4 Recovery of cells from liquid nitrogen
Cells in 91 % FBS and 9 % DMSO were stored in liquid nitrogen. When required, a 
cryovial (approximately 10  ^ cells) was thawed at 37 °C for 2 minutes, transferred into 
20 ml o f appropriate medium, then centrifuged at 1000 xg for 5 minutes. The pellet was 
resuspended into 10 ml o f fi'esh medium, and put into a 25 cm^ vented flask. The 
medium was replaced after 24 hours to remove any dead cells; once the remaining cells 
had reached 80 % confluency, they were sub-cultured into a 75 cm^ vented flask.
2.2.4.S Counting of the cells
A flask o f confluent cells was trypsinised and the cells resuspended in 8 ml o f fresh 
medium. An improved neubauer haemocytometer was covered with a cover glass; a few 
drops from the cell suspension were applied to the edge of the cover glass until the 
counting surface was covered by capillary flow. Cells within the large, outlined square 
(0.1 mm^) were counted manually and multiplied by 10,000, to give the concentiation in 
cells/ml.
2.2.4.6 Cell seeding
A flask of cells reaching 80 % confluency was trypsinised as described in section 
2.2.4.3 and counted using a haemocytometer. The cells were diluted and seeded in 
either 96-well or 6-well tissue culture plates at 10,000 cells/ml (lOOpl /well or 2.5 ml
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/well, respectively). When seeding in 96-well plates, the outside wells were not used 
because o f potential evaporation of medium from these wells which could cause 
variation in results (Dr V. Bombail, personal communication)', instead, these wells were 
filled with PBS (100 pl/well). The plate was incubated at 37 °C overnight (in a 
humidified chamber to prevent media evaporation) to allow cell attachment.
2.2.4.7 Xenobiotic treatment
All xenobiotic experiments were performed in cells within passage 5 to passage 14 from 
receipt; this was to maintain a stable phenotype as cells outside this window respond 
enatically to classical inducers, or even not at all. This suggests that as the cells age 
their phenotype changes, possibly due to the loss in expression o f putative transcription 
factor and nuclear receptors involved in the xenobiotic response. When the cells were 
approximately 80 % confluent, transfection/growth medium was removed and replaced 
with fresh medium containing xenobiotic (as shown in table 2.9) or vehicle (DMSO). 
Dosing was carried out for 48 hours in at least triplicate for each data point. All dose 
solutions were prepared fresh for each experiment to prevent compound degradation 
through repeat freeze-thaw cycles. Stock solutions o f compound were lOOOx the 
working concentration in 100 % vehicle; hence, the final concentration o f vehicle in all 
experiments was 0.1 %.
Table 2.9: Concentrations of xenobiotics used in dosing experiments
Xenobiotic Concentration (pM)
Perfluorodecanoic acid 1 ,5 , 10, 50, 100 and 250
Rifampicin 0 .1 ,1 ,5 ,1 0 , 50 and 100
Dexamethasone 0.1, 1 ,5 , 10, 50 and 100
Clotrimazole 0.1, 1 ,5 , 10, 25 and 50
Pregnenolone 16a-carbonitrile 0.1, 1, 5 ,10 , 50 and 100
Hyperforin 0.01 ,0 .05 ,0 .1 ,0 .5 , 1 and 2.5
Hydrocortisone 50
Phénobarbital 50
Clofibric acid 50
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2.2.4.S Transient transfection protocol for reporter gene assay
2.2.4.8.1 Plasmids
The basic vector SEAP (secretory alkaline phosphatase) was used as a negative control, 
with all the test inserts being cloned into this vector. Expression plasmids for liver- 
enriched transcription factors (HNF 3p and 4a) and ligand-activated receptors (VDR, 
PFARa, RXRa and GRa,) were used for co-transfection assays as indicated.
2.2.4.8.2 Huh7 cell transfection
DNA was introduced into Huh7 cells using the multi-component lipid-based 
transfection reagent Fugene 6 (Roche). The positive charge contributed by the cationic 
lipid component exceed the negative charge contributed by the DNA, thus produces a 
net positive charge on the lipid-DNA complex, which facilitates the interaction o f the 
complex with the negatively charged cell surface. A Fugene/DNA charge ratio o f 6:2 
was used; Fugene (0.3 pl/well) was first added to a sterile tube containing the required 
amount of serum free medium, and then DNA was added and left to incubate for 30 
minutes. DNA transfections were performed when cells in each well o f the 96-well 
plate were between 50 and 80 % confluent. The transfection mixture (100 pl/well) was 
added to the seeded cells without prior removal o f existing growth medium, and the 
plate incubated at 37 °C overnight. For basal expression experiments, cells were 
incubated 48 hours and then SEAP activity determined.
2.2.4.8.3 FaO cell transfection
Transfast (Promega) is another cationic liposomal transfection reagent that interacts 
with negatively charged DNA to form stable complexes. The method outlined in the 
manufacturer’s technical manual was followed to successfully transfect the FaO cell 
line. A Transfast/DNA charge ratio o f 9:1 was used; DNA (0.25 pg/well) was first 
added to a sterile tube containing the required amount of serum free medium, and then 
Transfast was added and left to incubate at room temperature for 15 minutes. The 
growth medium was removed from each well and replaced with 40 pi of the transfection
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mixture. The plate was then incubated at 37 °C for 1 hour, after which time, the cells in 
each well, were overlaid with 80 pi serum-containing medium, and incubated overnight.
2.2.4.S.4 Cotransfection of expression plasmids
The total amount o f DNA per well remained the same for all cotransfection 
experiments, 75% of which reporter construct DNA. For single cotransfections (e.g. 
HNF4a), the cotransfected plasmid contributed the remaining 25 % to the total DNA 
input. Whereas, in multiple cotransfection experiments (e.g. PPARa and RXRa), each 
cotransfected plasmid contributed 12.5 % to the total input of DNA. Figure 2.1 
illustrates the steps involved in each transfection and SEAP assay.
Figure 2.1; Methodology for transient transfection and SEAP assay
Transfection 
reagent + D +/- Expression plasmid Q
24 hours
SEAP
assay
SEAP secretion 
into growth 
medium
+/- Xenobiotic
48 hours Hepatoma cell
Cells were plated into 96-well plates and incubated overnight. Transfection reagent and DNA were added 
to serum free media, and left to incubate at room temperature for at least 30 minutes. When using 
Fugene, 100 pi o f  the mixture was added to each well ; i f  using Transfast, 40 pi o f mixture was added, 
which was overlaid with 80 pi complete media after incubating at 37 °C for 1 hour. Cells were incubated 
at 37 °C until SEAP assay was performed.
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2.2.4.8.S Detection of SEAP reporter activity
Following 48 hours incubation time, medium was removed from the cells, and assayed 
for the amoimt o f alkaline phosphatase secreted by the cells using a chemiluminescent 
alkaline phosphatase assay (Aurora kit, MP Biomedical). The protocol in the 
manufacturer’s technical manual was scaled down and adapted as follows. 10 pi of 
medium was diluted with 18 pi of IX dilution buffer in a 96-well optiplate (polystyrene 
microplate) and incubated for one hour at 65 °C to destroy any endogenous alkaline 
phosphatase activity. The plate was then incubated on ice for 2 minutes and left to 
reach room temperature for about 15 minutes. Twenty four microlitres o f assay buffer 
was added and the samples were left at room temperature for a further 5 minutes. 
Twenty-four microlitres o f reaction buffer (containing the substrate CSPD disodiumS- 
(4-methoxyspiro [ 1,2-dioxetane-3,2 ’ -(5 ’ -chloro)tricyclo(3.3.1.1 )decan -4-yl)phenyl 
phosphate.]) were then added and left at room temperature for 20 minutes. The action of 
SEAP on the substrate, which emits light at 477 nm, was measured using a Lumicount 
plate reader (Packard).
2.2.5 Generation of PXR proximal promoter deletion constructs
1500 bp o f the rat PXR proximal promoter was amplified from rat genomic DNA as 
described in section 2.2.1.3, which was used as a template for the generation of seven 
daughter constructs. PCR was carried out using nested primers, which contained 
restriction sites that allowed for direct ligation into the SEAP basic vector. Table 2.10 
shows the primers used to amplify the fragments, amplicon length and the introduced 
restriction sites. The fragments underwent preparation for ligation into the SEAP basic 
vector as described in sections 2.2.15 and 2.2.17.
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Table 2.10: Primers used to generate deletion constructs
The mutated nucleotides are indicated in bold
Length
(bp)
Sense primer Antisense primer Enzymes to generate 
insert
1428
Acc65I
5 ’-gatcatggtacctatcacagcaac-3 ’
HindlllT5 ’-gaaactaagcttgttcttgccc-3 ’ Acc65I + Hindlll
1343
Acc65IT5 ’-ggagatggtacctctggtctacc-3 ’
Hindlll
▼5 ’-gaaactaagcttgttcttgccc-3 ’ Acc65I + Hindlll
1170
Acc65I
5 ’-tcgaatggtaccaaggatgctga-3 ’
Hindlll▼5 ’ -gaaactaagcttgttcttgccc-3 ’ Acc65I + Hindlll
830
Acc65IT5 ’ -tcctctggtaccttcctaacttg-3 ’
Hindlll 
5 ’-gaaactaagcttgttcttgccc-3 ’ Acc65I +Hindlll
634
Acc65I▼5 ’-agtgctggtacctccctaacttg-3 ’
Hindlllr5 ’-gaaactaagcttgttcttgccc-3 ’ Acc651 + Hindlll
239
Acc65IV5 ’-agacacggtacctccagtgg-3 ’
Hindlll 
5 ’-gaaactaagcttgttcttgccc-3 ’ Acc65I + Hindlll
198
Bglll
5 ’ -gagggcagatcttggcccagaa-3 ’
Hindlll 
5 ’ -gaaactaagcttgttcttgccc-3 ’ Bglll + Hindlll
2.2.6 Site-directed mutagenesis
PCR with primers containing a unique restriction site within the SEAP-PXR construct, 
were used for the mutation o f the HNF4a and HNFSp sites within the proximal 240 bp 
promoter. For each site, two sets of primers were designed, which mutated three bases 
within the core element o f the consensus sequence. One set amplified the fragment 
upstream of the putative HNF binding site on the PXR promoter, while the other set 
amplified the region downstream of this site. The adopted strategy, exemplified by the 
-60 bp HNF4a site, is shown in figure 2.2. The primer sequences and the restriction 
sites introduced to disrupt the putative HNF response elements are shown in table 2.11.
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Table 2.11: Primer sequences for PXR promoter HNF mutants
The mutated nucleotides are indicated in bold
HNF site and 
location
Fragments Sequence Tn,(°C)
Downstream
Sense
S^el
5’-GCTGGAACTAGTACTTAGGA-3’ 40.5
HNF4a (-60 bp) Antisense 5’-TGTAGTCATCTGGGTACTCA-3’ 41.9
Upstream
Sense 5 ’-AGTGGACTCTTGTTCCAAAC-3 ’ 45.4
Antisense
Spel
5 ’-CTAAGTACTAGTTCCAGCACCT-3 ’ 44.6
Downstream
Sense
NsilT5 ’-AGAGTATGCATGGTAATTCTG-3 ’ 41.4
HNF3P (-97 bp) Antisense 5 ’-TGTAGTCATCTGGGTACTC A-3 ’ 41.9
Upstream
Sense 5 ’-AAAACTTG ATTAGGGTG ATG-3 ’ 43.5
Antisense
Nsil▼
5’-TTACCATGCATACTCTTGTT-3’ 42.1
Downstream
Sense
A^al
5 ’-TCCAGTGGGCCCAGCACCCTCAG-3 ’ 67.8
HNF4a (-233bp) Antisense 5 ’-TGGCCAGGGGTATCTCAGGCCCC-3’ 67.4
Upstream
Sense 5 ’-ACCTGACGCGCCCTGTAGCG-3 ’ 61.9
Antisense
Apal
5 ’-GGTGCTGGGCCCACTGGAGGTA-3 ’ 63.8
The sense primer of the downstream fragment was designed to overlap with the 
antisense primer of the upstream fragment. When the PCR products were digested with 
the appropriate restriction enzyme, compatible ends were produced allowing both 
products to be ligated. These were used as templates to amplify the PXR promoter 
using nested primers, giving fragment lengths o f 198 bp and 239 bp (see table 2.10). 
The forward primer contained a restriction site for the Acc65I/BglII cutting site and the
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reverse primer contained a HindlII site', digestion with both enzymes allowed for direct 
cloning into SEAP.
Figure 2.2: Site-directed mutagenesis strategy for rat PXR -60 bp HNF4a mutation
HNF40
J PXR SEAP
Sense Antisense
< -
Sense Antisense
A
Spel
Upstream fragment Downstream fragment
A unique restriction site was generated within the HNF4a site for the enzyme Spel. PCR was performed 
using the 198 bp construct as a template; the upstream and downstream fragment products were then 
ligated and used as template for a second round of PCR using nested primers. The resulting fragment was 
digested and ligated into the SEAP Basic vector.
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2.2.7 Messenger RNA transcript analysis
2.2.7.1 Total RNA extraction
Following 48 hours incubation time, total RNA extraction was carried out using the 
QIAGEN RNeasy Miniprep Kit, an affinity column based system, according to the 
manufacturer’s instructions. Cells were first tiypsinised as described in section 2.2.4.3, 
followed by lysis and homogenisation in the presence of a highly denaturing guanidine 
isothiocyanate (GITC)-containing buffer, which immediately inactivates RNases to 
ensure isolation o f intact RNA. Ethanol is added to provide appropriate binding 
conditions, and the sample is then applied to an RNeasy mini column where the total 
RNA binds to the membrane and contaminants are efficiently washed away. High- 
integrity RNA is then eluted in 50 pi RNase-ffee water.
Human total RNA (Stratagene) was supplied at a concentration o f 950 ng/pl, and had 
been extracted from a liver of a single adult male donor aged 45 years. The site of liver 
resection was the normal margin to trabecellar carcinoma. Rat total RNA was extracted 
from male 240 g Wistar rat liver using the QIAGEN RNeasy Miniprep Kit, according to 
the manufacturer’s recommendations.
2.2.7.2 Measurement of RNA integrity
Five microlitres of total RNA extract was combined with 5X loading dye and visualised 
on a 1 % agarose gel. The RNA was considered good quality if  the ribosomal bands 
were sharp with the 28 s ribosomal band appearing approximately twice as intense as 
the 18 s RNA band. If  the ribosomal bands appeared as a smear o f smaller sized RNAs, 
the extracted RNA was likely to have suffered degradation duiing preparation; in this 
case, the RNA extraction would be repeated. High molecular weight bands were 
considered a sign of DNA contamination; which would be removed by DNase treatment 
prior to cDNA synthesis.
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1.2 J 3  RNA quantification
In order to obtain reliable results from real time quantitative PCR, the amount of RNA 
used needs to be accurately deteimined. High sensitivity RNA quantification was 
performed using the RiboGreen RNA Quantification Kit (Invitrogen, USA), according 
to the manufacturer’s instructions. Briefly, IX  TE buffer was used to prepare a dilution 
series o f ribosomal RNA ranging from 1000 ng/ml to 15.62 ng/ml, and also used to 
dilute unknown RNA samples 2,000 fold. One hundred microlitres o f each RNA 
standard and unlmown sample were aliquotted onto a 96-well plate. Care was taken to 
ensure that the fluorescent RiboGreen dye was fully defrosted before diluting 200 fold 
with IX TE buffer, and also to protect from photodegeneration. One hundred 
microlitres of diluted probe was added to each well and the plate was mixed. The 
fluorescence was measured using the Gemini XS and SOFTMax Pro software 
(Molecular Devices, USA). Sample concentrations were calculated using the standard 
curve and accounting for dilution factors.
2.2.7.4 cDNA synthesis
2.2.7.4.1 DNase treatm ent
Total RNA extracts were treated with DNase I prior to cDNA synthesis to remove any 
genomic DNA contamination. One microgram of each total RNA sample was 
aliquotted, and if  required, made up to 8 pi with nuclease-free water. One microlitre 
each of RNase-free DNase and lOX buffer were added, and the sample was incubated at 
37 °C for 30 minutes. The reaction was teiminated by addition o f 1 pi 20 mM EGTA, 
pH 8.0 ‘stop buffer’ and incubation at 65 °C for ten minutes, to inactivate the DNase.
2.2.7.4.2 cDNA synthesis
Invitrogen Superscript First-strand Synthesis System for RT-PCR was used to 
synthesise cDNA. The manufacturer’s protocol was followed with some minor 
changes. 1.5 pi 0.5 mg/ml Oligo (dT)i5 primer and 1.5 pi lOmM dNTPs were added to 
each DNase treated total RNA sample. The volume in each tube was made up to 15 pi
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by addition o f 1 pi nuclease-free water, and the mixture was incubated at 65 °C for five 
minutes, and then allowed to cool on ice for at least two minutes. Bulk buffer mix was 
prepared using volumes from the table 2.12 and 5 pi was added to each sample and 
carefully mixed. The efficacy o f the DNase treatment was deteimined through the 
random selection of six RNA samples for cDNA synthesis in the absence o f Superscript 
II RNase H- reverse transcriptase. Samples were incubated at 42 °C for 50 minutes, 
followed by incubation at 70 °C for 15 minutes. After which time they were placed on 
ice prior to the addition o f 80 pi nuclease-free water, giving a total volume o f 100 pi at 
approximate cDNA concentration o f 1 pg/100 pi or 10 pg/ml. Samples were stored at 
-20 °C.
1.1.1.S Real time quantitative R T-PC R  (TaqM an)
2.2.7.5.1 P rim er and probe design and optimisation
Specific primers and probes sets for human PXR, rat PXR and multi-species (human, rat 
and mouse) GAPDH were designed using Primer Express (Applied Biosystems, Foster 
City, CA, USA), following the guidelines in table 2.13; the probe was carefully 
designed against a single exon o f PXR mRNA, ensuring that the sequence does not 
cross an exon-intron boundary, allowing the use of a genomic DNA standard curve to 
quantify copy number. Primer and probe sequences are shown in table 2.14.
Table 2.12: Reagent volumes for cDNA synthesis bulk mix
Component Volume per RNA sample (pi)
0.1 M DTT 2
RNase OUT RNase inhibitor 1
Nuclease-free water 1.75
Superscript™ II RNase H- reverse transcriptase (200 U/pl) 0.25
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Unmodified oligonucleotide primers and the 5 ’-fiuoroscently-labelled probe were 
diluted in nuclease-ffee water to working concentrations of 10 pM and 5 pM, 
respectively, and stored at -20 °C.
Table 2.13: Design parameters for cDNA primers and probes
Primer
Tm 58-60 °C 
20-80 % GC 
9-40 bases in length
Less than 2 °C difference in Tm between the two primers 
A maximum o f two G/C at the 3’ end
Probe
Tm 10 °C higher than the primer Tm
20-80 % GC
9-40 bases in length
No G on 5 ’ end
Less than four contiguous G’s
Must not contain more G’s than C’s
Amplicon
50-150 base pairs in length
The 3 ’ end o f  the primer should be as close to the probe as possible
Table 2.14: TaqMan primer and probe sequences
Target Forward primer Reverse primer Probe
hPXR
rPXR
GAPDH
5 ’-cgagctccgcagcatca 
5 ’ -tcttctccccagatcgccc 
5 ’-caaggtcatccatgacaactttg
5 ’ -tgtatgtcctggatgcgca 
5 ’ -caaatcgctcctgcagctg 
5 ’ -gggccatccacagtcttctg
5 ’-tgctcagcacacccagcggct 
5 ’-tctaccacgctacgttgaaccacgcc 
5 ’ -accacagtccatgccatcactgcca
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2.2.7.S.2 Genomic DNA standards
Human genomic DNA (Promega) was supplied at a concentration o f 169.4 ng/pl, which 
according to the theory shown in section 9.2, contains 1.14 x lO*’ single strands per pg. 
The genomic DNA was sheared by passing through a 21 gauge needle 10 to 20 times 
and diluted accordingly with nuclease-free water to provide a standard containing 1 x 
10  ^single stand copies/ 5 pi. The 1x10^ standard was used to prepare 1 x lO"^ , 1x10^,  
1 X 10  ^ and 1 x 10^  standards through serial dilution of 20 pi of the higher 
concentration standard in 180 pi nuclease-free water, producing a 1:10 dilution. Rat 
genomic DNA (Promega) was supplied at a concentration of 285 ng/pl, and therefore 
contained 1.4 x 10  ^single stranded copies per pg.
2.2.7.S.3 Real time quantitative polymerase chain reaction
For each TaqMan reaction plate, a bulk mix was prepared using the volumes in table 
2.15; 20 pi o f which were added into each well of a 96-well optical reaction plate 
(ABgene, UK) along with 5 pi o f the prepared cDNA sample or 5 pi of the appropriate 
genomic DNA standard in duplicate.
Table 2.15: Reagent volumes for TaqMan reactions
pi per well pi per 96-well plate
Forward primer (10 pM) 1 1 1 0
Reverse primer (10 pM) 1 1 1 0
Probe (5 pM) 0.5 55
Nuclease-ffee water 5 550
TaqMan Universal PCR Mastermix 12.5 137
Five microlitres o f nuclease-free water was added as a buffer blank. Contents o f the 
reaction plate were mixed and the plate was firmly sealed with an optical adhesive cover 
(ABgene, UK). The plate was centrifuged at 200 xg for 30 seconds to collect reaction 
mixture, and loaded into the ABI Prism 7000HT Sequence Detection System (Applied
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Biosystems, USA). Reaction conditions were as stated in table 2.16, following the 
molecular mechanism outlined in figure 2.3.
Table 2.16: Thermal cycler conditions for TaqMan RT-PCR
Stage Temperature (®C) Time Cycles
1 50 2  mins 1
2 95 1 0  mins 1
95 15 secs3 4060 I mill
Upon reaction completion, analysis was performed using the ABI Prism software; the 
relative fluorescent emission threshold was adjusted to within the exponential phase of 
the standard curves, and baseline set from cycle 2 to the cycle (highest standard Ct 
value minus 3). This analysis provides Ct values and uses the standard curve to 
calculate the copies o f RNA per well from these values. Data were normalised to copy 
numbers o f the ubiquitously transcribed glucose 3-phosphate dehydrogenase (GAPDH) 
gene.
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Figure 2.3: Molecular basis of TaqMan RT-PCR
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When the probe is intact, the proximity o f  the reporter dye (R) at the 5 ’ end to the quencher dye (Q) at the 
3’end, results in suppression o f reporter fluorescence. During PCR, if  the target is present, the probe is 
cleaved and an increase in fluorescence is detected.
2.3 Statistical analysis
The results obtained from xenobiotic induction were analysed for significant differences 
using a two-way ANOVA with BonfeiToni all means post hoc test. A one-way 
ANOVA with the same statistical test was adopted for all other data sets (GraphPad 
Prism Software version 4.00, San Diego, CA, USA).
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3. Species differences in the level of PXR ligand activation: an 
in silico analysis
3.1 Introduction
Species differences in PXR ligand activation have been well documented, which are 
most strikingly exemplified by responses to the antiglucocorticoid PCN and the 
macrolide antibiotic rifampicin (Lehmann et al. 1998; Jones et al. 2000; Savas et al. 
2000; Chrencik et al. 2005). Whereas PCN was an effective activator of mouse and rat 
PXR, it had much less activity on the rabbit and human receptors. Conversely, 
rifampicin activated human and rabbit PXR but had virtually no activity on the mouse 
and rat PXR. Other compounds which exhibit a human-specific activation profile 
include the anti-depressant hyperforin and the cholesterol-lowering drug SRI2813. 
This phenomenon has been termed ‘directed promiscuity’, to reflect the fact that each 
species’ PXR is promiscuous only in a specific subset of xenobiotic and endogenous 
compounds (Watkins et al. 2001). Over the past few years, many efforts have been 
made to understand the stmctural basis o f PXR ‘directed promiscuity’, which ultimately 
may aid in the development o f animal models that better predict PXR activation and 
dmg-dmg interactions in humans.
Ciystal structures of human PXR LED have been reported in its apo (unliganded) state, 
as well as with small drug-like and herbal ligands (e.g. SRI2813 and hyperforin), and 
the large macrolide ligand rifampicin (Watkins et al. 2002; Watkins et al. 2003a; 
Watkins et al. 2003b; Chrencik et al. 2005); in addition, the crystal structure of the 
human PXR in complex with the endogenous ligand, 17(3 estradiol was recently 
reported (Xue et al. 2007). These structures have revealed that human PXR contains an 
expansive and stmcturally conformable ligand binding pocket that is capable of 
changing in shape in order to accommodate ligands of distinct sizes and structure 
(Chrencik et al. 2005). Furthermore, it has also been noted that the PXR LED deviates 
more significantly in sequence across species relative to other nuclear receptors (Jones 
et al. 2000), which would suggest that ligand binding properties o f this nuclear receptor
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will also vary more across evolution compared to other members o f the nuclear receptor 
superfamily. However, a crystal stmcture of PXR from non-human species has not 
been reported to date; this would provide invaluable information o f how this PXR 
interacts with ligand and hence, allow visual comparison of the PXRs from two 
different species. In the absence of these data, site-directed mutagenesis studies have 
identified the critical amino acid residues within the ligand binding pockets o f human 
and rodent PXR which confer species-specific receptor activation (Ostberg et al. 2002; 
Tirona et al. 2004).
On my part, in order to investigate this phenomenon, the initial investigation involved 
three in silico studies o f ligand binding domains (LBDs) from diverse species. Through 
the use o f in silico analysis it is possible to identify amino acids within the LED which 
confer the species-specific responsiveness o f the receptor. Furthermore, the availability 
o f online phylogeny software provides the means of visualising the effect o f the amino 
acid substitutions that have occurred within the PXR LED thi'oughout the coui'se of 
evolution. Moreover, the use of molecular modelling enables the prediction of the 
quaternary structure o f PXRs from species for which there are no crystallographic or 
NMR structural data available. Therefore, in the absence o f a non-human PXR LED 
crystal stmcture, this will provide preliminary evidence for a stmctural rationale behind 
the observed species differences in receptor activation.
3.2 Identification of the PXR LED amino acid sequence
The full-length amino acid sequence o f PXR of several species are freely available from 
the ExPASy (the Expert Protein Analysis System) world wide web sei-ver (Gasteiger et 
al. 2003). The regions corresponding to the Icnown human ligand binding domain were 
identified for six species, as presented in table 3.1.
78
Table 3.1: Amino acid residues of LED within PXR from diverse species
Species Accession number LED amino acid positions
Human 075469 205-434
Rhesus monlcey Q8SQ01 205-434
Dog Q8SQ02 100-329
Rabbit Q9TU02 182-411
Rat Q9R1A7 202-430
Mouse 054915 202-431
3.2.1 Multiple sequence alignments of PXR LED
Multiple sequence alignment analyses alloAv for structural, functional, and evolutionary 
inferences to be made. Traditionally, the alignments have been used to identify 
characteristic motifs and consei*ved regions within protein families, evolutionary 
conservation among proteins, and to improve secondary and/or tertiary structure 
predictions. Furthermore, they can identify critical amino acid residues that play 
important stmctural and functional roles, thus pointing to potential candidates for 
mutagenesis studies (Fielden et al. 2002). Comparison of LED sequences using the 
alignment tool Dialign (http://bibiserv.techfak.uni-bielefeld.de/dialign/) (Morgenstern 
2004), identified two sub-groups within the residues that have been previously been 
shown to be directly involved in ligand binding, as presented in figure 3.1. Collectively, 
the two groups o f amino acids have been previously identified in several studies by 
others, whom have either reported crystal structures of the human PXR LED, or have 
performed site-directed mutagenesis studies. In figure 3.1, residues can be divided 
according to their conservation across the species; those which are the evolutionally 
conserved were highlighted in blue; whereas, residues which differed between primates 
and lower mammals were highlighted in red.
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3.3 Phylogeny of PXR between species
In an effort to understand the evolution and hence biological function o f PXR, a 
phylogenetic tree o f the six species’ LBD sequences together with the amino acid 
sequence o f the zebrafish PXR LBD was constructed using the PHYLIP software 
package (http://evolution.genetics.washington.edu/phylip.html) (Felsenstein 1985). 
Zebrafish PXR was selected to be an ‘out-group’ as bony fish are the evolutionally most 
distant organisms from mammals from which PXR genes have been cloned (Krasowsld 
et al. 2005). Out-groups serve to sei*ve root the phylogenetic tree, which provide a 
reference for polarising the historical changes to the amino acid sequence across 
evolutionary time (Graham et al. 2002). From the data presented in figure 3.2, it can be 
seen that the divergence o f the rat and mouse PXRs from human PXR occurred far 
earlier in evolutionaiy time than did the divergence o f the higher mammal species fiom 
human PXR. Both these findings are not surprising however, as primates and rodents 
diverged from the human lineage approximately 5.5 and 40 million years ago, 
respectively (Kumar and Hedges 1998).
Figure 3.2: Phylogenetic tree showing evolutionary changes of amino acids in the 
PXR ligand binding domain
Zebrafish
Hunan
Monkey
Rabbit
Mouse
Based on the LBD sequence o f each receptor, the phylogenetic relationships o f the seven PXR receptors 
were derived from the distance matrix method. Zebrafish PXR was designated as the out-group, and 
served as a root to the tree.
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3.4 Comparative modelling of PXR from different species
The Protein Data Bank (PDB; http://www.pdb.org/) is a repository for three- 
dimensional protein structures containing over 13,000 structures including human PXR 
in both its unliganded state and also when bound to ligand (rifampicin, SR12813 and 
hyperforin) (Westbrook et al, 2003). However, in most instances the three-dimensional 
structure o f a protein o f interest is unknown, which is true for the remaining five species 
under investigation in this study. Experimentally determining the structure o f a target 
protein either by X-ray crystallography or nuclear magnetic resonance (NMR) can be 
challenging; whereas, computational molecular modelling is relatively easy, which 
enables investigators to analyse predicted 3D stiuctures of a target protein in the 
absence o f crystallographic or NMR stmctural data. Computational molecular 
modelling is a technique that predicts the 3D stmcture o f a protein based primarily on a 
sequence alignment to one or more proteins o f known stmcture. Molecular modelling 
theory assumes there are a limited number o f native folds a protein can adopt, and the 
fold adopted depends on the primary stmcture (i.e. sequence) o f the protein. If  an 
appropriate stmcture is known, it can be used as a template to build a model (Fielden et 
al. 2002). The starting point is the amino acid sequence; using the sequential data, the 
first step is a secondary stmcture prediction. The resulting secondary stmcture is then 
converted into a three-dimensional geometry. The resulting tertiary stmcture is 
optimised by energy minimalisation, which repairs distorted geometries by moving 
atoms to release internal constraints.
Using Swiss-Model (http://swissmodel.expasy.org) (Schwede et al. 2003), three crystal 
stmctures o f human PXR were used (apo- and when in complex with SRI 2813 and 
SR12813/SRC-1) to constmct 3D models from the full length amino acid sequence of 
the rhesus monkey, dog, rabbit, rat and mouse PXRs. After energy minimalisation with 
the GROMOS 43B1 force field, each of these models was further validated using 
Procheck (http://biotech.ebi.ac.uk:8400/) (Laskowski et al. 1993); a program which 
evaluates in silico models using a number o f stereochemical and spatial characteristics. 
An overall average G factor value was calculated, which represents a carefully weighted 
average o f all the analyses perfoimed on the 3D structure such as torsion angles and 
covalent geometry. Each amino acid residue within the structure was measured for
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peptide bond torsion angles and main chain bond lengths and angles; when applied to a 
given residue, a low G-factor indicated that the property corresponds to a low- 
probability conformation. If a protein had a low overall average G factor value (less 
than -0.5), it was regarded as poor and not biologically viable. The results of these 
analyses are presented in figure 3.3, which shows that all five models were biologically 
viable.
Figure 3.3: Procheck analyses of modelled PXR structures
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The biological viability o f each modelled PXR was determined by full geometric analysis o f the 
stereochemical properties at a resolution o f 3 Angstroms. For comparison, the analysis o f the human apo- 
PXR crystal structure analysis is also presented.
3.5 Quantitative characterisation of each PXR ligand binding pocket
The modelled PXR structures were characterised using the online resource CASTp 
(Computed Atlas o f Surface Topography o f proteins; http://cast.engr.uic.edu) (Dundas 
et al. 2006), which provides the means o f locating, delineating and measuring concave 
surface regions on 3D protein structures. O f particular importance to this study is its 
ability to identify all pockets and cavities o f a protein and measure their volume and 
area analytically. In addition, the number, area and circumference of the mouth 
openings for each pocket are also measured. For each PXR structure, the largest cavity
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was selected as the ligand binding pocket, as previous analysis by others has revealed a 
general trend that ligand binding sites tend to involve the largest pocket on the protein 
(Liang et al. 1998).
Previous analysis o f the crystal structure of the human apo-PXR ligand binding pocket 
showed that it was 1294 Â in volume (Watkins et al. 2003b), which is similar to the 
result obtained from using CASTp (-1500 A); as shown in figure 3.4a. In contrast, the 
volume o f the human CAR LED was much smaller (675 A), reflecting its lack o f novel 
sequence motifs that allow the flexible expansion o f the PXR pocket (Xu et al. 2004). 
The volume of the PXR ligand binding pockets of rhesus monlcey, dog and human were 
all very similar, which is reflective of the high amino acid similarity shared between the 
LBDs of receptors. Rodent and rabbit PXR ligand binding pockets were slightly larger, 
which consistent with the greater period since divergence for these species compared to 
higher mammals under study herein. There is greater variability between in the mouth 
circumferences of the ligand binding pockets; the mouths of rodent PXR pockets were 
much larger than those o f higher mammals, which suggest that this gives ligand 
molecules greater access to the binding site. Taken together, these results suggest that 
there are considerable differences in the geometries of the ligand binding pockets of 
rodent PXRs and PXR in higher mammals, which may account for the species-specific 
xenobiotic activation profiles described herein.
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Figure 3.4: Measurement of binding site geometry of each modelled PXR LBD
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The ligand binding pocket geometry o f each modelled PXR LBD was analysed by CASTp using a solvent 
probe o f 1.4 Â. For comparison, the analysis o f the human apo-PXR is also presented. All measurements 
are given as molecular surface (Connelly’s surface). Analysis o f the (a) ligand binding pocket is presented 
as the sum o f the volume enclosed by o f the wall o f atoms o f the pocket; published data for the human 
CAR LBD (Xu et al. 2004) are included for comparison. Analysis o f the (b) mouth opening o f the pocket 
is presented as the total sum o f the circumference o f all the mouth openings o f the pocket.
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3.6 Discussion
3.6.1 Species-specific PXR activation is partly attributed by changes in residues 
lining the ligand binding domain pocket
The ligand binding cavity o f human PXR is largely hydrophobic and is lined by 28 
amino acid residues, o f which eight are polar and capable of forming hydrogen bonds 
with ligands (Watkins et al. 2001). O f these, there are six amino acid side chains that are 
consistently involved in ligand binding in all PXR LBD structures determined to date: 
three polar residues (Ser-247, Gln-285 and His-407) and three hydrophobic residues 
(Met-243, Trp-299 and Phe-420) (Watkins et al. 2001; Watkins et al. 2003a; Watkins et 
al. 2003b; Chrencik et al. 2005). The directed promiscuity exhibited by the different 
species o f PXR may be attributed partly to changes in these binding residues. For 
example, the residues Gln-285, His-407 and Met-243 are not conserved in mouse PXR, 
which exhibits no or minimal activity with SR12813, hyperforin or rifampicin (Orans et 
al. 2005). Furthermore, numerous single-site mutations have been introduced to into the 
LBD of human and rat PXR, with varying effects on transactivation. For instance, 
rifampicin and hyperforin sensitivity was conferred to rat PXR when Phe-305 was 
converted to leucine, whereas attenuation of sensitivity was observed when Leu-308 of 
human PXR was replaced with phenylalanine (Tirona et al. 2004). Similarly, mutation 
o f Pro-205 to serine in the mouse PXR LBD resulted in reduced responsiveness to PCN 
(Chrencik et al. 2005).
The effect of these different amino acid compositions of the ligand binding pockets was 
realised upon alignment o f the LBD sequences of the PXR family members, which 
revealed that they have diverged through evolution. Differences in diet were originally 
thought to be the driving force for PXR’s directed promiscuity; however, it has recently 
been hypothesised however, that bile acids served as evolutionary ligands. As PXR 
species specificity for bile salts has paralleled the increasing complexity of the bile salt 
synthetic pathway during vertebrate evolution (Krasowski et al. 2005), it has been 
proposed that they drove the receptor’s increasing degree o f promiscuity over time.
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3.6.2 PXR ligand binding pockets exhibit complex geometries
Comparison of PXR LBD from diverse species in terms of the sizes of the ligand 
binding pocket and of their month openings identified further differences which may 
account for species-specific xenobiotic activation o f PXR. The critical difference 
between human PXR and the rodent PXRs is the predicted size o f the mouth opening to 
the ligand binding pocket; the total mouth circumferences o f the rodent PXRs were 
significantly larger that of human PXR; in contrast, the mouth opening to the ligand 
binding pocket of rabbit PXRs were similar in size to that o f human PXR. Taken 
together, these data suggest that the amino acid sequence of the LBD confers ligand 
specificity, but the larger mouth volume/circumference of rat and mouse PXR 
represents the ability of these lower species to handle large molecules and/or new 
chemicals, which may prove advantageous as rodents tend to live in ‘dirtier’ 
environments than higher mammals. Larger ligand binding pockets might also suggest 
that they could accommodate multiple ligands at once, as has been suggested for 
CYPSAs (Yano et al. 2004).
The accuracy of a comparative model is related to the percentage sequence similarity on 
which it is based, coiTelated to the relationship between the structural and sequence 
similarity of two proteins. Hence, high-accuracy comparative models are obtained 
when more than 50 % sequence identity exists between receptors and the modelling 
target (Baker and Sali 2001). As the PXR LBDs of the species of interest share at least 
76 % amino acid similarity with human PXR, one would expect veiy accurate models. 
However, the human PXR LBD contains regions of mobility which have been observed 
to change position to enhance contacts with distinctly shaped ligands; for instance, the 
ligand binding pocket is capable o f expanding fi*om 1280 Â (Watkins et al. 2003b) in 
volume in the SR12813 complex to more than 1600 Â in other structures (Watkins et 
al. 2003b; Chrencik et al. 2005). Consequently, modelling based upon a single PXR 
crystal structure will provide information on the expected conformation o f other PXR 
LBDs under similar conditions; it will not, however, provide information on how 
flexible each LBD is and whether they too share the ability o f the human PXR to 
increase its volume by 25 % to accommodate certain ligands. An interesting further 
approach would be to model PXR LBDs based upon the PXR; SR I2813 crystal
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structure and examine if  successful models could be built; such an approach would 
suggest if  PXR LBDs from other species also share the potential to increase their 
volume so dramatically.
3.7 Conclusion
The directed promiscuity of PXR may be attributed to both the spatial geometry of the 
ligand binding pocket and the amino acid residues lining the walls o f the pocket. 
Whereas the shape and size o f the ligand binding pocket markedly alter across species, 
the biological significance of this is not currently clear. However, the contribution 
made by this variation in pocket shape/size of pocket to the species-specific 
responsiveness of PXR to ligand is most probably limited compared to the effect that 
key amino acid substitutions can have on receptor activation.
4. Species differences in PXR transcriptional expression
4.1 Introduction
Several studies have shown that the expression of PXR is drastically altered at the 
transcriptional level by certain xenobiotics as well as certain physiological conditions. 
Reduction o f PXR gene expression has mainly been observed following exposure to 
inflammatory stimuli; for instance, the levels o f PXR mRNA are rapidly decreased in 
rats treated with the endotoxin lipopolysaccharide (Fang et al. 2004). In addition, in 
human hepatocytes, the pro-inflammatoiy cytokine interleukin-6 has been shown to 
markedly reduce the levels of PXR mRNA, which in turn, reduced the induction of 
PXR-regulated genes such as CYP3A4 (Pascussi et al. 2000c). In contrast to 
suppression, several chemicals have been shown to markedly increase PXR expression. 
In primary human hepatocytes, for example, dexamethasone increases the mRNA for 
both PXR and RXRa (Pascussi et al. 2000a). Further examples in rodents have been 
reported; in mice treated with the antiglucocorticoid PCN, for example, the level of 
PXR was significantly increased (Maglich et al. 2002). Similarly in rats, PXR mRNA 
levels were markedly increased following treatment with a variety o f chemicals 
including two non-CYP3A inducers, isoniazid and perfluorodecanoic acid (PFDA) 
(Zhang et al. 1999). An interesting point to take from these findings is that the 
endogenous compounds appear to have a repressive effect whereas the xenobiotics have 
an inductive effect on the expression o f PXR mRNA transcripts.
Whereas these findings are extremely interesting they do not provide mechanistic 
rationales behind the observed effects. In general, studies are made at the transcript or 
protein level and hence, cannot distinguish transcriptional effects fi*om post- 
transcriptional events such as mRNA stabilisation. To further such studies, we have 
examined the effect of xenobiotics on the expression of PXR mRNA in both human and 
rat cell lines using TaqMan.
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4.2 Basal PXR mRNA expression
Total RNA was extracted from adult human liver and adult rat liver in addition to 
untreated Huh? and FaO cells, and used to synthesise cDNA as described in sections
2.2.7.1 to 2.2.7.4. TaqMan reactions were performed using primers and probes for 
human and rat PXR as described in section 2.2.7.5. Absolute mRNA levels, expressed 
as copies detected per nanogram of total RNA of these receptors are shown in figure 
4.1. Significant differences in the basal level o f mRNA expression were observed, in 
which PXR was expressed at a 4.5-fold and 3-fold greater level in rat liver than in the 
FaO cell line and human liver, respectively. A similar pattern is evident for human 
PXR, in which the level of in vivo expression was 3-fold greater than the in vitro 
expression level.
Figure 4.1: Absolute basal expression levels of human and rat PXR in hepatocytes 
and respective cell lines
600-1 * * * ***
5 0 0 -
4 0 0 -
3 0 0 -
2 0 0 -
c  1 0 0 -
Values are given as mean copies o f PXR mRNA detected per nanogram of total RNA after normalisation 
to GAPDH. Error bars represent the SEM for three biological repeats (n=3). Significance PXR mRNA 
expression was calculated by a one way ANOVA with Bonferroni all means post hoc test where 
*=p<0.05, ***=p< 0.001.
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4.3 The effects of xenobiotics on human and rat PXR mRNA levels
4.3.1 Pilot study: The effect of various xenobiotics on human and rat PXR mRNA 
expression
To examine the ability of hepatoma cell lines to support xenobiotic-mediated activation 
of PXR gene expression in vitro^ we next examined the levels of human PXR and rat 
PXR expression after treatment with eight different compounds. This broad range was 
selected because it included both known and unloiown inducers of PXR gene 
expression; collectively however, they share little chemical structure similarity, as 
shown in figui'e 4.2.
Figure 4.2: Chemical structures of compounds used in this study
*Only used in reporter gene assay experiments (Chapter six)
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As can be seen in figure 4.3, induction profiles were dissimilar for human and rat PXR 
gene expression in response to the chemicals. In the human cell system, significantly 
increased transcript levels were only achieved with clotrimazole. In contrast, both 
rifampicin and PCN produced significant increases in PXR transcript levels in the rat 
cell line FaO; 25pM clotrimazole also appeared to have some effect in this cell line, 
eliciting a 4-foId increase that neared statistical significance.
Figure 4.3: Human and rat PXR mRNA expression levels in respective cell lines 
after treatment with various xenobiotics
a) Huh? cell line 
6-1
b) FaO cell line
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PXR mRNA expression in (a) Huh? and (b) FaO cell lines following 48 hours exposure to 100 pM 
perfluorodecanoic acid (PFDA), 50 pM dexamethasone (Dex), 50 pM hydrocortisone (Hyd), 25 pM 
clotrimazole (Clot), 50 pM phénobarbital (PB), 50 pM rifampicin (Rif), 50 pM pregnenolone 16a- 
carbonitrile (PCN) or 50 pM clofibric acid (Clofib). Values are given as fold induction over DM SO 
vehicle control, after GAPDH normalisation. For each data point n=3. Interexperimental variation was 
less than 25 %, with the exception o f the clotrimazole induction in Huh? cells which was 35 %. 
Significant difference in PXR mRNA expression levels in each set o f drug treated cells compared to 
expression levels in cells treated with DMSG control was calculated by a one way ANOVA with 
Bonferroni all means post hoc test where *=p<0.05, ***=p<0.001.
On the basis of the results presented in figure 4.3, plus current literature, a selection of 
these eight compounds was next studied over a wide concentration range to further 
characterise any alterations in PXR transcript levels.
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54.3.2 The effect of perfluorodecanoic acid on PXR expression
Perfluorodecanoic acid (PFDA) is a member o f a group of xenobiotic compounds 
named peroxisome proliferators, which are a large class o f structurally diverse 
industrial and pharmaceutical chemicals with little obvious similarity except for the 
presence of a carboxylic acid, and an aromatic ring or aliphatic chain (Boujrad et al.
2000). PFDA is a hypolipidaemic agent which acts as a ligand o f the nuclear 
peroxisome-proliferator-activated receptor-a (PPARa) and transcriptionally regulates a 
wide variety o f lipid metabolising enzymes, including CYP4A (Vanden Heuvel 1996). 
It has previously been shown to cause a 10-fold increase in the accumulation o f PXR 
mRNA in rats in vivo (Zhang et al. 1999).
Figure 4.4: Human and rat PXR mRNA expression levels after treatment with 
perfluorodecanoic acid
a) Huh? cell line
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PXR mRNA expression in (a) Huh? and (b) FaO cell lines following 48 hours exposure to 1 -  250 pM 
perfluorodecanoic acid. Values are given as fold induction over DMSG vehicle control, after GAPDH 
normalisation. For each data point n=3. Interexperimental variation was less than 25 %. Significant 
difference in PXR mRNA expression levels in each set o f drug treated cells compared to expression 
levels in cells treated with DMSG control was calculated by a two way ANGVA with Bonferroni all 
means post hoc test where *=p<0.05, ***=p<0.001.
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In agreement with the findings o f Zhang et al., a statistically significant increase in PXR 
transcript levels was achieved following 48 hours exposure of FaO cells to 100 pM 
PFDA. As seen in figure 4.4b, no effect was elicited at 50 pM, although a previously 
unreported significant repression was obsei*ved in response to 10 pM and 250 pM 
PFDA concentrations; the latter probably due to cellular toxicity. Contrary to these 
results, there were no significant increases in human PXR mRNA expression for all the 
drug concentrations tested.
4.3.3 The effect of dexamethasone on PXR expression
Dexamethasone is a synthetic glucocorticoid used therapeutically in many, mainly 
inflammatory and autoimmune conditions. It is also given to cancer patients 
undergoing chemotherapy; to counteract certain side-effects of their anti-tumour 
treatment. It has been shown to activate the transcription of CYP3A genes via 
activation of both the glucocorticoid receptor and the pregnane X receptor in a dose- 
dependent manner (Huss and Kasper 2000). 100 pM dexamethasone has previously 
been shown to be a potent inducer o f human PXR mRNA expression in primary human 
hepatocytes, ranging from 2.3- to a 6-fold increase, depending on the hepatocyte donor 
(Pascussi et al. 2000a). It has also been shown to elicit a moderate increase in 
accumulation of rPXR mRNA in vivo (1- to 3-fold) (Zhang et al. 1999). While we 
were able to reproduce the observed increase in rat PXR transcript levels in the rat cell 
line, no statistically significant increase in human PXR was observed in Huh? cells 
following exposure to dexamethasone (Figure 4.5). Interestingly, both the profile for 
dexamethasone-mediated rat PXR levels appears to exhibit a biphasic response, in that 
concentrations at the extremes o f the concentration range result in the greatest PXR 
expression. This biphasic response appears to be robust, being reproducible on at least 
three independent occasions.
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Figure 4.5: Human and rat PXR mRNA expression levels after treatment with 
dexamethasone
a) Huh? cell line 
6-1
FaO cell line
Concentration (^M) Concentration
PXR mRNA expression in (a) Huh? and (b) FaO cell lines following 48 hours exposure to 0.1 -  100 pM 
dexamethasone. Values are given as fold induction over DMSG vehicle control, after GAPDH 
normalisation. For each data point n=3. Interexperimental variation was less than 25 %. Significant 
difference in PXR mRNA expression levels in each set o f drug treated cells compared to expression 
levels in cells treated with DMSG control was calculated by a two way ANGVA with Bonferroni all 
means post hoc test where **=p<0 .0 1 , ***=p<0 .0 0 1 .
4.3.4 The effect of clotrimazole on PXR expression
Clotrimazole is an antimycotic imidazole derivative widely used for the treatment of 
yeast infections and its fungistatic action has been attributed to the inhibition of sterol 
14a-demethylase, a microsomal cytochrome P450-dependent enzyme (Snajdrova et al. 
1998). Clotrimazole has been shown to be a potent activator of human PXR in vitro 
(Luo et al. 2002) and a moderate inducer of human PXR mRNA (2.5-fold) at 25 pM 
concentration (Teng et al. 2003). In rats, clotrimazole has been shown to be an 
efficacious inducer of CYP3A23 mRNA in rats in vivo (Hostetler et al. 1989); however, 
induction of rat PXR mRNA has not been reported to-date.
95
Figure 4.6: Human and rat PXR mRNA expression levels after treatment with 
clotrimazole
a) Huh? cell line
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PXR mRNA expression in (a) Huh? and (b) FaO cell lines following 48 hours exposure to 0.1 -  50 pM 
clotrimazole. Values are given as fold induction over DMSG vehicle control, after GAPDH 
normalisation. For each data point n=3. Interexperimental variation was less than 25 %, with the 
exception of the 25 pM clotrimazole induction in Huh? cells which was 30 %. Significant difference in 
PXR mRNA expression levels in each set o f  drug treated cells compared to expression levels in cells 
treated with DMSG control was calculated by a two way ANGVA with Bonferroni all means post hoc test 
where *=p<0.05, **=p<0.01, ***=p<0.001, n.d.=not detectable.
The results presented in figure 4.6 are in agreement with these findings of Teng et al., 
with a 25 pM concentration o f clotrimazole eliciting a significant 5-fold increase in 
human PXR mRNA expression. At the next highest dose, 50 pM, no significant effect 
was observed, although this may have been due to a cytotoxic effect of the chemical, as 
very little RNA was extracted from the cells. However, a cytotoxicity assay, such as 
LDH secretion would need to be undertaken to confirm this. Clotrimazole elicited little 
effect in rat PXR transcript levels throughout the concentration range used; although 
some points reached statistical significance, the low fold changes observed (<2-fold) 
are probably biologically silent.
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4.3.5 The effect of rifampicin on PXR expression
Rifampicin is a semisynthetic derivative of the rifamycins, a class of macrolide 
antibiotics which are now in wide clinical use and have proved especially effective in 
the treatment of tuberculosis (Wehrli 1983) and opportunistic infections caused by the 
use o f immunosuppressant drugs such as cyclosporin A. However, such concomitant 
use can be dangerous as many studies have shown that rifampicin to be a potent 
CYP3A4 inducer, potentially resulting in drug-drug interactions with coadministered 
drugs, including cyclosporin A. Rifampicin is a known to be an efficacious activator of 
human PXR, through which it in turn induces CYP3A4 expression, but it is only a 
weak activator of rat PXR (Lehmann et al. 1998). However, the induction of human 
and rat PXR mRNAs by rifampicin in vitro has not been reported to date.
Figure 4.7: Human and rat PXR mRNA expression levels after treatment with 
rifampicin
a) Huh? cell line 
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PXR mRNA expression in (a) Huh? and (b) FaO cell lines following 48 hours exposure to 0.1 -  100 pM 
rifampicin. Values are given as fold induction over DMSG vehicle control, after GAPDH normalisation. 
For each data point n=3. Interexperimental variation was less than 25 %, with the exception o f 50 pM 
rifampicin induction in FaG cells which was 30%. Significant difference in PXR mRNA expression 
levels in each set o f drug treated cells compared to expression levels in cells treated with DMSG control 
was calculated by a two way ANGVA with Bonferroni all means post hoc test where *=p<0.05,
**=p<0.01, ***=p<0.001.
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The data presented in figure 4.7 shows a marked species difference in PXR transcript 
levels in response to rifampicin. A statistically significant minimum 4-fold induction of 
PXR transcript levels was observed for 5 pM, 50 pM and 100 pM concentrations of 
rifampicin in the rat cell line, with maximal induction (5-fold) elicited by 5pM of dmg.
4.4 Discussion
4.4.1 Real Time PCR Methodology
Real time quantitative RT-PCR (TaqMan) was selected to study the effects of 
xenobiotics on PXR expression because it offered a rapid, reliable accurate, specific and 
very sensitive technique, able to detect mRNA levels even at very low copy numbers 
(Heid et al. 1996) However, there are disadvantages associated with the technique; the 
instrumentation and reagents are expensive and the design o f the fiuorogenic probes is 
complicated. In addition to these problems, the substantial sensitivity o f the system 
amplifies even the slightest error in the preparation of the cDNA sample.
Huh? and FaO cells were dosed in triplicate for 48 hours with xenobiotic and total RNA 
was subsequently extracted, and these tiiplicate samples were used for the TaqMan 
reactions. This may have introduced experimental errors, since each sample was only 
measured once, rather than in triplicate, and more replicates may have made some of the 
trends observed significant. However, Taqman has been shown to be highly 
reproducible and so the lack of the tiiplicate measurements should not adversely affect 
the accuracy of the results to any great degree (Yin et al. 2001).
All the primer/ probe sets used for RT-PCR analysis were designed to amplify the major 
PXR transcript produced from each species; however, they do not distinguish between 
alternatively spliced transcripts. This is presently not an issue for rat PXR, as only a 
single transcript has been identified to date (Zhang et al. 1999); however, four human 
PXR mRNA splice variants have been identified in human liver (Lamba et al. 2004). 
Three o f the four transcripts are expressed in human liver, with PXR-1 being the
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predominantly expressed transcript (93 % o f PXR transcripts) for the liver samples 
analysed (Lamba et al. 2004). The relative transcript levels o f the three liver-expressed 
PXR variants in Huh? cells have not been investigated, and therefore, while it can be 
presumed that the PXR transcript levels reported herein reflect mainly the PXR-1 
variant, t]hiis cannot be stated absolutely, as PXR-1, PXR-2 and PXR-3 transcripts could 
have b6en detected in the RT-PCR assay. Although probably only o f minor relevance, 
such a possibility does represent an alternate explanation for the observed species 
difference described herein, which may not be detected in this assay.
4.4.2 Basal PXR mRNA expression
PXR was expressed at levels approximately 3-fold lower and 4-fold lower in Huh? and 
FaO cells relative to their respective in vivo liver levels; the result for human PXR 
expression is in agreement with previous findings from our lab, with the transcripts for 
several proteins involved in drug metabolism being expressed only at low levels 
(Phillips et al. 2005). Hepatoma cell lines are, by definition ‘stably transformed’, 
although several limitations in their use do exist. For example, cell lines exhibit 
significant alterations in higher chromatin order, a consequence of their transformation, 
and this has been shown to have a direct effect on the rate of gene expression (Plant 
2004). It has been observed that the chromatin conformation o f the human PXR 
promoter is relatively closed (Phillips et al. 2005), thus providing a potential 
explanation for the reduced basal expression in Huh? compared to in vivo tissue.
There was also a marked species difference between the level of PXR expression, both 
in vivo and in vitro. Rat PXR was basally expressed approximately 3-fold greater than 
human PXR in vivo and 2-fold greater in vitro, which maybe explained by chromatin 
conformation differences that exist between the PXR promoters o f these species, 
although no such reports exist to-date. Another plausible explanation would be 
differing levels of basic cellular processes (e.g. nutrient transport, metabolic capacity or 
xenobiotic transporter availability) that may exist between the cell lines. The low basal 
level of expression of PXR in the Huh? cell line therefore, may impact on the 
significance of any xenobiotic induction observed in the cell line. An alternative
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approach for looking at xenobiotic-mediated PXR induction would be the use of 
primary hepatocytes, which express PXR at a far greater copy number, therefore 
allowing for more significant increases in expression that would make species 
differences more evident.
4.4.3 The effect of xenobiotics on human and rat PXR mRNA levels
PXR receptor activation is of utmost importance to the phaimaceutical industry when 
developing a new drug. Dmgs that activate PXR have the potential to reduce the 
clinical efficacy o f more than one-half o f all other drugs that are coadministered, often 
with life-threatening consequences. This phenomenon is a particular problem in the era 
of polypharmacy, in which patients are often taking multiple medications at any one 
time. Groups particularly likely to receive multiple concomitant therapeutics include 
the elderly, those individuals with psychotic disorders, and sufferers o f complex disease 
states such as HIV infection (AIDS) and cancer (Plant and Gibson 2003). Ideally, new 
drugs should not activate PXR, or at least activate it to a minimum degree (Kliewer
2003); therefore it follows that they should not induce genomic activation o f PXR. As 
extrapolating data from studies utilising rodents has proven to be an unreasonable 
approach due to species-specificity o f xenobiotics response (Quattrochi and Guzelian
2001), the differences that exist between species for the xenobiotic induction of PXR 
expression need to be identified.
In this study, human and rat hepatoma cells were dosed for 48 hours with various 
xenobiotics, which was sufficient time for the drugs to be transported across the cell 
membrane, and for the cell to subsequently elicit a response to the chemical, and (in 
some cases) induce transcription of mRNA coding for PXR protein. The results of the 
initial pilot study together with the present literatuie identified four compounds that 
showed promise in identifying species differences in PXR induction which were 
investigated further through the generation o f dose-response profiles.
100
4.4.3.1 The effect of perfluorodecanoic acid on PXR expression
Perfluorodecanoic acid was a poor inducer o f PXR in both species, producing no 
significant induction in Huh? cells, and only induction at a single, high concentration in 
FaO cells and did not exhibit any species differences in mRNA expression. This was an 
unexpected as PFDA has been identified as an inducer of rodent PXR transcript levels 
in rat liver (Zhang et al. 1999) and human PXR in vitro through reporter gene studies 
(Dr S. Aouabdi, personal communication). The inductive effect in humans is likely to 
be mediated by a functional PPARa response element located in the first 2200 bp o f the 
human PXR proximal promoter, which has previously been shown to mediate activation 
of PXR gene expression by peroxisome proliferators (Aouabdi et al. 2006). By 
comparison, the lack o f rat PXR induction by PFDA suggests that the putative PPARa 
binding site identified in the proximal 1500 bp o f the rat PXR promoter is either non­
functional or an artefact o f the in silico screening process (Chapter five). This lack of 
correlation between in vitro genomic activation, in vitro reporter activation and in vivo 
data exemplifies the difficulty in extrapolating data from in vitro to in vivo, and across 
species. In this particular case, the rationale behind the lack of correlation is unknown, 
but is possibly due to altered transcription factor/ coregulator levels between in vivo and 
in vitro, meaning that chromatin conformation is not favourable for maximal activation 
of gene expression. In comparison, activation o f reporter genes is not modulated by 
chromatin, and hence, its activation should not be limited to the same degree by 
alteration in transcription factor/ coregulator profile; a hypothesis that will be examined 
further in chapter six.
4.4.3.2 The effect of dexamethasone on PXR expression
Dexamethasone was an efficacious inducer o f rat PXR but did not significantly increase 
the level of human PXR mRNA throughout the concentration range examined. 
However, both species exhibited a biphasic response to the glucocorticoid, albeit a more 
obvious one in the rat, a mechanism which has been reported in vitro for human 
(Pascussi et al. 2001) and rat CYP3A induction (Huss and Kasper 2000). Both groups 
identified the glucocorticoid receptor (GRa) and PXR as being involved in the induction 
of CYP3A mRNA in the human HepG2 and rat H4IIE cell lines, respectively. They
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concluded that the response to glucocorticoid is divided into two steps, one mediated by 
submicromolar glucocorticoid concentrations and the other triggered at higher 
concentrations. At low dexamethasone levels (0.1 pM), activation o f GRa causes an 
increase in cellular PXR and RXRa levels which, in turn are able to transactivate 
CYPSA in a xenobiotic-independent manner. The second stage of the mechanism 
involved direct activation o f PXR by high concentrations (>10 pM) o f PXR-specific 
ligands such as dexamethasone. This biphasic model may also apply to PXR mRNA 
induction in both species, whereby submicromolar concentration of dexamethasone 
activates GRa, which induces the expression o f PXR mRNA. Supramicromolar 
concentrations of dexamethasone then induce the second phase of PXR mRNA 
expression directly through both the activation of GRa and PXR. The decrease in 
transcript levels relative to the next highest/lowest concentration following exposure to 
10 pM dexamethasone suggests that at this concentration, some interference between 
the two response phases occurs, minimising the expression of the PXR gene; such a 
mechanism, sometimes called receptor squelching, is now becoming an accepted part of 
transcriptional regulation (Cahill et al. 1994)
The observed species difference in the absolute level of PXR mRNA expression is 
endorsed by the finding that FaO cells can support a larger induction o f dexamethasone- 
mediated CYP3A gene expression than HepG2 cells, which are another human 
hepatoma cell line (Swales et al. 2003). However, the results most probably reflect the 
low level of PXR expression within the Huh? cell line.
4.4.3.3 The effect of clotrimazole on PXR expression
Clotrimazole was a far better inducer o f human PXR than rat PXR mRNA expression, 
in that a significant increase in human PXR transcript levels was observed for the 25 
pM concentration. In addition to the ability o f clotrimazole to activate PXR (Moore et 
al. 2000b), and hence cause CYP3A4 induction via transcriptional activation; it has also 
been observed that clotrimazole seems to act via mRNA stabilisation, which also acts to 
increase the CYP3A4 transcript pool size (Hostetler et al. 1989). The large induction of 
PXR gene expression by clotrimazole shown herein could also be a combination of
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transcriptional activation o f the PXR gene and stabilisation of the resultant transcript. 
Such a hypothesis would need to be tested in two ways. First, the use o f a reporter gene 
assay, as reported in chapter six herein, or DNA run-on experiments could be used to 
prove transcriptional activation. Second, using actinomycin D, an inhibitor of 
transcription, in experiments would show whether or not clotrimazole influences the 
decay of PXR mRNA. If  clotrimazole decreases the degradation of PXR mRNA, then 
the increase in PXR transcript pool size in response to clotrimazole exposure would be 
shown to occur through stabilisation o f its mRNA. To further clarify if  this to be the 
case, one could monitor the accumulation o f PXR protein synthesis and compare it the 
level of PXR mRNA induced after treatment with clotrimazole. A disproportionately 
large increase in PXR protein relative to the rise in PXR mRNA, would suggest that the 
antimycotic acts via stabilisation of PXR mRNA.
4.4.3.4 The effect of rifampicin on PXR expression
Rifampicin has long since been regarded as a human-specific activator o f human 
CYP3A4, being only a weak activator o f rat CYP3A23; a species difference that has 
now been shown to be mediated by the species-specific activation of PXR (Wrighton et 
al. 1985). It has been shown that rifampicin is an efficacious activator of PXR in 
humans but only weakly activates rodent PXR (Lehmann et al. 1998). The induction 
profiles presented herein are therefore perplexing, suggesting that rifampicin is having 
an opposite effect at the genomic level than it is at the proteomic level. The results for 
human PXR mRNA expression are in agreement with others who have observed that 
rifampicin does not induce human PXR (Prof. P. Maurel, personal communication), and 
indeed this is consistent with the observation by this group that over-expression of 
human PXR produces a suppression of PXR reporter gene activation as opposed to a 
stimulation (Aouabdi et al. 2006). However, no group to date have reported rifampicin- 
mediated induction o f rat PXR. The rat PXR induction profile appears to be biphasic, in 
which low concentration (5 pM) and high concentration (50 pM) o f rifampicin both 
result in a large increase in PXR mRNA, which like the response to dexamethasone, 
suggests the involvement of another receptor. However, as only a single intermediate 
concentration (10 pM) was used it is difficult to ascertain whether two phases o f rat
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PXR mRNA induction do exist. Further experiments are obviously required to 
delineate the reason behind such an inductive response, and its implications at the whole 
animal level. Increased expression of PXR without a corresponding increase in ligand 
(as is the case in the rat study herein) may increase the pool o f unliganded PXR, 
potentially disrupting gene expression o f PXR target genes, and leading to unwanted 
biological effects such as disruption of cellular homeostasis.
4.5 Conclusion
Analysis o f PXR mRNA transcripts in vitro has identified marked differences between 
humans and rats, both at the basal level and in response to xenobiotic. The basal level of 
PXR expression in the cell lines is greater in the rat than in the human, which may 
reflect differences in the chromatin conformation of the PXR promoters. The low basal 
level of PXR expression in the Huh? cell line may therefore, impact on the significance 
any xenobiotic inductions observer in vitro. The four chemicals examined for their 
ability to increase PXR mRNA copy number produced varying results; for instance 
PFDA did not elicit any species differences in PXR expression, whereas clotrimazole 
was a far better inducer o f human than rat PXR. Dexamethasone and rifampicin both 
resulted in a biphasic induction profile o f rat PXR, although this was more prominent 
when dosing with dexamethasone. Both these results are indicative of the involvement 
o f another transcription factor, possibly the glucocorticoid receptor.
Further in vitro analysis is now required to investigate the mechanisms o f the described 
inductions, and identify any potential differences in the regulation of PXR expression 
between humans and other species.
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5. Comparative in silico analysis of putative binding sites 
within PXR proximal promoters
5.1 Introduction
My initial investigation into the potential differences in the regulation of PXR gene 
expression between human, primates and rodents involved in silico analysis o f the 
respective promoters. Computational methods of predicting transcription factor binding 
sites in DNA are very important for understanding the molecular mechanisms of gene 
regulation. Although the identification of a putative binding site within a promoter does 
not necessarily equate to biological function, it does however, provide a source o f well 
supported hypotheses for further experimental verification (Kel et al. 2003).
Although it has been well documented that the species-specific responses to certain 
compounds are in part, determined by differences in the amino acid composition o f the 
PXR ligand binding pocket, little work has been undertaken in comparing the regulatory 
mechanisms of PXR gene expression between species. The majority o f previous work 
has studied the different activation profiles of PXRs, and the target genes they interact 
with the promote transcription (Jones et al. 2000). However, another potential 
determinant o f a species-specific activation profile is the control o f the level o f PXR 
expression itself, which has not been fully investigated to date. The potential o f PXR to 
be regulated at the transcriptional level has been reported in both human and rodent 
models. Pascussi et al. first reported that in human hepatocytes, glucocorticoids are 
capable of producing an in vivo increase in the level o f several transcription factors 
including PXR, which in is in part mediated by GRa (Pascussi et al. 2000a). More 
recently, an extensive study o f the human proximal PXR promoter identified that 
PPARa mediates its activation of human PXR gene expression via a PPRE located 
within the PXR proximal promoter (Aouabdi et al. 2006). In comparison, research into 
the regulation of PXR gene expression o f other species has been limited to a handful of 
papers, such as that by Zhang et al., who reported in vivo increases in rat PXR mRNA 
levels following the administration o f several different compounds (Zhang et al. 1999).
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Furthermore, others have reported that the proximal PXR promoter in murine foetal 
cells contains a binding site for HNF4a in the first 100 base pairs (Kamiya et al. 2003). 
However, there have been no further studies on PXR proximal promoters of other 
species. There has certainly never been a bona fide  investigative comparison of the 
molecular mechanisms of regulation o f PXR gene expression in multiple species, such 
as in human, chimpanzee and rat, as described herein.
In order to fully investigate the regulation o f PXR gene expression, it was imperative to 
first correctly identify the PXR promoters in silico, and then identify putative 
transcription factor binding sites within these regions. The human PXR proximal 
promoter was previously identified and analysed by Dr Sihem Aouabdi; its 
characterisation therefore, will not be discussed further. The presentation o f the 
sequenced chimpanzee and rat genomes within the NCBI (National Centre for 
Biotechnology Information) database makes identification o f proximal promoter 
sequences relatively straightforward. Furthermore, online databases such as 
TRANSFAC and interrogation tools such as Matlnspector and Match provide a means 
o f identifying putative binding sites for transcription factors within promoter sequences. 
TRANSFAC is a database that collects data which are relevant for gene expression at 
the transcriptional level (Wingender et al. 1996) and provides information about 
genomic binding sites o f eukaryotic transcription factors and binding proteins 
(Heinemeyer et al. 1999). The TRANSFAC approach has already been used to detect a 
putative PPARa binding site in the human PXR promoter, which was subsequently 
shown to be functional (Aouabdi et al. 2006).
5.2 Identification of the proximal promoters
The proximal promoters o f chimpanzee and rat PXR were identified from the NCBI 
database using the following protocol. The complete mRNA reference sequence was 
identified (Chimpanzee: AF 454671; rat: NM 052980) and its corresponding position 
within the respective genome was located using the BLAST algorithm 
(http://www.ncbi.nlm.nih.gov/BLAST), or through previous genome annotation. The
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DNA region immediately upstream of the first exon was designated the PXR proximal 
promoter. The exact extent o f a promoter sequence is difficult to determine and 
whereas many of the most important elements are often contained within the first few 
hundred bases upstream o f the transcription start site, promoter regulatory elements in 
some genes have been identified several kilobases away. One method for looking for 
regions likely to be important is through the conservation o f these regions across 
evolutionary time. Whereas coding sequences may be largely retained across a large 
evolutionary gap, regulatory regions often diverge within tens o f millions o f years; 
hence an alignment o f the proximal promoter regions between primates and rodents 
should identify potentially important regulatory regions only.
Using the VISTA alignment program; http://genome.lbl.gov/vista/index.shtml (Mayor 
et al. 2000), approximately 10 kb o f DNA immediately upstream, together with the first 
exon o f the PXR genes from human, chimpanzee, mouse and rat were aligned. As can 
be seen from figure 5.1, over this large region human and chimpanzee show a large 
degree o f identity, which is not surprising given the small amount o f time (5.5 million 
years) since these two species diverged. By comparison, both rat and mouse sequences 
show very little conservation over this 10 kb non-coding region (40 million years since 
divergence from human lineage) (Kumar and Hedges 1998), and indeed there is even a 
large degree of divergence in the non-coding first exon. Figure 5.2 shows an enlarged 
section of the alignment, covering the approximate 1.5 kb upstream from the start o f the 
first exon; it can clearly be seen that in this region there is some identity between the 
rodent and human sequences, which reaches significance for the first 250 bp between 
human and rat sequences. On this basis it was decided to analyze the first 1500 bp 
immediately upstream of the putative transcription start site as this region is most likely 
to contain gene regulatory sequences.
107
Figure 5.1: Alignment of 10 kb DNA upstream and first exon of PXR genes of 
chimpanzee, mouse and rat against human PXR
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VISTA alignment o f the 10 kb DNA upstream and first exon o f (I) chimpanzee, (2) mouse and (3) rat 
PXR genes against human PXR. Peaks represent regions o f DNA which share identity with the human 
PXR gene. The exon DNA is presented in blue; DNA upstream o f the transcription start site is 
highlighted in pink.
Figure 5.2: Alignment of 1.5 kb DNA upstream and first exon of PXR genes of 
chimpanzee, mouse and rat against human PXR
I l l ' l l ------ 1------- 1 ' 1 1-----------r*
VISTA alignment o f the 1.5 kb DNA upstream and first exon o f (1) chimpanzee, (2) mouse and (3) rat 
PXR genes against human PXR. Peaks represent regions o f  DNA which share identity with the human 
PXR gene. The exon DNA is presented in blue; DNA upstream o f  the transcription start site is 
highlighted in pink.
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5.2.1 Putative binding sites
The matrix-based approach o f identifying putative transcription factor binding sites 
within DNA sequences was first presented by Quandt et aL, whereby the frequency of 
each nucleotide at each position within the response element is assigned a score (Quandt 
et al. 1995). Putative transcription factor binding sites were identified for the 1500 bp 
proximal promoter sequences o f chimpanzee and rat PXR, using Matlnspector and 
Match to interrogate the TRANSFAC database. The putative sites were identified using 
core and matrix similarities o f >0.80, which minimised missing true positive sites and 
also limited the identification o f false positive sites. The TRANSFAC database is 
essentially a huge matrix, which represents DNA binding profiles for individual or 
groups o f transcription factors (Wingender et al. 2000). The matrix similarity describes 
the quality o f a match between the matrix and the input sequence. The core similarity 
describes the quality of the match between the core sequence o f a matrix (the five most 
conserved positions within the matrix) and a part of the input sequence. The search for 
sites starts with only matches to the core region taken into consideration; the matrix 
similarity is then only calculated if  the core similarity reaches a pre-defined threshold 
(Quandt et al. 1995).
TRANSFAC analyses o f the chimpanzee and rat PXR promoters each identified several 
hundred putative transcription factor binding sites, which were then selected or 
discarded from the final map based upon the following criteria:
1. Accept sited identified by both Matlnspector and Match interrogations of 
TRANSFAC database.
2. Discard sites for transcription factors known not to be expressed in the liver, and 
accept sites which are known to be expressed in the liver.
Following the selection procedure, 30 and 33 putative binding sites were identified for 
the chimpanzee and rat promoters, respectively. These sites are presented in table 5.1, 
with their location in each PXR proximal promoters indicated in figures 5.3 
(chimpanzee) and 5.4 (rat). For comparison, figure 5.5 shows the sites in the 1500 bp 
DNA proximal to the human PXR previously identified by Aouabdi et al.
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The putative binding sites identified in all three gene promoters included those for 
general transcription factors such as the TATA binding protein, in addition to factors 
associated with the maintenance o f basal gene expression. Transcription factors 
identified in this collective included hepatic nuclear factors (H NFla, 3(3, 4a) CCAAT 
enhancer binding proteins (C/EBPa, (3), CCAAT, octamer binding protein, and chicken 
ovalbumin upstream promoter transcription factor (COUP-TF). A selection of putative 
binding sites for ligand-activated transcription factors was also identified. These 
included the famesoid X receptor (FXR), vitamin D receptor (VDR), peroxisome 
proliferator activated receptor (PPAR), glucocorticoid receptor (GR), and estrogen 
receptor (ER). However, certain transcription factor binding sites were not identified in 
all promoters examined; for instance, the chimpanzee promoter did not contain a 
putative binding site for the progesterone receptor nor the aiyl hydrocarbon receptor. 
Although these sites were not identified in the chimpanzee PXR promoter, it does not 
preclude their presence further upstream (>1500 bp) of the transcription start site. This 
is supported by the observation that a putative binding site for the aryl hydrocarbon 
receptor was identified further upstream than 1500 bp from the transcription start site of 
the human PXR gene (Aouabdi et al. 2006).
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5.3 Discussion
In most mammalian genes, the TATA box is found 29-32 bp upstream o f the 
transcription start site, and is central to the efficient attachment of RNA polymerase II 
and its associated factors (Ponjavic et al. 2006). A putative TATA box was located 
32 bp upstream o f the designated transcription start site of the chimpanzee PXR gene, 
which is within the expected area for high transcriptional specificity. This therefore 
increases my confidence in the assignment of this transcription start site.
In contrast, a putative TATA box was located 108 bp upstream of the designated 
transcription start site o f the rat PXR gene. Two possibilities exist: first that the site is 
an artefact o f the in silico screening process and therefore not a functional TATA box, 
or second that the TATA box is conect and the transcription start site is incorrect. The 
assignment o f the transcription start sites of the chimpanzee and rat PXR genes could 
have been determined experimentally using in vitro techniques such as 5’-RACE 
(5’-Rapid amplification o f cDNA ends), as described previously for the human PXR 
gene (Kurose et al. 2005). However, this approach was beyond the scope of the current 
project. The present assignment is based upon the alignment of the rat PXR transcripts, 
identifying the common start point; as such, it is prone to eixors of a few bases, but it is 
unusual for such as assignment to be over 70 bp inaccurate, as would have to be the case 
in this situation. This would therefore suggest that the rat PXR proximal transcript is 
generated from a TATA-less promoter, a situation usually reserved for genes associated 
with ‘housekeeping’ genes which comprise approximately 10 % of the genome. Some 
TATA-less promoters retain the ability to direct transcription initiation from a specific 
nucleotide, whereas others appear to direct transcription initiation from multiple start 
sites (Smale 1997). In the absence of a TATA box, other sites within the core promoter 
mediate the recruitment of the RNA polymerase II complex, such as the CCAAT, 
C/EBPp and Spl binding sites (Kabe et al. 2005), all o f which are present in the rat 
PXR proximal promoter close to the transcription start site. A previous survey of 
TATA-less promoters o f >170 genes determined that the CCAAT box is located 
approximately 41-60 bp upstream of the transcription start site (Mantovani 1998); this is 
in agreement with my findings for the rat PXR gene. Furtheimore, following a previous 
report that a C/EBPp binding site located 31-41 bp upstream in the TATA-less promoter
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of the rat catalase gene is critical for transcription (Taniguchi et al. 2005); the same site 
was identified in the rat PXR promoter in a similar position. Finally, several Spl sites 
were identified within the rat proximal promoter; an observation which is supported by 
evidence o f other TATA-less promoters which use multiple binding sites for Spl to 
stabilise interactions with the basal transcription factor TFIID (Rodenburg et al. 1997). 
Taken collectively, these three reports increase my confidence in the assignment o f the 
transcription start site o f the rat PXR gene as being correct, and more interestingly 
suggest that this gene is TATA-less in its function.
As stated earlier, in general the approximate 10 % of genes that do not contain a TATA 
box are thought to mainly encode proteins involved in development and/or general 
cellular functioning. As such they are required to be expressed constitutively at 
relatively low levels. It is not clear as to why such a situation should exist for the rat 
PXR, but an initial examination o f the mouse proximal promoter also suggests that it is 
TATA-less, corroborating the view that this is a true result. Such a finding would also 
suggest that the TATA box for PXR was included subsequent to the divergence o f the 
rodents from the primates, approximately 40 million years ago, although more complete 
analysis across evolutionary divergent species would be required to confirm this. The 
divergence of PXR and CAR from a single ancestral gene, which occurred at least 300 
million years ago (Handschin et al. 2000), suggests that through time these nuclear 
receptors have become more specialized to cope with their role as xenosensors. An 
intriguing possibility is that the inclusion of a TATA box in the regulatory regions of 
higher mammals is an extension of this specialization, allowing more refined control of 
the expression o f this xenosensing nuclear receptor.
5.3,1 Putative binding sites for general transcription factors
Several of the putative binding sites identified within the chimpanzee and rat PXR 
promoters included those for general transcription factors as well as ligand-activated 
transcription factors; brief descriptions o f their major functions follow.
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5.3.1.1 TATA box
The presence of a TATA box within the core promoter defines the minimal DNA 
element required for accurate transcription initiation, and is bound by the TATA 
binding protein (TBP) (Lee and Roeder 1981; Roeder 1996). The core promoter 
extends to up to 60 bp upstream of the transcription start site and is responsible for 
binding the basal transcription factors; a process which is hierarchical and dynamic. It 
starts from chromosomal derepression (through chromatin remodelling and nucleosome 
disruption) and transcription factor binding, and results in the activation o f transcription 
via a multitude interaction among basal and regulatory factors (Zhang 1998). The 
initiation o f transcription involves assembly of a preinitiation complex on the core 
promoter, consisting o f the TATA box binding protein with the TFIID and TFIIA B, F, 
E, H and RNA polymerase II (Roeder 1996). However, it is a common misconception 
that ‘typical’ RNA polymerase II eukaryotic core promoters have a TATA box guiding 
the preinitiation complex (Ponjavic et al. 2006); whereby an increasing number of 
TATA-less gene promoters are being identified, in which some retain the ability to 
direct transcription initiation from a specific nucleotide, whereas others appear to direct 
transcription initiation from multiple start sites (Smale 1997). A TATA box in the 
chimpanzee PXR promoter was identified 32 bp upstream o f the transcription start site 
(as shown in table 5.1 and figure 5.3), thereby suggesting that the assignment of the start 
site was coixect.
5.3.1.2 HNFs
The HNFs have been demonstrated to be involved in regulation the transcription of 
several CYP genes. For instance, H N Fla is reported to be a positive regulator of 
CYP1A2 and CYP2E1 expression; in contrast, it is also involved in down-regulating the 
expression o f CYP4A1 and CYP7A1 (Cheung et al. 2003). It has also been shown to 
regulate the gene expression o f the membrane transporter OATP-C (Jung et al. 2001); 
binding as a homodimer to the GTTAATnATTAAC motif (Kuo et al. 1991). Similarly, 
HNF3 has been shown to regulate xenobiotic-induced expression o f the CYP3A4 gene 
(Bombail et al. 2004) in which HNF3y has a synergistic effect on C/EBPa-mediated 
increase in CYP3A4 mRNA (Rodriguez-Antona et al. 2003). HNF3 bind to the
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consensus recognition sequence A(A/T)TRTT(G/T)RYTY in target genes (where R 
indicates A or G; Y indicates T or C) (Cereghini 1996). Furthermore, the analysis of 
promoter and enhancer sequences has shown the existence o f putative HNF4a binding 
sites within the regulatory regions of CYP genes in various species, such as part of the 
XREM of the human CYP3A4 distal promoter (Tirona et al. 2003), and the proximal 
promoter o f rat CYP3A23 (Huss and Kasper 1998). HNF4a is also reported to maintain 
PXR gene expression in murine hepatocytes (Kamiya et al. 2003). A consensus 
sequence derived from the HNF4 binding sites present in these genes is an almost 
perfect direct repeat o f the motif AGGTCA, separated by one nucleotide (DRl) 
(Cereghini 1996).
Previous work in our lab on the regulation o f human PXR gene expression using in vitro 
transfection with a reporter gene for human PXR and expression plasmids for HNF3P 
and HNF4a showed that both HNFs act as positive regulators o f human PXR gene 
expression (Gibson et al. 2006). An identical approach could be taken to determine the 
role of HNFs in the regulation of rat PXR and chimpanzee PXR gene expression, which 
would help to increase our laiowledge of the mechanisms o f regulation of rodent, 
primate and human PXRs, and either identify species differences or potential conserved 
regulatory mechanisms.
5.3.1.3 CCAAT box
The CCAAT box is one of the most common elements in eukaryotic promoters. It is 
generally bound by the CCAAT -binding factor (CBF), also named nuclear factor Y 
(NF-Y) (Coustiy et al. 1995), a well-conserved, ubiquitously expressed transcription 
factor that activates basal transcriptional activity of various promoters. In the absence 
o f a TATA box, NF-Y is essential in facilitating preinitiation complex formation by 
recruitment of RNA polymerase II and general transcription factors to the core promoter 
(Kabe et al. 2005). This feature is reflected by the observation that CCAAT boxes 
appear in relatively higher frequency in TATA-less promoters (Mantovani 1998). A 
CCAAT box in the rat PXR promoter was identified 41 bp upstream of the transcription 
start site (as shown in table 5.1 and figure 5.4), which is in a similar location as in other
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TATA-less promoters (Mantovani 1998), and thereby suggesting that the assignment of 
the start site was correct.
5.3.1.4 C/EBP alpha
CCAAT/enhancer binding protein alpha was the first member o f the C/EBP protein 
family identified that are capable o f interacting with the CCAAT box consensus binding 
m otif (Antonson and Xanthopoulos 1995). The ubiquitously expressed factor foims 
both homo- and heterodimers with other family members as well as with transcription 
factors o f the NFkB family (Lekstrom-Himes and Xanthopoulos 1998). C/EBPa 
regulates the transcription of genes involved in the cellular differentiation of adipocytes 
and hepatocytes, as well as having a role in the inflammatory response (Ramji and Foka
2002). It is also involved in the transcriptional regulation of some CYP genes, such as 
CYP3A4, for which it maintains basal expression via binding to its proximal promoter 
(Rodriguez-Antona et al. 2003) and confers responsiveness to rifampicin, phénobarbital 
and metyrapone (Bombail et al. 2004). Similarly, C/EBPa has been identified as having 
an active role in the dexamethasone-responsiveness of the rat CYP3A1 gene (Rodrigues 
et al. 2003). Taken collectively, together with the identification of C/EBPa sites in each 
PXR promoter examined, these reports suggest that C/EBPa could explain the 
coexpresion of CYP3A and PXR in the liver and intestine, a feature which is shared by 
both human and rodents.
5.3.1.5 C/EBP beta
CCAAT/enhancer binding protein beta is the second identified member o f the C/EBP 
protein family. It shares overlapping functions as those previously described for 
C/EBPa, such as regulating liver-specific gene expression; however, it is expressed at 
various levels in a wider variety o f tissues than C/EBPa (Thomassin et al. 1992). 
Similar to the C/EBPa isoform, C/EBPp has been identified as a transcriptional 
regulator o f the CYP3A4 gene, in which the factor activates transcription fi-om a distal 
enhancer site in the gene promoter (Martinez-Jimenez et al. 2005). C/EBPp has also
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been implicated in inducing rat CYP2D5 promoter activity (Lee et al. 1994) and 
modulating transcriptional activity o f the rat CYP7A1 gene (Gonzalez and Lee 1996).
5.3.1.6 Specificity protein 1
Specificity protein 1 (Spl) is an ubiquitously expressed general transcription factor 
which binds to purine-rich elements in gene promoters, such as the GC box 
(GGGGCGGGG) and the related GT/CACCC box (GGTGTGGGG). This extremely 
versatile protein is involved in the expression o f a large number o f different genes, such 
as housekeeping, tissue-specific and cell cycle-regulated gene, and has a role in 
chromatin remodelling (Suske 1999). Spl has been shown to bind to both the proximal 
promoter and phénobarbital response element (PBRE) of the CYP2B1 gene, and 
increase both basal and xenobiotic-induced activity (Muangmoonchai et al. 2001). 
Furtheimore, in vitro studies on the CYP2D5 gene promoter have demonstrated a 
cooperative binding interaction involving Spl and C/EBPp to control expression of this 
gene. In the absence o f Spl, C/EBP(3 is unable to bind to the promoter. In the presence 
of Spl alone, a low level transcription is possible whereas in the presence of both 
factors, higher rates are achieved through interaction with the transcription machinery 
(Lee et al. 1994). In our laboratory, two putative Spl sites were identified in the 
proximal promoter of the CYP3A4 gene, whereby mutation of the proximal Spl site 
resulted in a reduced responsiveness to phénobarbital and metyrapone (Bombail et al.
2004).
5.3.1.7 Octamer binding site
The octamer sequence motif (ATTTGCAT), together with the previously described 
CCAAT box and GC box are the three most common elements found close to the 
transcription start site o f both cell-type specific and ubiquitously expressed genes 
(Nakshatri et al. 1995). The consensus sequence octamer m otif is bound by two 
proteins, the ubiquitous transcription factor Octl and the lymphoid-enriched 
transcription factor Oct2; this site has been found in the promoters of most 
housekeeping genes such as histone 2B (Kemler et al. 1991), plus in many other
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eukaryotic genes including the CYP gene family, which result in their up or down- 
regulation (Gibson et al. 2002). Octl controls the transcription of these genes by a 
mechanism which involves selective recruitment of other transcription factors to the 
octamer site such as TFIIB and the TATA binding protein, which then go on to form a 
preinitiation complex (Nakshatri et al. 1995). The presence of an Octl site within the 
proximal 100 bp o f both PXR promoters examined suggests that either an increase of 
decrease in PXR expression could be mediated by this factor; reporter gene assays 
would be helpful to detemiine if  this is a regulatory feature shared between species.
5.3.1.8 Tumour suppressor p53
The p53 tumour suppressor protein activates transcription of a number o f genes through 
binding specifically to a core consensus sequence of TGCCT in target gene promoters 
(Scharer and Iggo 1992). Target genes include those encoding proteins that suppress 
entry into the S phase of the cell cycle; as a result, alteration or loss o f p53 is associated 
with a wide variety o f tumour cells (Liu et al. 1993). One such p53 target is the gene 
encoding the membrane transporter, M DRl, for which is was shown to bind to the 
downstream promoter in a sequence-specific manner, and repress transcription o f the 
gene (Strauss et al. 1995). It is believed that the factor directly interacts with the TATA 
binding protein and TBP-associated factors in order to bring about transcriptional 
repression (Farmer et al. 1996). The identification of a putative binding site for p53 in 
all three promoters would suggest that PXR could be involved in cell cycle control, 
thereby further increasing the number o f its biological roles.
5.3.1.9 COUP-TF
Chicken ovalbumin upstream promoter transcription factor (COUP-TF) is an orphan 
member o f the nuclear receptor family, meaning no endogenous ligand has been 
identified to date (Pereira et al. 1995). COUP-TF binds to a wide spectrum of response 
elements encompassing AGGTCA direct repeats and palindromes with various 
spacings; however, it has the highest affinity for a direct repeat o f AGGTCA with one 
nucleotide spacing (DRl element) (Cooney et al. 1992). COUP-TF predominantly
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down-regulates gene transcription by one o f two methods. First, direct competition for 
the hormone response elements that are recognised by receptors for retinoic acid (RAR), 
thyroid hormone (TR), estrogen (ER), and vitamin D3 (VDR), thereby inhibiting the 
transcriptional activity of these factors. Second, it can form a heterodimer with RXR 
(Kliewer et al. 1992), the essential cofactor for effective binding and functional activity 
o f TR, VDR and RAR, Thus, the effective concentration o f RXR is reduced, resulting 
in indirect inhibition of the activation functions o f these nuclear receptors (Cooney et al. 
1993).
Furthermore, the COUP-TF binding elements identified in various genes such as human 
apolipoprotein CIII, have been shown to be capable of also binding HNF4; however, 
upon binding, COUP-TF repress whereas HNF4 activated transcription o f this gene 
(Mietus-Snyder et al. 1992). Similarly, the reduced dexamethasone-responsiveness of 
CYP3A2 has been proposed to the result o f preferential binding o f COUP-TF to the 
proximal promoter (Huss et al. 1999). In contrast, COUP-TF can also up-regulate gene 
transcription by enhancing the HNF4 transcriptional activity in target genes (Ktistaki 
and Talianidis 1997). Therefore, the role o f this factor on PXR could be either up- or 
down-regulation, as putative HNF4a binding sites were identified in all three PXR 
promoters. Further experiments would therefore need to be perfoimed to investigate 
this and deteimine if  this is a conserved feature o f PXR regulation between species.
5.3.2 Putative binding sites for ligand-activated transcription factors
The identification o f putative binding sites for several LATFs within the PXR proximal 
promoter sequences reflects the complex network of nuclear and steroid receptor 
signalling, o f which PXR plays a central role in responding to many structurally 
unrelated external chemicals, and its ability in regulating the transcription o f genes 
involved in drug metabolism, steroid metabolism and bile acid homeostasis. In 
addition, the fact that several of these sites are conserved between rodents and primates 
suggests that they are functionally important, underlining the importance o f PXR in 
responding to fluctuations in cellular status. However, it should o f course be 
remembered that until these sites are empirically shown to be biologically functional
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then they are only computer predictions; hence discussions on their individual roles 
must be guarded, and comments on their consei*vation/interaction even more so.
5.3.2.1 Glucocorticoid receptor
Previous studies into the role o f the glucocorticoid receptor (GR) in CYP3A4 induction 
showed that at a submicromolar concentration o f dexamethasone, GR mediated an 
increase in human PXR mRNA in vitro, which subsequently increased the level of 
CYP3A4 expression (Pascussi et al. 2000a). Similarly, cotransfection o f a 2.2 kb 
human PXR reporter gene construct with a GRa expression plasmid resulted in a 2-fold 
increase in basal gene expression (Aouabdi et al. 2006). GR binds to the partly 
palindromic sequence GGTACAnnnTGTTCT, refeixed to as the glucocorticoid 
response element (GRE) (Adler et al. 1992). The presence o f this putative element 
within the human PXR promoter suggests that the observed increases in PXR mRNA 
and genomic activation respectively were mediated by GR interacting directly with the 
PXR promoter. Putative GREs were also identified in the chimpanzee and rat PXR 
promoters, suggesting that this is a common mechanism for mediating glucocorticoid 
activation of PXR gene expression. A similar approach to that used for the human PXR 
promoter could be used to confirm such a hypothesis, using reporter gene assays, 
followed by mutagenesis o f the putative conserved site.
5.3.2.2 Vitamin D receptor
After being bound by ligand, the vitamin D receptor (VDR) translocates to the nucleus 
and forms a heterodimer with RXRa (Cheskis and Freedman 1994). Once within the 
nucleus, this active heterodimer transactivates vitamin D response elements present in 
the regulatory regions o f target genes. VDR recognises the direct repeat consensus 
sequence arranged as a direct repeat with a spacing o f three nucleotides of 
AGTTCAnnnAGTTCA (Towers et al. 1993). The VDR/RXRa heterodimer can also 
bind to the PXR response element located upstream of the CYP3A4 gene (Schmiedlin- 
Ren et al. 2001), and it has been recently reported that PXR directly binds to and 
transactivates the two proximal vitamin D response elements present in the CYP24
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promoter (Pascussi et al. 2005). This promiscuity in response element recognition is 
probably an important part o f the regulation of cellular levels o f vitamin D, with VDR- 
mediated activation o f CYP3A4 gene expression being reported to be involved in the 
synthesis o f the active form of vitamin D (Gupta et al. 2004), whereas the PXR- 
mediated up-regulation o f CYP24 gene expression would result in an accelerated 
catabolism o f vitamin D (Pascussi et al. 2005). As vitamin D is a high affinity ligand 
for VDR but a low affinity ligand for PXR, it is plausible that at low concentrations of 
vitamin D, VDR is activated, leading to increased anabolism; whereas at higher 
concentrations, PXR-activated gene expression results in increased catabolism. Such a 
hypothesis is supported by the presence o f a putative binding site for VDR in the all 
three examined PXR proximal promoters, suggesting that this feature is evolutionally 
conserved.
5.3.2.3 Estrogen receptor
The estrogen receptor (ER) is a steroid receptor which is intimately involved not only in 
the control o f reproduction and reproductive behaviour, but also in other non- 
reproductive processes, such as skeletal physiology, tumourgenesis and growth 
(reviewed by Rissman et al. 1997). The ER is expressed in two forms, ERa and ERp, 
which both form homodimers upon ligand activation (Mosselman et al. 1996), and bind 
to a consensus sequence composed of an inverted repeat with a three nucleotide spacing 
(IR3; AGGTCAnnnTGACCT) (Lucas and Granner 1992). The ERa and PXR share 
some common characteristics, in that they both have some common ligands, and have 
been implicated in cross-regulating the metabolism o f estrogens. For instance, the 
endogenous estrogen 17p-estradiol is an activator o f ERa (Cidlowski and Muldoon 
1978) and PXR (Bertilsson et al. 1998), and a substrate for both C Y PlA l and CYP3A4 
enzymes (Badawi et al. 2001). Furthermore, the reports of ERa inducing C Y PlA l 
transcription in a human cancer cell line (Wang et al. 1996), and the identification o f a 
putative binding site for in the CYP3A4 proximal promoter (Hashimoto et al. 1993) are 
mirrored by those which show PXR mediating an induction of CYPlAl and CYP3Â4 in 
human hepatocytes (Maglich et al. 2002); collectively this illustrates that ERa and PXR 
regulate overlapping genes involved in estrogen metabolism. Therefore, the presence
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of a putative binding site for ERa within each PXR promoter gives an additional layer 
o f complexity, in which PXR, in addition to being activated by estrogens, is 
transcriptionally-induced by the hormone itself, which results in an increased 
metabolism of the hormone by C Y PlA l and CYP3A4.
5.3.2.4 Famesoid X receptor
The famesoid X receptor (FXR) is a nuclear receptor with high affinity towards primary 
and secondary bile acids, and is regarded as the endogenous bile acid sensor and an 
important regulator o f cholesterol homeostasis (Wang et al. 1999). It forms a 
heterodimer with RXRa, enabling it to bind to the consensus sequence presented as an 
IR l (e.g. AGGTCAnTGACTT) (Laffitte et al. 2000). FXR down-regulates the 
expression of CYP7A1, an enzyme responsible for synthesising bile acids from 
cholesterol via the activation o f SHPl and subsequent inhibition o f LRHl (Goodwin et 
al. 2000). PXR also serves as a bile acid sensor and is capable of down-regulating the 
expression of CYP7A1, although PXR is generally activated by higher ligand 
concentrations, and by tertiary bile acids (Xie et al. 2001). Furthermore, the SHPl gene 
has recently been reported as a primary PXR target gene (Frank et al. 2005), indicating 
an alternative or additional pathway, in which PXR, by sensing elevated bile acid 
concentrations, increases SHPl protein levels, which ultimately represses CYP7A1 
expression. Thus, the presence o f a putative binding site for FXR within each examined 
PXR proximal promoter suggests a safety mechanism, in which upon exposure to 
increased levels of bile acids, FXR up-regulates the expression of PXR; PXR, a low 
affinity ligand for bile acids, is then activated by (near)-toxic levels of bile acids, and 
alters gene expression to reduce these levels.
5.3.2.5 Peroxisome proliferator activated receptor
The peroxisome proliferator activated receptor (PPARa) forms a heterodimer with 
RXRa and binds to a response element which contains imperfect direct repeats o f the 
nuclear receptor consensus recognition sequence with a spacing of one nucleotide 
(DRl), AGGTCAnAGGTCA (Palmer et al. 1995). The PPARa ligands
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perfluorodecanoic acid and clofibrate have been shown to induce expression o f rat PXR 
mRNA (Zhang et al. 1999), although these chemicals aie not considered to be PXR 
ligands. The presence o f a PPARa binding site in the rat PXR promoter (as shown in 
table 5.1 and figure 5.4), therefore provides a rationale for these observations. Recent 
work from our lab demonstrated that transcriptional activation of human PXR was 
mediated by PPARa via a binding site located approximately 1.3 kb upstream of the 
putative transcription start site (Aouabdi et al. 2006), suggesting that control o f PXR 
expression by PPARa is conserved between humans and rodents. However, further 
analysis on the functionality o f the PPARa binding site in the rat PXR promoter would 
need to be carried out to confirm this.
5.3.2.6 Progesterone receptor
Progesterone plays a central role in the reproductive events associated with pregnancy, 
being important in both the establishment and maintenance phases, as well as in non- 
reproductive activities such as the regulating vascular smooth muscle proliferation; its 
effects are mediated through the progesterone receptor (PR) (reviewed by Conneely et 
al. 2002). PR binds to a consensus sequence (PRE) containing an inverted repeat with a 
three nucleotide spacing (IR3; AGAACAnnnTGTTCT), which is also recognised by the 
glucocorticoid receptor (Strahle et al. 1987). Progesterone is an activator o f both human 
PXR (Bertilsson et al. 1998) and rodent PXR (Kliewer et al. 1998), with products o f the 
classical PXR target genes CYP3A being involved in the catabolism of progesterone 
(Yamazaki and Shimada 1997). Hence, the presence of putative binding sites for PR 
within the PXR promoters suggests that PXR, in addition to being activated by 
progesterone, is transcriptionally-induced by the horaione itself, thiough the PRE, in 
order to increase the expression o f the CYP3A enzyme for the metabolism o f the 
progesterone. This may be a conserved mechanism; however, the functionality o f the 
putative PR binding sites will need to be investigated in order to help confirm this. 
However, it should be noted that as the GRa can also bind to this site, we cannot 
exclude the possibility that PR does not interact with the PXR proximal promoter, or 
that this site is only activated by GRa.
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S.3.2.7 Aryl hydrocarbon receptor
Unlike the previously mentioned LATFs (5.3.2.1-5.3.2.6), the aryl hydrocarbon receptor 
(AhR) is not by definition, a nuclear receptor, which utilises a basic helix-loop-helix 
structure rather than a zinc-finger to bind to DNA. In the absence of ligand, AhR is 
predominately located within the cytoplasm; with ligand binding resulting in nuclear 
translocation and heterodimer formation with the aryl hydrocarbon nuclear translocator 
(Amt) (Dolwick et al. 1993). The AhR:Amt heterodimer binds to DNA containing the 
consensus sequence TA/TGCGTG, referred to as the dioxin response element (DRE), 
activating expression of genes such as C Y PlA l (Denison et al. 1988). The presence of 
a putative binding site for the Ahr/Amt heterodimer in each PXR promoter would 
suggest that AhR/Amt induces expression o f PXR in response to its ligands, thus 
implicating the PXR in the metabolism o f the PAHs and PCBs, and related 
carcinogenesis in all three species. In fact, a study by Maglich et al. showed that 
rifampicin-activated PXR induced the AhR receptor and its target gene C Y PlA l in 
human hepatocytes; however, in contrast, AhR was not stimulated in murine liver after 
dosing with the rodent PXR ligand PCN (Maglich et al. 2002), thus highlighting an 
important species difference in the regulation o f AhR by PXR. Furthermore, recent 
work into the activation o f PXR identified further species differences, such as that 
certain PCBs were able to activate rodent PXR but not human PXR, although these 
same PCBs were able to bind directly to human PXR and antagonise its activation and 
target gene induction (Tabb et al. 2004). Taken together, these results prompt additional 
investigation to determine if there are further species differences in how these nuclear 
receptors regulate each other’s expression.
5.3.2.S Barbie box
The Barbie box was first identified in Bacillus megaterium, within the promoters of the 
barbiturate-inducible P 4 5 0 b m - i and P 4 5 0 b m -3 genes, and consisting o f a core consensus 
sequence AAAG, that is critical for DNA-protein interaction (He and Fulco 1991). It 
has since been identified in the proximal promoters o f several mammalian genes such as 
CYP2B1/2, CYP2C1 and CYP3A2 (Liang et al. 1995). However, its role of mediating 
a response to barbiturates is questionable as no specific binding was observed to the
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Barbie box and deletion or mutation of the site did not affect the responsiveness of 
CYP2B genes to phénobarbital (reviewed by Sueyoshi and Negishi 2001). 
Furthermore, the responsiveness to phénobarbital and phenobarbital-type compounds 
was later discovered to be conferred by the PBREM (PB-responsive enhancer module) 
(Honkakoski and Negishi 1997). The PBREM contains two nuclear receptor binding 
sites, N R l and NR2, which bind the CAR/RXRa heterodimer and mediate the 
phénobarbital response (Honkakoski et al. 1998); however, it does not contain any 
Barbie box-like sequences (Honkakoski et al. 1996), thereby suggesting that the Barbie 
box motif does not have a major transcriptional role. Barbie boxes were identified in 
each promoter; although whether this site confers responsiveness of PXR to 
phénobarbital needs to be confirmed for all three species.
5.3.2.9 Nuclear factor kappa B
The transcription factor NFxB plays a critical role in regulating the expression of many 
factors involved in the immune system such as cytokines and growth factors (Hayden 
and Ghosh 2004). In addition, it also plays an important role in protecting cells against 
the actions of tumour necrosis factor. Tumour necrosis factor (TNF) is an anti­
inflammatory cytokine that induces apoptosis; however, NFkB inhibits TNF-induced 
apoptosis and induces the expression o f anti-apoptotic genes (Liu et al. 1996). 
Consequently, it has been proposed that after TNF stimulation, NFicB activation is 
critical in determining whether a cell enters into a pathway leading to survival or to cell 
death (reviewed by Xu et al. 1998). NFkB binds to the consensus binding motif 
sequence GGGRNNYYCC (where R indicates A or G; Y indicates T or C; N indicates 
any nucleotide) (Pany and Mackman 1994); this motif was identified in each PXR 
promoter, thereby suggesting that PXR has a role in regulating apoptosis. Such a 
putative role is supported by the recent finding that PXR can regulate the expression of 
the anti-apoptotic proteins Bcl-2 and Bcl-xL (Zucchini et al. 2005). Zucchini and 
colleagues showed that in both human and rat hepatocytes, PXR ligands were capable of 
increasing Bcl-2 and Bcl-xL expression, ultimately suppressing apoptosis. The presence 
o f an NFkB binding site within the PXR proximal promoter could have a similar effect,
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with activation of the NFkB anti-apoptotic pathway signalling, at least in part, through 
PXR-mediated activation of Bcl-2 and Bcl-xL.
5.4 Conclusion
In silico analysis has allow the identification o f the chimpanzee PXR and rat PXR 
proximal promoter regions, and the putative transcription factor binding sites present 
therein. Together with the previously described human PXR promoter region by 
Aouabdi et al., two major conclusions can be made. The first is that as several putative 
binding sites have been identified that are common to all three gene promoters, there 
exists strong evidence of evolutionary conservation of the regulatoiy mechanisms 
governing the transcription of the PXR gene. This suggests that whereas the response to 
specific ligands may occur in a species-specific manner, the overall regulation of PXR 
and its interaction with other transcription factors remains fairly constant across 40 
million years of evolution. Second, the multitude of putative sites identified for both 
general and ligand-activated transcription factors may reflect the ability of PXR to 
respond to a diverse range o f chemicals and coordinate the expression of genes in many 
cellular processes; this highlights the complexity and inter-connectivity of nuclear 
receptor signalling pathways. In vitro analysis is now required to further investigate the 
regulation of PXR gene expression and determine the functionality o f these interaction 
sites, which may underpin potential differences in the gene transcription of PXR of 
humans, primates and rodents.
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6. Species differences in transcriptional regulation of PXR by 
liver-enriched and ligand-activated transcription factors
6.1 Introduction
PXR is central in the regulation and maintenance of cellular homeostasis. In response 
to fluctuating chemical levels, the orphan nuclear receptor is capable o f binding a broad 
range o f endogenous and xenobiotic compounds, and then activating the transcription of 
a large and expanding repertoire o f target genes, including phase I (e.g. CYP3A) and 
phase II (e.g. UGTIA) dmg metabolising enzymes as well as those encoding drug 
transporters. However, little is loiown about PXR gene regulation and the function of its 
promoter; more significantly, nothing is known o f the regulatory mechanisms governing 
PXR expression in different species, and o f how they compare.
Several studies o f the PXR promoter have shown that gene transcription is regulated by 
both liver-enriched and ligand-activated transcription factors, although these have 
generally not examined if  such interactions are direct (i.e. transcription factor 
interaction with PXR regulatoiy elements) or indirect (i.e. action o f a transcription 
factor on other cellular factors that then interact directly with PXR regulatory elements). 
Previous work has demonstrated that HNF4a may regulated mouse PXR in foetal 
hepatocytes (Kamiya et al. 2003); by inactivation of the HNF4a in murine foetal 
hepatocytes, the expression o f both PXR and its target gene CY P3AI1 was effectively 
suppressed. Similarly, it has been shown that HNFs have a positive effect on human 
PXR transcription, whereby, cotransfections o f the human PXR proximal promoter with 
expression plasmids for HNF3P and HNF4a resulted in increases in PXR gene 
expression (Gibson et al. 2006). Whether the human and rat PXRs are regulated in the 
same manner by these factors needs to be explored. Furthermore, the transcriptional 
activities o f human and rat PXR have been shown to be activated by several 
compounds, including dexamethasone, a GRa ligand (Zhang et al. 1999; Pascussi et al. 
2000a) and the PPARa ligand, PFDA (Zhang et al. 1999). These findings suggest that 
both GRa and PPARa may regulate PXR gene expression, and mediate a xenobiotic
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response. Indeed, a functional PPARa binding site was identified in the human PXR 
proximal promoter (Aouabdi et al. 2006); in contrast, whether the glucocorticoid 
receptor binds directly to the PXR regulatory regions is currently unknown. The 
findings o f these initial studies were confirmed herein by further analysis o f human and 
rat PXR mRNA transcripts in vitro, as described in chapter four, work which also 
identified increases in PXR transcriptional activity following treatment with rifampicin 
and clotrimazole, the extent of which differed significantly between humans and rats. 
The regulatoiy mechanisms governing these species differences observed following 
treatment with these chemicals need to be fully investigated. To date, there have been 
no studies into the regulation o f chimpanzee PXR gene expression.
The in silico data described in chapter five showed that that the proximal promoters of 
human, rat and chimpanzee PXRs contain several putative binding sites for liver- 
enriched transcription factors (LETFs) and ligand-activated transcription factors 
(LATFs). The presence o f putative binding sites for both classes o f transcription factor 
was suspected, firstly because PXR is highly expressed in the liver, and secondly 
because PXR is capable of responding to a diverse range o f chemical stimuli, and 
coordinate the expression o f genes in many cellular processes. These data opened the 
opportunity to further explore the role o f selected putative PXR activating factors in 
regulating both basal and xenobiotic-induced PXR transcription, and determine whether 
their functionality underpins potential difference in gene expression in humans, 
primates and rodents. My initial investigation o f the molecular mechanisms of PXR 
gene regulation involved the generation of 1500 bp PXR proximal promoter constructs 
for all thi'ee species (human, chimpanzee and rat); the rat PXR promoter was then used 
for the creation o f a series o f deletion constructs. Initially, the basal activity o f both, the 
whole 1500 bp rat PXR proximal promoter construct and the daughter constructs were 
examined in FaO cells. Following this, the 1500 bp proximal promoter constructs of all 
three species were used in dosing experiments in both Huh? and FaO cells. Expression 
plasmids for liver-enriched and ligand-activated transcription factors were used in the 
basal and xenobiotic experiments, respectively and their effect on the PXR reporter 
genes examined.
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6.2 Isolation of rat and chimpanzee PXR proximal promoter regions
The regions -1534 to +28 bp of the rat PXR promoter and -1526 to +64 bp o f the 
chimpanzee PXR promoter were amplified by PCR using Pf>c and Taq DNA polymerase 
at an annealing temperature o f 60 °C and 57°C, respectively for 35 cycles. Figure 6.1 
shows that the amplicon obtained from these reactions correlated with the expected 
sizes o f 1500 bp. Each resulting DNA was used as a further template for PCR using 
nested primers containing restriction sites for enzymes, which allowed for correctly 
orientated insert ligation into SEAP Basic vector. Once cloned, the sequence of both 
regions was confirmed using DNA sequencing, the results of which, showed 100 % 
identity to the original template.
Figure 6.1: Amplification of the 1.5 kb proximal promoter regions of rat and 
chimpanzee PXR
Ladder Rat Rat Chimp Chimp
2 kb 
1 kb
PCR amplification o f rat and chimpanzee PXR proximal promoter regions was carried out using 
respective genomic DNA templates for each species. Rat PXR was amplified using Pjx DNA polymerase 
and an annealing temperature o f 60 °C; whereas PCR amplification o f chimpanzee PXR was performed 
using Taq polymerase at 57°C annealing temperature.
6.3 Generation of rat PXR proximal promoter deletion constructs
1500 bp of the rat PXR proximal promoter was amplified from rat genomic DNA and 
used as a template for the generation o f a series of seven daughter constructs. Figure
6.2 shows the steps undertaken to generate the deletion constructs. Precise details o f the 
PCR primers used to amplify the fragments are given in section 2.2.5.
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Figure 6.2: Strategy employed for the generation of the rat PXR deletion 
constructs
Amplification o f 1500 bp proximal promoter
i
PCR with nested primers containing 
restriction sites for enzymes, using 1500 bp 
construct as template
/ \
Restriction digest of 1428,1343,1170, 
830,634 and 239 bp fragments with 
Acc65I and Hindlll
Restriction digest o f 198 bp fragment 
with Bglll and HindlH
i i
Restriction digest o f SEAP basic 
vector with Acc65I and HtndUI
Restriction digest o f SEAP basic 
vector with BglH and Hindlll
\ /
Gel purification of 1428,1343,1170,830, 
634,239 and 198 bp fragments
Ligation into SEAP basic vector
Figure 6.3 shows the digested clones and vector with the respective restriction enzymes. 
All the inserts were confirmed by sequencing. Although the strategy outlined in figure
6.2 ensured all correct insert orientations upon ligation into the SEAP basic vector, 
sequencing was performed using forward and reverse SEAP primers to confirm these to 
be correct, and that sequence fidelity had been maintained.
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Figure 6.3: Restriction digests of nested PCR products and SEAP basic vector 
Ladder 1428 1343 1170 830 634 239 198 SEAP Ladder
1500 bp
500 bp
100 bp
5 kb
2 kb 
1 kb
Each nested PCR product and the SEAP basic vector were double digested to produce compatible DNA 
overhangs and allow correct ligation together. The digests were run on a 1 % agarose gel together with 
the 100 bp DNA and 1 kb step ladders, and electrophoresed for 20 minutes. Each nested PCR product 
digest produced two bands: the insert plus excess DNA as a by-product o f the enzyme digest.
6.4 Optimisation of the reporter gene assay
In order to determine the optimum conditions for the reporter assay in the rat cell line, 
and to ensure robust, reproducible experiments, the mass of DNA used per well in each 
transfection of FaO cells needed to be examined. The high basal expression level o f the 
SEAP vector when driven by an SV40 promoter made it ideal for transfection 
optimisation, as it was able to distinguish within a broad range of reporter activity. 
SEAP activity was measured at 72 hours post transfection following transfection with 
0.05-0.25 pg DNA (Figure 6.4). It can be seen that after using 0.05 pg and 0.1 pg 
DNA, there is no significant SEAP activity compared to control (no DNA), but a 
significant increase is observed after transfection with 0.25 pg DNA. This mass of 
DNA per well was used for all reporter gene constructs in all subsequent transfections 
of the FaO cell line. Furthermore, from previous work undertaken in our lab, it was 
shown that measurement of SEAP activity at 48 rather than 72 hours post transfection 
produced the most reliable effects (Dr S. Aouabdi, personal communication). 
Therefore, a 48 hours reading was chosen as the time for SEAP activity to be measured.
134
Figure 6.4: Determination of the optimal mass of DNA per well for each FaO 
transfection
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The SEAP vector driven by the SV40 promoter was transfected into FaO cells in addition to a blank 
transfection representing the negative control. SEAP activity was measured 72 hours post transfection 
following addition o f  0.05, 0.1 and 0.25 pg DNA per well. Each data point represents the mean plus 
SEM, for six biological repeats (n=6 ). Significance o f SEAP activity compared to control were calculated 
by a one way ANOVA with Bonferroni all means post hoc test where ***=p< 0.001, n.s.=not significant.
6.5 Assessment of potential species differences in basal PXR activity
6.5.1 Comparison of basal activity of the human, chimpanzee and rat PXR 
promoters
SEAP activity was measured following transfection of both Huh? and FaO cells with 
constructs containing 1500 bp proximal promoter of human, chimpanzee and rat PXR 
genes, as presented in figure 6.5. Basal PXR expression measured in Huh? cells was, as 
expected, greatest from the human promoter construct; significant PXR expression was 
detected from the chimpanzee promoter, although at a far lower level, but no significant 
PXR expression was detected following transfection of the rat PXR promoter. In 
contrast, when the same construct was transfected into FaO cells, a significant level of 
PXR activity was detected, which was not too dissimilar to the expression level o f the
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human promoter construct in the Huh? cell line. No significant PXR activity was 
detected from the chimpanzee promoter construct; however, the human construct 
resulted in moderate basal PXR expression, despite being transfected into a rat cell line.
Figure 6.5: Basal activity of human, chimpanzee and rat PXR
a) Huh? cell line
14000-1
b) FaO cell line
14000-1
S  12000-  
9^ 10000-
^ 8000  ^«/>2  60004
o> 4000-
2000-
12000-
S , 10000-
6000-
(u 4000-
Transfection in (a) human Huh? and (b) rat FaO cell lines o f the 1500 bp reporter gene constructs o f  
human, chimpanzee and rat PXR together with the empty vector representing the negative control. SEAP 
activity was measured at 48 hours post transfection as described in materials and methods. Each data 
point represents the mean plus SEM for twelve biological repeats (n=12). Significant difference in PXR 
aetivity compared to negative control was calculated by a one way ANOVA with Bonferroni all means 
post hoc test where **=p<0.01, ***=p<0.001. RLU: Relative light units.
6.5.2 Determination of the PXR activity of each rat PXR deletion construct
The activity of each reporter construct compared to the next smaller one gives the 
relative effect of the DNA binding elements contained in this region as part of the larger 
construct; thus, the 1428 (1500) bp construct represents the net activity of all other 
constructs. Using this system it is possible to identify positive and/or negative regions 
within the rat PXR promoter. Figure 6.6 shows PXR activity of each construct when 
transfected into FaO cells. Significant and varying differences in activity were observed 
for each construct, which is indicative of the unique regulatory elements contained 
within each fragment, and illustrative of the complexity of the gene promoter.
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Fragment lengths o f 198, 1170 and 1471 base pairs showed a net positive regulatory 
effect on PXR expression when compared to the next smaller construct. In contrast, 
each of the 634, 830 and 1343 bp fragments showed a net negative effect on PXR 
expression. However, the overall effect of the largest fragment was, as expected, o f 
positive regulation of the rat PXR gene.
Figure 6.6: Positive and negative transcriptional elements in the rat PXR proximal 
promoter
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Transfections o f a deletion construct series from the parent 1500 bp rat PXR reporter gene construct. 
SEAP activity o f each fragment was measured at 48 hours post transfection and compared to its smaller 
daughter construct. Regions o f  the rat PXR proximal promoter were designated as containing positive (+) 
and negative (-) basal regulatory elements. TSS: putative transcription start site. Each data point 
represents the mean plus SEM, representative o f experiments undertaken on two separate occasions 
giving 18 biological repeats (n=18). Significant difference in SEAP activity relative to previous 
construct was calculated by one way ANOVA with Bonferroni all means post hoc test where *=p<0.05,
**=p<0 .0 1 , ***=p<0 .0 0 1 .
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6.5.3 Assessment of the role of hepatic nuclear factors on rat PXR gene expression
The in silico analysis presented in chapter five only indicated the positions of putative 
binding sites within the rat PXR promoter, and thereby provided hypothesises from 
which the functionality o f these sites can be investigated. In order to understand the 
molecular mechanisms o f rat PXR expression and draw comparison to the previously 
described human PXR, it was necessary to investigate the role of transcription factors to 
confirm their involvement in regulating rat PXR gene expression. This work focussed 
on the hepatic nuclear factor family o f transcription factors.
Hepatic nuclear factors are liver-enriched transcription factors which play role in the 
constitutive and tissue-specific expression o f many hepatic genes (Aldyama and 
Gonzalez 2003). Several hepatic nuclear factor (HNF) family members (HNFl, HNF3, 
and HNF4) have been reported to be involved in the regulation o f many CYP (Gonzalez 
and Lee 1996) and membrane transporters genes (Jung et al. 2001). Of particular 
interest is that several of these genes are also regulated by PXR. Furthermore, HNFs 
appear to regulate each others expression. For instance, HNF3p acts as a positive 
regulator o f HNF la , HNF3a and HNF4a genes (Duncan et al. 1998); similarly, HNF4a 
has been reported to regulate the transcription o f HNF la  (Miura and Tanaka 1993). 
Taken together with the facts that PXR is highly expressed in the liver, and that several 
putative binding sites for HNFs were identified in the PXR promoter, these data suggest 
that transcriptional regulation o f rat PXR is in part, mediated by the HNFs.
Previous work in our lab on the regulation o f human PXR showed that the HNFs can 
serve as both positive and negative regulators o f gene expression, depending on the 
length o f promoter which they are acting upon (Gibson et al. 2006). Similarly, it has 
been reported that HNF4a controls the expression o f PXR gene expression in murine 
foetal hepatocytes, by binding to a HNF4a site located in the first 100 base pairs of the 
proximal promoter (Kamiya et al. 2003). Therefore, an investigation into the role that 
HNFs play in regulating the transcription o f rat PXR will allow for further species 
comparison.
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6.5.3.1 Reporter gene assay for the transcriptional regulation of rat PXR by HNFs
Initially, the full 1428 bp rat PXR proximal promoter construct was cotransfected with 
expression plasmids for HNF3p and HNF4a as presented in figure 6.7, which showed 
that both factors down-regulate the expression of rat PXR. This is a similar 
phenomenon as previously observed from cotransfection using a 2200 bp human PXR 
construct (Gibson et al. 2006), with greater repression by HNF3p than by HNF4a 
reported from both cotransfection experiments.
Next, the effects of these factors were examined using shorter fragments of the rat PXR 
proximal promoter, which provided a means of comparing my data with the previous 
findings fi^om our lab and also those of Kamiya et al. (2003). This latter group 
demonstrated that an HNF4a binding site in the mouse PXR promoter was required for 
activation of the promoter in foetal hepatocytes, whereby inactivation of HNF4a 
suppressed expression of both PXR and its target gene CYP3A11 (Kamiya et al. 2003). 
Likewise, cotransfections o f HNF3p and HNF4a with 76 and 200 bp human PXR 
reporter constructs both resulted in an increase in PXR gene expression (Gibson et al. 
2006). Reporter constructs containing the 198 and 239 bp rat PXR proximal promoters 
were cotransfected with expression plasmids for HNF3p and HNF4a. These shorter 
constructs were specifically chosen because o f the presence of a putative binding site 
for HNF3p site at 97 bp and two sites for HNF4a at 60 and 233 bp upstream o f the 
designated transcription start site. Figure 6.7 shows the effects o f the HNFs on the 
198 bp construct (6.7a) and on the 239 bp construct (6.7b), in which both HNFs resulted 
in increased PXR gene expression. The results show an identical pattern than those 
fi"om the human PXR study, in which greater activation by HNF3p than by HNF4a was 
observed. Furthermore, cotransfection with HNF4a shows that this factor may mediate 
PXR gene expression in the rat, human and mouse in a similar manner. However, the 
effect o f the HNF4a on the entire promoter construct showed that this factor represses 
the transcription o f both rat PXR (Figure 6.7c) and human PXR, which is contrary to 
mouse PXR, as reported by Kamiya et al. (2003). These results therefore suggest that 
the mechanism o f PXR regulation by HNF4a does not differ between humans and 
rodents, but is different between adult and foetal rodents.
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Figure 6.7: Effect of hepatic nuclear factors on rat PXR basal expression
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FaO cells were transfected with SEAP 
constructs for the (a) 198, (b) 239 and (c) 
1428 base pairs o f the rat PXR promoter. 
They were cotransfected with the expression 
plasmids for HNFSP and HNF4a. Putative 
binding site positions o f these factors within 
the PXR proximal promoter are shown. 
SEAP activity was measured 48 hours post 
transfection. Data is representative o f  
experiments undertaken on two separate 
occasions giving ten biological repeats 
(n=10). Significant difference in SEAP 
activity relative to non- cotransfected control 
was calculated by one way ANOVA with 
Bonferroni all means post hoc test where 
*=p<0.05, **=p<0.01, ***=p<0.001.
Taken together, these results suggest that the in silico predictions of the HNF3P and 
HNF4a sites were correct. However, further investigation needs to be undertaken to 
determine the functionality o f these binding sites.
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6.S.3.2 Decreased PXR activation following ablation of the putative binding sites 
for HNF3P and HNF4a
A putative binding site for HNF3p was identified in the region from 83 to 97 base pairs 
upstream of the transcription start site; two further sites for HNF4a were identified in 
the regions from 42 to 60 and from 215 to 233 base pairs in the rat PXR promoter. 
HNF3P binds to the consensus recognition sequence A(A/T)TRTT(G/T)RYTY in target 
genes (where R  indicates A or G; Y indicates T or C) (Cereghini 1996); for comparison, 
the putative binding site found using Matlnspector to interrogate the TRANSFAC 
database was TCTCATTTATGCCAT. in which the nucleotides underlined show the 
core sequence, which is defined as the first five most conserved consecutive positions 
within a motif. With regard to the other two sites, HNF4a binds to an imperfect D Rl 
recognition site for nuclear receptors, namely AGGTCA (Cereghini 1996). The 
putative binding sites found at positions -42 to -60 bp and -215 to -233 bp were 
ACGACCTGAACCCTGAATC and CAGTGGCAAAAGCACCCTC. respectively.
The functionality of these three putative HNF binding sites was investigated by site- 
directed mutagenesis. For each site, four nucleotides were selected for mutation as they 
represented the most highly conserved bases within the putative binding site, following 
the in silico analysis. The resulting mutants were as follows; HNF3P (-83 to -97 bp); 
TCTCATACGTACCAT: HNF4a (-42 to -60 bp): ACGACCTTGATCATGAATC; 
HNF4a (-215 to -233 bp): CAGTGGGCCCAGCACCCTC. The nucleotides underlined 
indicate the changes to the core sequence. The effects of these mutations were then 
examined using the reporter gene assay, as previously described.
The mutations had vaiying effects on the PXR activity relative to their wild type 
constructs, as shown in figure 6.8. The mutations of the HNF3p and HNF4a sites 
within the 198 bp reporter construct both significantly down-regulated the expression of 
rat PXR. In contrast, the mutation o f the HNF4a site within the 239 bp construct had 
little effect on PXR expression, which suggests that either the in silico prediction o f the 
site was incorrect, the site-directed mutagenesis was insufficient to prevent binding of 
HNF4a, or as this was a single mutation, the loss o f this site was compensated for by the 
active HNF4a site at -60 bp.
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Figure 6.8: Mutation of the HNF3p and HNF4a sites down regulate PXR
activation of the 198 bp fragment but not the 239 bp fragment
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Separate and independent mutations were made in the HNF sites within the reporter gene constructs for 
the (a) 198 and (b) 239 base pairs o f the rat PXR promoter, which were then transfected into FaO cells 
and SEAP activity was measured 48 hours post transfection. Data is representative o f experiments 
undertaken on two separate occasions giving ten biological repeats (n=10). Significant difference in 
SEAP activity relative to wild type control was calculated by (a) one way ANOVA with Bonferroni all 
means post hoc test and (b) unpaired t-test where ***=p<0 .0 0 1 , n.s.-not significant.
Next, cotransfection experiments using expression plasmids were carried out in order to 
determine the ability of the 198 bp mutant reporter constructs to mediate HNF3p- and 
HNF4a-stimulated expression of the rat PXR gene. As can be seen from figure 6.9, 
both the mutants showed a complete loss o f HNF-mediated activation o f the PXR gene. 
Together, these data demonstrate that the putative HNF3(3 and HNF4a binding sites 
identified within the proximal 200 bp are functional, and that complete ablation of them 
results in a loss of HNF3p- and HNF4a-mediated activation o f rat PXR gene 
expression.
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Figure 6.9: Mutation of the HNF3P and HNF4a sites prevents HNF-mediated
increase in activation of the 198 bp PXR fragment
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SEAP reporter gene construct containing 198 bp o f  the human PXR proximal promoter, representing the 
wild type construct, (a) site-directed mutagenesis (SDM) HNF3P mutant or (b) SDM HNF4a mutant, 
were transfected into FaO cells with or without cotransfection o f the expression plasmids for (a) HNF3P 
and (b) HNF4a. SEAP activity was measured 48 hours post transfection. Data is representative o f  
experiments undertaken on two separate occasions giving ten biological repeats (n=10). Significant 
difference in SEAP activity relative to non-cotransfected construct was calculated by one way ANOVA 
with Bonferroni all means post hoc test where ***=p<0.001, n.s.=not significant.
143
6.6 Assessment of potential species differences in xenobiotic-induced PXR activity
Following examination of the activity o f each promoter constmct under basal 
conditions, I next examined the effect o f chemical stimuli on these constructs. Each 
1500 bp proximal promoters construct was transfected into both the human and rat cell 
lines. This was decided as it was anticipated that it would show both the effect o f the 
promoter base sequence and also of the factors present in the host cell, as previously 
demonstrated for CYP3A by others (Barwick et al. 1996; Swales et al. 2003). Thus, any 
observed species differences could be explained by differences in the compliment o f 
putative transcription factor binding sites in each promoter and/or intrinsic differences 
in the host cell. For example, after exposure to clotrimazole, if greater expression of the 
human PXR promoter was observed in the rat cell line than in the human cell line, it 
would suggest that under these conditions, the rat cell is more permissive to 
transcription o f PXR than is the human cell. This may be due to the abundance/ratio of 
transcription factors being correct in the rat cell but not in the human cell. Therefore, 
this approach will aid in the identification o f putative transcription factors that regulate 
PXR gene expression following xenobiotic exposure, and provide a rationale for 
obseived species differences.
Six compounds were selected as potential candidates that induce species differences in 
PXR transcription. Four of these compounds were previously used in the mRNA 
transcript analysis, as described in chapter four. In addition, hyperforin and PCN were 
selected, as they were known to be species-specific activators o f human PXR and rat 
PXR, respectively (Kliewer et al. 1998; Moore et al. 2000a). Each compound was 
used over a 6-point concentration range in accordance to previous findings and the 
current literature. One drug at a single concentration was then selected, which was the 
focus o f further investigation into the regulatory mechanisms controlling the induction 
of PXR gene expression.
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6.6.1 Effects of perfluorodecanoic acid on transcriptional activation of PXR
Greater PXR expression was observed for all three constructs in the human cell line 
than in the rat cell line. As expected, greater PXR expression was observed for the 
human and chimpanzee constructs than the rat construct, with the greatest fold 
inductions at 1.0 pM and 100 pM, thereby showing a biphasic profile, which is 
indicative of the involvement of another transcription factor. In contrast, no such 
profile was observed following transfection into the rat cell line. All three constructs 
were only activated at 100 pM PFDA concentration, suggesting that the factor(s) 
mediating the transcriptional response in the FaO cell is only active at high PFDA 
concentrations. These findings are mirrored by results of the rat PXR mRNA transcript 
analysis in chapter four, which also showed a maximal response at 100 pM. 
Furthermore, they are in agreement with previous work showing that PFDA up- 
regulates the transcription of rat PXR in vivo (Zhang et al. 1999).
Figure 6.10: PXR transcriptional activation following treatment with
perfluorodecanoic acid
a) Huh? cell line b) FaO cell line
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Transfection o f (a) Huh? and (b) FaO cells with 1500 bp reporter gene constructs o f human, chimpanzee 
and rat PXR proximal promoters. SEAP activity was measure 48 hours post administration of 
perfluorodecanoic acid, as described in materials and methods. Each data point represents fold induction 
over DMSO vehicle control following normalisation by each post/pre dose ratio for six biological repeats 
(n=6 ). For each data point, interexperimental variation was less than 25 %. Significant difference in 
SEAP activity o f drug treated cells relative to DMSO control was calculated by a two way ANOVA  
with Bonferroni all means post hoc test where *=p<0.05, **=p<0.01, ***=p<0.001.
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6.6.2 Effects of dexamethasone on transcriptional activation of PXR
In the human cell line, the profile of PXR expression of the human construct was 
mirrored by that o f the chimpanzee construct, both of which were suggestive of 
biphasic induction. In contrast, no induction of rat PXR expression was observed in the 
human cell line, an absence which was replicated in the rat cell line. By comparison, 
both the human and chimpanzee constructs were activated in this cell line to far greater 
extents than previously observed in the human cell line, with the human construct also 
exhibiting a possible biphasic induction profile. Greater induction of both the human 
and chimpanzee constructs in the rat cell than the human cell suggests that the former is 
more permissive to activating the PXR reporter constructs following dexamethasone 
exposure than the latter. The lack of activation from the rat promoter was unexpected 
as previous in vivo studies have shown moderate increases in rat PXR mRNA following 
dexamethasone treatment (Zhang et al. 1999); likewise, the mRNA transcript analysis 
in chapter four showed significant induction of rat PXR over the concentration range.
Figure 6.11: PXR transcriptional activation following treatment with
dexamethasone
a) Huh? cell line b) FaO cell line
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Transfection o f (a) Huh? and (b) FaO cells with 1500 bp reporter gene constructs o f human, chimpanzee 
and rat PXR proximal promoters. SEAP activity was measure 48 hours post administration o f  
dexamethasone. Each data point represents fold induction over DMSO vehicle control following 
normalisation by each post/pre dose ratio for six biological repeats (n=6 ). For each data point, 
interexperimental variation was less than 25 %. Significant difference in SEAP activity o f drug treated 
cells relative to DMSO control was calculated by a two way ANOVA with Bonferroni all means post 
hoc test where *-p<0.05, **=<0.01, ***=p<0.001.
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6.6.3 Effects of rifampicin on transcriptional activation of PXR
In the human cell line, no significant induction of the human PXR construct was 
observed; this was true also for the chimpanzee and rat promoter constructs, except for 
increases in chimpanzee PXR expression when dosing with 0.1 and 50 pM rifampicin. 
The results for human PXR expression are in agreement with others who have observed 
that rifampicin does not induce human PXR (Prof. P. Maurel, personal communication). 
However, induction of human PXR expression was observed in the rat cell line when 
dosing with high concentrations o f drug. Similarly, the chimpanzee and rat constructs 
were activated by this drug concentration. These results suggest that the FaO cell 
contains factors which mediate the response to rifampicin, which the Huh? cell is 
lacking. Rat PXR mRNA transcript analysis previously showed a potential biphasic 
induction profile to rifampicin in FaO cells; however, this was not evident in the data 
presented in figure 6.12b.
Figure 6.12: PXR transcriptional activation following treatment with rifampicin
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Transfection of (a) Huh? and (b) FaO cells with 1500 bp reporter gene constructs o f human, chimpanzee 
and rat PXR proximal promoters. SEAP activity was measure 48 hours post administration o f rifampicin. 
Each data point represents fold induction over DMSO vehicle control following normalisation by each 
post/pre dose ratio for six biological repeats (n=6 ). For each data point, interexperimental variation was 
less than 25 %, with the exception o f 100 pM rifampicin induction o f rat PXR in FaO cells which was 
30 %. Significant difference in SEAP activity o f drug treated cells relative to DMSO control was 
calculated by a two way ANOVA with Bonferroni all means post hoc test where *=p<0.05,
***=p<0 .0 0 1 .
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6.6.4 Effects of hyperforin on transcriptional activation of PXR
Hyperforin is known to be a high-affmity ligand and activator o f human PXR, but only 
a weak activator of rat PXR (Tirona et al. 2004), whereas its effect on the transcription 
of human and rat PXR has not been reported to-date. As shown in figure 6.13, 
hyperforin was a poor inducer of all three promoter constructs in both cell lines. 
However, in the human cell line, all three constructs showed a peak induction at 
0.1 pM hyperforin. The significance of this finding may be explained by comparison 
to those from a previous study (Moore et al. 2000a), which used transient transfection 
o f CVl cells with a reporter plasmid containing the CYP3A1 together with an 
expression plasmid for human PXR, in order to generate a dose-response profile for 
hyperforin. It was reported that the maximal activation of human PXR by hyperforin 
was achieved at a concentration of 0.1 pM, thus providing a rationale for the observed 
induction of the human and chimpanzee PXR reported constructs.
Figure 6.13: PXR transcriptional activation following treatment with hyperforin
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Transfection o f (a) Huh? and (b) FaO cells with 1500 bp reporter gene constructs o f human, chimpanzee 
and rat PXR proximal promoters. SEAP activity was measure 48 hours post administration o f hyperforin. 
Each data point represents fold induction over DMSO vehicle control following normalisation by each 
post/pre dose ratio for six biological repeats (n=6 ). For each data point, interexperimental variation was 
less than 25 %. Significant difference in SEAP activity o f drug treated cells relative to DMSO control 
was calculated by a two way ANOVA with Bonferroni all means post hoc test where *=p<0.05,
**=p<0 .0 1 , ***=p<0 .0 0 1 .
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6.6.5 Effects of PCN on transcriptional activation of PXR
In contrast to hyperforin, pregnenolone 16a-carbonitrile (PCN) is considered to be a 
ligand for rodent PXR but not for human PXR (Moore et al. 2000b). Previous studies 
however, have identified the opposite trend for activation o f PXR gene transcription, in 
which PCN induced human PXR mRNA in vitro (Teng et al. 2003), but did not alter the 
expression of rat PXR mRNA in vivo (Cheng and Klaassen 2006). These observations 
are mirrored by the results presented in figure 6.14, which show an induction of the 
human PXR promoter in the human cell line, and a lack o f significant induction of the 
rat promoter construct in the rat cell line. Furthermore, the induction of the rat PXR 
construct in the human cell line at high PCN concentration suggests that the Huh7 cell is 
more permissive than the FaO cell to activation of the PXR promoters in response to 
PCN.
Figure 6.14: PXR transcriptional activation following treatment with PCN
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Transfection o f (a) Huh? and (b) FaO cells with 1500 bp reporter gene constructs o f human, chimpanzee 
and rat PXR proximal promoters. SEAP activity was measure 48 hours post administration o f PCN. 
Each data point represents fold induction over DMSO vehicle control following normalisation by each 
post/pre dose ratio for six biological repeats (n=6 ). For each data point, interexperimental variation was 
less than 25 %, with the exception o f 0.1 pM PCN induction o f chimpanzee PXR in FaO cells which was 
30 %. Significant difference in SEAP activity o f drug treated cells relative to DMSO control was 
calculated by a two way ANOVA with Bonferroni all means post hoc test where *=p<0.05, **=p<0.01,
***=p<0 .0 0 1 .
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6.6.6 Effects of clotrimazole on transcriptional activation of PXR
Activation of the human and chimpanzee PXR constructs was greatest in the human cell 
line, with the rat PXR construct being activated to a lesser extent in both cell lines. This 
is in agreement with findings from the mRNA transcript analysis in chapter four, which 
showed far greater induction o f human PXR than rat PXR mRNA in the respective cell 
lines.
Figure 6.15: PXR transcriptional activation following treatment with clotrimazole
a) Huh? cell line b) FaO cell line
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Transfection of (a) Huh? and (b) FaO cells with 1500 bp reporter gene constructs o f human, chimpanzee 
and rat PXR proximal promoters. SEAP activity was measure 48 hours post administration of 
clotrimazole. Each data point represents fold induction over DMSO vehicle control following 
normalisation by each post/pre dose ratio for six biological repeats (n=6 ). For each data point, 
interexperimental variation was less than 25 %. Significant difference in SEAP activity o f drug treated 
cells relative to DMSO control was calculated by a two way ANOVA with Bonferroni all means post 
hoc test where *=p<0.05, **=p<0.01, ***=p<0.001.
O f particular interest is the maximal induction of all three constructs in the human cell 
line at 10 pM clotrimazole, which suggests that a host cell-specific effect is mediating 
the response, and that this factor(s) is present in the Huh? cell, but may not be at the 
same level in the FaO cell. However, the different extents to which the constructs were 
activated indicate that although the Huh7-specific factor(s) work on all three promoters, 
there are also promoter/species-specific effects which contribute to the observed 
inductions. Therefore, each o f the PXR proximal promoters needs to be examined.
150
Using proximal promoter deletion constructs for human PXR and rat PXR in 
conjunction with the in silico data presented in chapter five, it is possible to identify the 
cellular factor(s) which is mediating the increase in the PXR transcriptional activity in 
response to clotrimazole.
6.6.6.1 Identification of putative binding sites mediating increased transcriptional 
responses to clotrimazole
The activity of each reporter construct compared to that o f the frill length (1500 bp) 
promoter gives an indication of the effect on the responsiveness to clotrimazole o f the 
DNA binding elements contained in this region. Therefore, any increase or decrease in 
PXR expression can be accounted for by the deletion of putative binding sites in the 
promoter constmct series. Using this system, it is possible to identify the putative 
binding sites within the PXR proximal promoters, and thereby, the transcription 
factor(s) which confer the inductions previously observed following administration of 
10 pM clotrimazole. Figure 6.16 shows activities o f each human PXR and rat PXR 
constmct when transfected into Huh? and FaO cells, respectively. A single significant 
decrease in PXR activity was observed in each promoter deletion series. Deletions of 
the GRE, VDR, PPARa and Spl binding sites within the distal 200 bp o f the 1500 bp 
human promoter, and of the GRE, ERa, C/EBPa, FXR and HNF3(3 binding sites within 
the distal 340 bp o f the 11?0 bp rat promoter both resulted in an approximate 40 % 
decrease in PXR activation. Interestingly, a GRE was present in both these deletions, 
suggesting that the glucocorticoid receptor may be responsible for mediating the 
increases in PXR activity following clotrimazole treatment. Moreover, both deletion 
series appear to recover PXR activity in the shorter sections; the rationale for this is not 
clear, but suggests a complex interplay o f positive and negative factors.
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Figure 6.16: Responsiveness of each proximal promoter fragment to clotrimazole
a) Human PXR proximal promoter
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Transfection o f (a) human PXR and (b) rat PXR proximal promoter deletion construct series into Huh? 
and FaO cells respectively. SEAP activity was measured 48 hours post administration o f 10 pM 
clotrimazole. Each data point represents the mean plus SEM for four biological repeats (nM). 
Significant difference in SEAP activity relative to the parent 1500 bp PXR reporter construct was 
calculated by a one way ANOVA with Bonferroni all means post hoc test where *=p<0.05. The positions 
o f the putative binding sites that were deleted which confer reduced responsiveness to clotrimazole are 
shown below each graph.
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6.6.6 2 Coexpresion of the glucocorticoid receptor enhances the clotrimazole- 
mediated increase in human PXR transcriptional activation
To examine the effects of transcription factors on the clotrimazole-induced increase in 
PXR promoter activity, and determine the contribution made by each factor to 
increasing PXR transcription, expression plasmids for GRa, VDR/RXR and 
PPARo/RXR were cotransfected with the fragment containing 1500 bp of the human 
PXR proximal promoter. As can be seen from figure 6.17, GRa expression positively 
influenced expression mediated by the 1500 bp construct, demonstrating that GRa 
expression up-regulated PXR gene expression following treatment with clotrimazole.
Figure 6.17: Reporter gene assay showing increased induction of human PXR by 
clotrimazole following cotransfection of the expression plasmid for GRa
8  2  150
GRE 
-1453 bp
VDR 
-1409 bp
PPARa 
-1335 bp
The 1500 bp human PXR construct was cotransfected with expression plasmids for GRa, VDR/RXR and 
PPARo/RXR into Huh7 cells. SEAP activity was measured 48 hours post administration o f 10 pM 
clotrimazole. Each data point represents the mean plus SEM for four biological repeats (n=4). Significant 
difference in SEAP activity relative to non-cotransfected control was calculated by a one way ANOVA 
with Bonferroni all means post hoc test where *=p<0.05. The putative binding sites present within the 
distal 200 bp o f  the 1500 bp construct are shown below the graph.
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6.7 Discussion
6.7.1 Basai expression
Although PXR expression levels in both Huh7 and FaO cells are much lower than in 
vivo (as shown in chapter four), the cell lines were selected as in vitro models to 
understand the control mechanisms underlying PXR transcription, and thereby 
determine potential differences in the regulation of PXR in humans, primates and 
rodents. When expressed in their ‘native’ hepatoma cell lines, the proximal promoters 
of the human PXR and rat PXR genes showed similar activity. This is an important 
observation, as it suggests that the extent o f any changes in activity o f either promoter 
will be relative to one another. In contrast, far lower activity of the proximal promoter 
o f chimpanzee PXR gene was observed in the either the human Huh7 or rat FaO cell 
lines. It would have been better to transfect this construct into a primate cell line; 
however, only monkey kidney epithelial or fibroblast cells were commercially available, 
which if  used, would add ‘cell type’ as another variable for consideration.
However, given the high similarity between the human and chimpanzee genomes, it is 
not illogical to presume that the chimpanzee should function at least to some extent in a 
human cell line. The reduced basal expression o f the chimpanzee promoter construct 
can be viewed in a number of ways. First, as stated above it might be that only a 
primate, or even rhesus-derived, cell line would be sufficient for accurate modelling of 
PXR regulatory sequences. Second, that regulation of chimpanzee PXR expression is 
genuinely lower than that seen in human and rodent species: A scenario for which no 
evidence exists to argue for or against. Third, that the chimpanzee promoter region 
cloned is not sufficient to confer high basal expression, and the presence o f more distal 
elements is required. Again, no real evidence exists to argue for or against such a 
scenario. However, whereas it would seem strange for the chimpanzee to have such 
radically different expression/regulation o f PXR compared to both the human and rat 
sequences there is some evidence to suggest such a scenario may be true. In trying to 
explain the difference between chimpanzees and humans at the phenotypic level given 
the marked similarity at the genome level, geneticists have come up with three main 
theories; gene loss, protein evolution and gene regulation (King and Wilson 1975;
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Olson 1999). As neither the loss o f only 53 genes (Mikkelson et al. 2005), nor the extent 
of amino acid substitutions between chimpanzee and humans can explain all the 
phenotypic differences observed, more credence is being given to the last o f these 
theories, that it is the regulation of important genes that varies sufficiently between 
chimpanzees and humans to explain the phenotypic differences.
Interestingly, the human promoter showed moderate activity in the rat cell line; which 
suggests that the FaO cell contains the correct abundance/ratio o f transcription factors to 
support human PXR expression. This cell line was then the focus for understanding the 
basal regulation o f the rat PXR gene. The overall activity of the proximal rat PXR 
promoter in the FaO cell line was positive, as demonstrated by using the 1500 bp 
reporter gene construct; however, further investigation was undertaken to identify which 
individual sub-regions confer this positive effect. The in silico analysis o f the rat PXR 
proximal promoter revealed multiple factors that could be involved in maintaining the 
basal expression o f PXR; therefore, a series o f deletion constructs was generated to 
fiirther refine important areas of regulation. Thus, the identification o f positive and 
negative regulatory regions o f the promoter may be indicative o f role o f the specific 
transcription factors binding to their associated sites on the rat PXR proximal promoter. 
Taken together, these sub-regions coordinate the overall response o f PXR to different 
transcription factors, and interactions between them are likely to be fundamental in 
determining the final PXR expression level.
Several regions o f both positive and negative regulation were present within the rat 
PXR proximal promoter. The deletion construct series suggested that the regions fi'om 
-1428 to -1343 bp, -1170 to -830 bp and -198 bp to the transcription start site contained 
positive elements, whereas regions from -1343 to -1170 bp and -830 to -239 bp 
contained negative elements. The fi-agment between -1428 and -1343 bp contained 
putative binding sites for HNF3P, PR and Barbie box; any or all o f these factors could 
be having a positive effect on rat PXR expression. Similarly, the positive effect o f the 
fragment -1170 to -830 bp could be mediated by the putative binding sites for GR, ER, 
C/EBPa, FXR and/or HNF3p. Likewise, the positive effect o f the smallest fragment 
could be due to HNF3p, HNF4a, CCAAT and/or C/EBPp. Conversely, the negative
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regulation of the fragment between -1343 to -1170 bp could be conferred by HNF4a, 
C/EBPa, AhR or HNF3P, and the negative effect o f  the fragment -830 to -239 bp could 
be due to VDR, COUPTF, HNF la , PPAR, SPl, C/EBPp, Barbie box, ER, HNF4a 
and/or CCAAT. However, as the net effect o f the proximal promoter is positive, the 
ability of the negative regulatory elements to suppress PXR expression is nullified by 
the presence of positive regulatory elements in the upstream fragments o f the promoter.
Overall, the data suggests that the rat PXR proximal promoter is complex, with several 
positive and negative regulatory regions interacting to produce the net expression level 
o f PXR. These findings are analogous to those from previous work on the human PXR 
proximal promoter (Aouabdi et al. 2006; Gibson et al. 2006), which also showed an 
overall positive activity. However, little comparison can be drawn between the two, as 
there are no common putative binding sites associated with either the positive or 
negative regulatory regions o f both promoters. The only exception being the proximal 
200 bp fragment of the human PXR promoter and the proximal 198 bp fragment o f the 
rat PXR promoter, both o f which contained positive regulatory elements. Within these 
promoter fragments, in silico analysis identified putative binding sites for the hepatic 
nuclear factors 3(3 and 4a: To fuither characterise whether these factors are important 
for both human and rat PXR expression, the frmctionality of these putative binding sites 
within the rat promoter was examined by cotransfection with expression plasmids for 
these factors.
6.7.2 Role of the hepatocyte nuclear factors
Analysis of liver-enriched transcription factors, such as the HNFs in hepatoma cell lines 
has revealed that their levels were as little as 15 % of those seen in freshly isolated 
hepatocytes (Jover et al. 2001). This may explain the generally low expression o f only 
a few, if  any, hepatic functions and drug-metabolising activities of the cell lines, 
compared with those o f the normal adult liver (Reviewed by Gomez-Lechon et al. 
2001). As PXR is central in regulating the expression o f many of these hepatic genes, it 
is therefore conceivable that their decreased expression is a consequence o f reduced 
PXR in the cell, which is also due to limited HNF transcription factor signalling. To 
investigate this, and to draw comparison to findings using the human PXR proximal
156
promoter, the ability o f HNFs to stimulate PXR expression was examined using over­
expression studies. Surprisingly, the effects o f the HNFs on the 1500 bp rat PXR 
proximal promoter were the opposite to what was expected in the above discussion, and 
resulted in the down regulation of PXR expression. However, a similar observation was 
made for the 2200 bp human PXR proximal promoter (Gibson et al. 2006).
There are three distinct members of HNF3 in mammals (HNF3a, -3(3 and -3y), whose 
genes are closely related to the Drosophila melanogaster gene forkhead, a gene which is 
essential for the proper formation of the foregut and hindgut in flies. Hence, it has been 
suggested that these factors are important during development. HNF3 proteins control 
the expression of more than 100 genes by modifying nucleosomal organisation, a 
process which de-compacts chromatin, and thereby facilitates the binding o f other 
transcription factors (McPherson et al. 1993). A putative binding site for HNF3(3 was 
identified at approximately 97 bp upstream of the rat PXR transcription start site, 
suggesting a direct effect of HNF3(3 on rat PXR gene expression. In contrast, it appears 
that neither HNF3a nor HNF3y regulate the transcription of the gene, as no binding sites 
were found within the promoter. Interestingly, HNF3P down-regulated the expression 
of PXR with the 1500 bp construct, and up-regulated PXR expression with both the 198 
bp and 239 bp constructs. Taken together, these apparent contradictory influences 
suggest that PXR expression from the downstream elements could be attenuated by 
inhibitory binding sites present in the longer construct that repress/modulate HNF3p 
function. This phenomenon was also obseiwed when using 2200 bp, 200 bp and 76 bp 
of human PXR proximal promoter (Gibson et al. 2006), thereby indicating an 
evolutionally conserved protective mechanism o f preventing PXR over-expression, and 
hence unwanted induction o f target genes in both humans and rodents.
HNF4a is indispensable for the constitutive expression o f several key hepatic genes 
encoding enzymes involved in fatty acid and cholesterol metabolism and lipid transport 
(Hayhurst et al. 2001); it also plays a significant role in the regulation o f the PXR target 
CYP3A (Huss and Kasper 1998; Jover et al. 2001). It has been postulated that HNF4a 
may function as a modulator o f chromatin structure, resulting in increased access of 
transcription factors to their binding sites (Li et al. 2000). Putative binding sites for
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HNF4a were identified at approximately 60 bp and 233 bp upstream of the rat PXR 
transcription start site. Cotransfection of the expression plasmid for HNF4a elicited 
increased expression with both the 198 bp and 239 bp deletion construct. However, 
despite the 239 bp construct containing two putative HNF4a sites, only a similar 
increase in PXR activity was observed as was for the 198 bp construct, which contained 
one HNF4a site, suggesting that the site located at -233 bp was either an artefact o f the 
in silico screening process, was not biologically functional, or it ablation could be 
compensated by other response elements. As seen with HNF3p cotransfection, 
expression o f the 1500 bp PXR construct was down-regulated by HNF4a, which 
probably reflects again, a mechanism of regulating against over-expression of PXR. 
Moreover, this mechanism is also evolutionally conserved following the observation of 
identical HNF4a-mediated expression of human PXR (Gibson et al. 2006). Taken 
together, these findings are consistent with PXR having a complex promoter in both 
humans and rats, which are governed by intricate regulatory mechanisms, as were 
suggested by the in silico data and the basal expression deletion constructs, which 
harbour both negative and positive regulatory elements.
The functionality o f the identified HNF3P and HNF4a sites in the 198 bp and 239 bp rat 
PXR promoter deletion constructs was investigated by site-directed mutagenesis, which 
showed that ablation o f the sites in the 198 bp promoter fragment resulted in reduced 
activation of rat PXR following over-expression o f HNF3P and HNF4a. These 
findings however, would need to be confirmed by investigation using electromobility 
shift assay (EMSA) data, which would show if  specific DNA: protein interactions 
occurred between the HNFs and these regions of rat PXR promoter. However, due to 
time-constraints, this was beyond the scope o f the project.
Therefore, having somewhat clearly demonstrated the activation of rat PXR by HNF3P 
and HNF4a, it is important to next consider why these are an evolutionally conserved 
mechanisms of PXR regulation. Evolutionary changes are noraially multi-factorial; in 
the case o f PXR, changes in the diets o f rodents to humans have driven substitutions in 
the amino acid composition o f the ligand binding pockets, resulting in different 
xenobiotic activation profiles (Chrencik et al. 2005). In the case of basal expression of
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PXR, in the absence of chemical stimuli, there appear to have been no/little evolutionary 
pressure applied to the regulatory mechanisms of rodent PXR regulation; consequently, 
no changes have occurred in the control of PXR transcription in the two species.
6.7.3 Effect of xenobiotics on human, chimpanzee and rat PXR activity
The mRNA transcript analysis described in chapter four identified important differences 
in how human PXR and rat PXR genes are activated by xenobiotics and provided 
hypotheses for the mechanisms o f the observed xenobiotic-mediated genomic 
activation. Further examination o f these hypotheses was carried out using reporter 
genes containing 1500 bp proximal promoter o f the human, chimpanzee and rat PXR 
genes. In this study, human and rat hepatoma cells were dosed for 48 hours, as was 
done for the mRNA transcript analysis. However, a caveat o f using cell lines derived 
fi'om different species is that they will not have identical levels of basic cellular 
processes (e.g. metabolic capacity or xenobiotic transporter availability). To overcome 
this, each reporter constmct was transfected into both cell lines, which would then 
indicate the effect of just the PXR promoter sequence on the observed response to 
xenobiotic treatment. The lack o f a primate hepatoma cell line is a possible limitation to 
the study. Ideally, the chimpanzee PXR reporter construct would be transfected into a 
chimpanzee hepatoma cell, which would contain a species-specific compliment o f 
transcription factors and other auxiliaiy factors that control chimpanzee PXR gene 
expression. However, initial sequencing o f the chimpanzee genome and subsequent 
comparison with the human genome identified that orthologous proteins in both species 
are extremely similar, with ~29 % being identical and the typical orthologue differing 
by only two amino acids (Mikkelson et al. 2005). Therefore, transfection of the 
chimpanzee reporter construct into the human cell line should mimic the response to 
xenobiotic exposure observed if  transfected into a primate cell line.
PXR receptor activation is o f utmost importance to the phaimaceutical industry when 
developing a new drug. Drugs that activate PXR have the potential to reduce the 
clinical efficacy of more than one-half of all other drugs that are coadministered, often 
with life-threatening consequences. This phenomenon is a particular problem in the era
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o f polypharmacy, in which patients are often taking multiple medications at any one 
time. Ideally, new drugs should not activate PXR, or at least activate it to a minimal 
degree (Kliewer 2003); therefore it follows that they should not induce genomic 
activation o f PXR.
As extrapolating data from studies utilising rodents has proven to be an unreasonable 
approach due to species-specifîcity o f the xenobiotic response, the differences that exist 
between species for the xenobiotic induction of PXR expression need to be identified, 
and furthermore, the molecular mechanisms governing these differences need to be fully 
understood.
6.7.3.1 Effect of perfluorodecanoic acid on PXR expression
Perfluorodecanoic acid was a weak inducer of all thi*ee reporter constructs in Huh? 
cells, which showed similar profiles across the concentration range, suggesting that all 
three constructs were activated by the same transcription factor present in the human 
cell. The inductive effect on the human construct is likely to be mediated by a functional 
PPARa response element located in the first 2200 bp of the human PXR proximal 
promoter, which has previously been shown to mediate the activation o f PXR gene 
expression by peroxisome proliferators (Aouabdi et al. 2006). Similarly, putative 
binding sites for PPARa were identified in the in silico screening o f the chimpanzee and 
rat PXR proximal promoters, which taken together suggest that PPARa in the human 
cell is mediating the activation o f all three constmcts by PFDA. Furthermore, activation 
o f the human PXR construct is in contrast to a lack of induction of human PXR mRNA 
(as shown in chapter four), which indicates the presence o f negative regulatory elements 
beyond 1500 bp upstream of the human promoter that nullify the positive effect o f the 
functional PPARa site, and thus further highlights the complexity o f PXR gene 
regulation.
Treatment o f FaO cells showed that perfluorodecanoic acid was an even weaker inducer 
o f the reporter constmcts in the rat cell line. Interestingly however, all three constmcts 
were maximally activated at 100 pM PFDA, an observation which is mirrored by the
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induction of rat PXR transcript levels both in vivo (Zhang et al. 1999) and in vitro (as 
presented in chapter four). Taken together, these results suggest that a transcription 
factor which is mediating PXR activation in the rat cell is only responsive to high PFDA 
concentration. This factor is most probably PPARa, as it is known to be expressed at a 
greater level in the rat than in the human both in vivo and in vitro (Palmer et al. 1998; 
Ammerschlaeger et al. 2004), and furthermore, it has been reported that maximal 
induction o f rat PPARa mRNA transcripts occurred when dosing with 100 pM PFDA in 
vitro (Sterchele et al. 1996).
In sum, it appears that PPARa is regulating the activation o f the human, chimpanzee 
and rat PXR genes in both Huh? and FaO, as part o f the cellular response to 
perfluorodecanoic acid. However, the hmctionality of the putative PPARa binding sites 
in the chimpanzee and rat PXR proximal promoters needs to be confiiined, and hence, 
the exact mechanism of PPARa-mediated activation of PXR remains to be elucidated. 
Early indications are that it is an evolutionally conserved mechanism, which probably 
reflects the importance of PXR and PPARa in regulating common metabolic pathways 
through the regulation of an overlapping set of target genes, which serve as a cellular 
‘safety net’ upon chemical exposure.
6.7.3.2 Effect of dexamethasone on PXR expression
It has previously been shown that the synthetic glucocorticoid dexamethasone induces 
the expression of human PXR mRNA, via a mechanism that is mediated by the 
glucocorticoid receptor (Pascussi et al. 2001), which can therefore be applied to explain 
the moderate activation o f the human and chimpanzee PXR reporter constructs in the 
Huh? cell line, as putative binding sites for GRa were identified in these proximal 
promoters. By contrast, the rat PXR promoter construct was not activated by 
dexamethasone, which was also replicated following transfection into the rat cell line. 
Moreover, this result disagrees with both the efficacious induction o f rat PXR mRNA 
seen in chapter four, and the moderate increase in rat PXR mRNA in vivo (Zhang et al. 
1999). Taken together these results suggest that the putative binding site for GRa 
identified in the rat PXR proximal promoter is either non-functional, an artefact o f the
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in silico screening process, or is in fact functional but insufficient to solely mediate the 
response to dexamethasone. This therefore does not preclude the presence of another 
GRa binding site located beyond the 1500 bp of the rat promoter, which may act 
cooperatively with the downstream GRa binding site to facilitate dexamethasone- 
induced transcription of the rat PXR gene.
Interestingly, activation o f the human PXR reporter construct was greater in the human 
cell line than in the rat cell line, an observation which is supported by the finding that 
FaO cells can support a larger induction o f dexamethasone-mediated CYP3A gene 
expression than HepG2 cells, which is another human hepatoma cell line (Swales et al. 
2003). Assuming that the glucocorticoid receptor is in fact mediating the 
dexamethasone response, this host cell-specific effect may be determined by one of two 
factors, or possibly both. The FaO cell may contain a greater pool o f unliganded GRa 
than the Huh? cell, which is capable o f activating the human PXR promoter; 
alternatively, the rat GRa may have a greater binding affinity for dexamethasone than 
human GRa. This is in fact true, as the dissociation constants for dexamethasone were 
4 nM and 1? nM for the rat and human receptors, respectively (Isohashi et al. 19?6; 
Bojar et al. 1980). Collectively, these data illustrate that changes in the abundance/ratio 
o f transcription factors within the host cell can have a profound effect on the regulation 
of gene transcription, which can ultimately facilitate expression o f PXR in a species- 
specific manner.
6.7.3.3 Effect of rifampicin on PXR expression
On the whole, rifampicin did not induce the expression of the reporter gene constmcts 
in the Huh? cell line throughout the concentration range used, of which, the results for 
human PXR activation are in agreement with both the findings o f the mRNA transcript 
analysis described in chapter four, and also of others who have observed that rifampicin 
does not induce human PXR (Prof. P. Maurel, personal communication). Furthermore, 
they are consistent with the observation that over-expression o f human PXR produces a 
suppression o f PXR reporter gene expression as opposed to a stimulation (Aouabdi et 
al. 2006). In contrast, rat PXR mRNA transcript analysis o f FaO cells dosed with
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rifampicin showed efficacious induction over the entire concentration; suggesting that 
the lack o f activation of the rat PXR promoter construct in Huh? is due to an absence of 
coregulator(s) in the human cell line that facilitate rifampicin-induced PXR expression 
in a species-specific manner.
Treatment o f FaO cells showed dose-dependent activations o f all three reporter 
constructs, with maximal induction at 100 pM rifampicin, which is suggestive of 
another transcription factor mediating the response to rifampicin in the rat cell line. A 
possible candidate is the rat glucocorticoid receptor. Since the rodent GRa ligand 
binding domain has been shown to share a high amino acid similarity (94 %) with that 
o f the human GRa (Stolte et al. 2006), a nuclear receptor which is known to be 
activated by rifampicin (Calleja et al. 1998), it then follows that the rat glucocorticoid 
receptor may be regulating the activation o f the human, chimpanzee and rat PXR genes 
in the FaO cell following rifampicin treatment. Moreover, it appears that the 
glucocorticoid receptor is confening its control through binding to the putative binding 
sites for GRa within the 1500 bp proximal promoters o f all three PXR genes; however, 
as the functionality of the putative GRa site within the rat promoter is in doubt, further 
experiments are required to delineate the reason behind such an inductive response. 
Interestingly, the previous induction profile o f rat PXR mRNA transcripts (as presented 
in chapter four) was not replicated by the rat reporter gene construct activation profile; 
suggesting that the promoter elements responsible for efficacious genomic activation of 
PXR are located beyond the 1500 bp o f  rat promoter.
Taken together, these results highlight species-specific activation o f PXR gene 
expression in response to rifampicin, which is contrary to activation o f PXR at the 
protein level. The ability of rifampicin to activate rat PXR gene expression despite 
only weakly activating PXR may have important consequences for cellular homeostasis, 
by increasing the pool of unliganded PXR, and hence potentially disrupting expression 
o f PXR target genes.
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6.7.3.4 Effect of hyperforin on PXR expression
Hyperforin was a weak inducer o f all three PXR constructs in the human cell line, 
except for significant peaks in PXR activation at 0.1 pM. Hyperforin is known to be 
potent ligand of human PXR, which induces the expression of CYP3A4. This was 
determined by cotransfection o f a reporter gene for CYP3A1 with an expression 
plasmid for human PXR, which generated a dose-response profile. Maximal activation 
of PXR was achieved at 0.1 pM hyperforin (Moore et al. 2000a). This therefore 
provides a rational for the observed activation of the reporter gene constructs at this 
concentration. A possible mechanism for this activation is as follows. At low 
concentration (0.1 pM), hyperforin binds to PXR and directly up-regulates the 
expression o f the reporter gene constructs. Although the PXR proximal promoters do 
not contain a readily identifiable PXRE, a previous study of the human PXR promoter 
led to the suggestion that PXR may bind to a non-consensus binding site (Gibson et al. 
2006); we therefore hypothesise that this is the case in the context of the chimpanzee 
and rat PXR proximal promoters as well. At high hyperforin concentration (>0.1 pM), 
the expression o f the PXR constructs is down-regulated by the recruitment o f a 
corepressor to the PXR complex. The corepressor SMRT has been reported to interact 
with to the PXR LED, and inhibit not only basal but also drug-induced transcriptional 
activity of PXR on the CYP3A4 promoter (Takeshita et al. 2002); thus, it is plausible 
that SMRT is responsible for the low level o f activation of the three reporter gene 
constructs at greater hyperforin concentrations.
In contrast, very little activation o f the reporter constructs was observed in the rat cell 
line across the same concentration range. This most probably reflects a marked species 
difference that rat PXR is poorly activated by hyperforin (Tirona et al. 2004), in 
concordance with the proposed mechanism described above. This again is an example 
o f the effect that the host cell environment can have on PXR gene transcription, in 
which the cellular compliment of tianscription factors and coregulators determines the 
species-specific manner of PXR expression.
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6.7.3.S Effect of PCN on PXR expression
PCN has long since been regarded as a rodent-specific activator o f human CYP3A23, 
being only a very weak activator o f human CYP3 A4; a species difference that has now 
been shown to be mediated by the species-specific activation o f PXR (Lehmann et al. 
1998). It has been shown that PCN is an efficacious activator of PXR in rodents but 
only weakly activates human PXR (Lehmann et al. 1998). The genomic activation 
profiles presented herein are therefore perplexing, suggesting that PCN is having an 
opposite effect at the genomic level than it is at the proteomic level. The result for the 
human PXR promoter construct in the human cell line is unprecedented; however, it 
may reflect the findings of others, whom have proposed that CYP3A4 may be induced 
by PCN (Barwick et al. 1996). They suggested that there may be two human 
populations, one responsive to PCN, and the other non-responsive to PCN, and that 
such heterogeneity o f inductive response was probably due to differences in the 
formation of liver transcription factors and nuclear receptor availability. Furthermore, 
the absence of activation of all three reporter constructs in the rat cell line, suggest that 
induction by PCN is determined by a promoter- and host cell-specific factor, the 
identification o f which is unknown. Further experiments are obviously required to 
delineate the reason behind such an inductive response, and its implications at the whole 
animal level.
6.7 3.6 Effect of clotrimazole on PXR expression
In the human cell line, clotrimazole was an efficacious inducer of all thiee reporter 
constructs, but especially the human PXR promoter construct, which is an agreement 
with previous findings by others (Teng et al. 2003). Likewise, a comparison o f the 
profile o f human reporter gene activation with the induction profile o f PXR mRNA 
transcripts seen in chapter four shows that they are relatively similar; however, the 8- 
fold reporter activation observed at 10 pM was absent for the induction o f human PXR 
mRNA at the same concentration, suggesting that upstream promoter elements may be 
nullifying the positive regulation o f the 1500 bp proximal promoter. Moreover, greatest 
induction o f the chimpanzee and rat PXR reporter constructs was also seen at 10 pM,
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thereby indicating the action o f a host cell effect, which is acting upon all three PXR 
promoters and mediating the response to clotrimazole.
Treatment o f FaO cells showed that clotrimazole was a weak inducer of the three 
reporter constructs in the rat cell line. Generally, across the concentration range, each 
construct was activated to a lesser degree in Huh? than in FaO, suggesting that the 
transcription factor mediating the response in the human cell line, is either more 
abundant/active than in the rat cell line, or is in fact an entirely different factor to the 
one present in the rat cell. The identification o f the factor(s) in both the human and rat 
cell would therefore provide a rationale for the observed increases in PXR activation, 
and furtheimore, would allow for a comparison o f the regulatory mechanisms governing 
xenobiotic-induced PXR gene expression in humans and rodents.
Measuring the responsiveness of each proximal promoter deletion construct provided a 
means of quickly identifying putative binding sites within the proximal promoters of 
human and rat PXR, which appeared to mediate the clotrimazole-induced increases in 
PXR activation in their respective cell lines. Significant decreases in the activity o f each 
deletion constmct compared to the previous larger one indicate the presence of positive 
DNA binding elements that are mediating the activation of the 1500 bp constmct by 
clotrimazole; conversely, an increase in the activity o f a deletion constmct suggests the 
presence of a negative DNA element. Using this system, regions of human and rat 
proximal promoter were identified which were responsible for up-regulating the 
expression of the PXR genes. The region o f the human PXR promoter from 1500 to 
1300 bp relative to the transcription start site contained four putative binding sites for 
GRa, VDR, PPARa and Spl. Likewise, several putative binding sites were identified 
within the rat PXR proximal promoter, for GRa, ERa, C/EBPa, FXR and HNF3p. The 
presence of a putative GRE in both proximal promoters thereby suggests that the 
glucocorticoid receptor is mediating the response to clotrimazole in both human and rat 
cell lines; this hypothesis will be discussed later. However, this statement is in 
disagreement with a previous suggestion made herein: that the GRE identified in the rat 
PXR proximal promoter is either non-functional or an artefact of the in silico screening 
process; hence, the functionality of this putative binding site needs to be determined.
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The potential of the other transcription factors mediating the response to clotrimazole 
will now be addressed. There have been no recorded observations of clotrimazole 
acting as a ligand for VDR, PPARa, ERa, or FXR, suggesting that these nuclear 
receptors are up- regulating the expression of human PXR. Furthermore, previous work 
from our lab on the xenobiotic-mediated regulation o f the CYP3A4 gene, showed that 
mutation of the putative binding sites for Spl and C/EBPa did not disrupt activation of 
the promoter by clotrimazole (Bombail et al. 2004), suggesting that in the very least, 
these factors do not mediate clotrimazole-induced increases in CYP3A4 expression. 
Taken together, it is doubtful that these factors are involved in the activation o f the 
human and rat PXR proximal promoters; however, further examination o f their potential 
roles needs to be undertaken.
Interestingly, the study o f the responsiveness o f the human PXR proximal promoter 
fragments showed that when the region o f the human PXR promoter from 1300 to 1200 
bp relative to the transcription start site was deleted, it resulted in an increase in PXR 
activity. This therefore indicates the presence o f negative DNA binding elements which 
upon exposure to clotrimazole, down-regulate the expression of the human PXR gene. 
This region contained two putative binding sites for COUP-TF and NFicB. COUP-TF is 
generally considered as a repressor of transcription, for which there are four 
mechanisms that account for its repressive effects. COUP-TF can act by directly by 
competing for occupancy o f other nuclear hormone receptor binding sites (Cooney et al. 
1992); it can also form a heterodimer with RXR (Kliewer et al. 1992), the essential 
cofactor for effective binding and functional activity o f most nuclear hormone receptors. 
Alternatively, it can function as a repressor through interaction with corepressor 
proteins (Shibata et al. 1997), and also by directly binding to the LBD of nuclear 
hormone receptors (Leng et al. 1996). As the human PXR promoter contains putative 
binding sites for several nuclear hormone receptors, COUP-TF could be exerting its 
repressive effect on the clotrimazole-mediated induction o f human PXR by any or all of 
these mechanisms.
Like COUP-TF, NFkB also plays an important role in the suppression of nuclear 
hormone receptor-regulated gene expression. It has been shown that activation o f NFicB
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resulted in the disruption o f the PXR/RXR complex with its cognate regulatory regions 
o f the CYP3A4 gene. (Gu et al. 2006). It was found that NFicB interacted with RXR; 
thus the mechanism of suppression by NFkB may be extended to other nuclear hormone 
receptors. Therefore, it is plausible that NFicB may repress the expression of the human 
PXR gene, by preventing the action o f nuclear hormone receptors which have binding 
sites within the PXR proximal promoter. Further examination o f the functionality o f the 
putative COUP-TF and NFicB binding sites would therefore need to be canied out in 
order to determine whether these two factors were negatively regulating the expression 
o f human PXR in response to dosing with clotrimazole.
Cotransfection of the 1500 bp human PXR proximal promoter construct with expression 
plasmids for GRa, VDR and PPARa indicated that GRa may be an important factor in 
regulating clotrimazole-induced PXR expression. By contrast, VDR and PPARa do not 
appear to be mediators of the clotrimazole response, which is consistent with the cuizent 
literature. Likewise, the finding that GRa may positively regulate human PXR 
expression is in concordance with a previous report that showed that clotrimazole binds 
to human GRa in vitro (Loose et al. 1983). This group showed that clotrimazole had the 
capacity to compete with dexamethasone for glucocorticoid receptor binding sites, 
which was dose-responsive and competitive in nature. Furthermore, clotrimazole 
inhibited tyrosine aminotransferase (TAT; a GRa target gene), which led to the 
conclusion that at least with respect to TAT induction, the drug was a glucocorticoid 
antagonist that acted at the level o f the hormone receptor. However, the ability of 
clotrimazole to activate the human PXR promoter via GRa despite being an 
antiglucocorticoid, is supported by evidence that GR-antagonist complexes can bind 
coactivator proteins such as cAMP-response element binding protein (CREB)-binding 
protein (CBP) or its close homologue, p300, which can then modulate GR 
transactivation of target genes (He et al. 2002) by recruitment o f RNA polymerase II 
complexes to the promoter (Glass and Rosenfeld 2000). In sum, it appears that 
transcriptional activation o f human PXR by clotrimazole in Huh? cells occurs through 
binding to GRa and recmitment o f coactivator proteins.
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The identification a putative binding site for GRa within the human PXR promoter as 
detailed in chapter five, could therefore proved a molecular rationale for this obseiwed 
transcriptional activation. Hence, the functionality of this putative GRE binding site 
would need to be investigated; this could be done using reporter gene assays, site- 
directed mutagenesis and EMSA. Furthermore, to support the evidence o f GRa 
involvement in clotrimazole-induced activation of the rat PXR proximal promoter, 
cotransfection o f the rat PXR reporter construct with an expression plasmid for GRa 
could be performed, which could also be confirmed by EMSA. However, due to time 
constraints, these proposals were beyond the scope of the project.
6.8 Conclusion
PXR plays a central role in maintaining cellular homeostasis; playing a key role in 
coordinating the distribution, metabolism and excretion of endogenous and exogenous 
compounds. The ability of PXR to induce a range of genes and the fact that it is 
activated by a whole set o f unrelated xenobiotics and endobiotics suggest that it is under 
a complex regulation. The species differences which exist in activation o f PXR at the 
proteomic level are reflected to a degree by the in vitro results presented herein, which 
show that regulatory interactions exist between nuclear receptors. In contrast to 
receptor activation, conserved mechanisms o f gene regulation exist between humans 
and rodents, both at the basal and xenobiotic-induced levels o f PXR expression. At the 
basal level, HNF3p and HNF4a decrease its expression, whereas GRa up-regulates its 
expression in response to xenobiotic.
Taken together, these results show that the regulation of PXR gene expression at the 
transcriptional level is under the control of many factors, by mechanisms which are 
evolutionally conseiwed.
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7. General discussion and future directions
7.1 Discussion
PXR is central in the regulation and maintenance of cellular homeostasis. It is regarded 
as the principal regulator of the most abundant and important drug metabolising 
enzymes, the CYP3As (Bertilsson et al. 1998). In addition to this role, it also regulates 
other phase I drug metabolising enzymes, as well as phase II metabolism enzymes and 
membrane transporters (Maglich et al. 2002), as part of an entire program of genes 
involved in the metabolism and elimination o f potentially toxic chemicals from the 
body. The promiscuous nature o f its LBD means that it is activated by a diverse range 
o f both endogenous and exogenous compounds, and as such is termed a broad substrate 
sensor. Ligand activation of PXR can also be exploited to treat human diseases; for 
example, the catatoxic steroid PCN affords protection against bile acid-induced toxicity 
through the activation of PXR, which may have implications in the treatment of human 
cholestatic liver disease (Staudinger et al. 2001). Although in general PXR plays a 
beneficial role in the body, its activation also represents the basis for many drug-dmg 
interactions which can lead to the loss o f therapeutic effect or an increase in toxicity.
The finding that PXR, which was more commonly associated with xenobiotic 
metabolism, could be activated by endogenous compounds has increased recognition 
that PXR serves as the master regulator o f the body homeostasis. For instance, PXR is 
activated by lithocholic acid, implicating it in the regulation of bile acid synthesis 
(Staudinger et al. 2001); coupled to the ability o f PXR to regulate expression of bile 
acid transporters such as MRP2 (Kast et al. 2002), this means that PXR plays a central 
role in determining/regulating bile flux within the body. In addition, all forms of 
vitamin E are reported to be activators o f PXR, resulting in the induction of PXR target 
genes CYP3A4/5 in reporter gene assays (Landes et al. 2003). This suggests that PXR 
could be involved in maintaining the antioxidant network. PXR is also activated by 
vitamin K, suggesting a novel role as a mediator o f bone homeostasis (Tabb et al. 2003).
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Taken together, the activation o f PXR by these endobiotics and xenobiotics shows that 
this receptor is an important endogenous sensor o f changes in homeostasis.
The phenomenon that PXRs from different species respond to distinct sets of 
compounds, has been termed ‘directed promiscuity’, to reflect the fact that each species’ 
PXR is promiscuous only in a specific subset of xenobiotic and endogenous compounds 
(Watkins et al. 2001). Hence, up-regulation of PXR target genes can occur in a species- 
specific manner, which may result in disruption of cellular homeostasis in one species 
and not in another. This is a particular concern when extrapolating data from animal 
model studies and makes prediction o f human drug responses difficult. Therefore, a 
cross-species study o f the regulation o f the PXR gene becomes an important matter to 
investigate not only because o f its importance in the body and its place in the centre of 
the activation network o f ligand-activated transcription factors, but also because it will 
contribute to the understanding o f species differences at the molecular level. Genomic 
activation o f PXR should not be regarded as a non-determinant o f the species-specific 
phenotype, as transcriptional activation o f PXR by chemicals that are not direct ligands 
can increase the pool o f unliganded PXR, which may then be activated by endogenous 
ligand or any co-administered chemical and resulting in a potential loss of cellular 
homeostasis.
In my project the aim was to investigate the molecular mechanisms underlying the 
regulation o f the PXR in human, chimpanzee and rat, and identify regulatory similarities 
and differences between these species o f study, in order to assess whether the species 
differences in responses to changes in the chemical flux through the body are 
determined, at least in part, by the regulation of PXR and its interaction with other 
nuclear receptors. There is substantial evidence to suggest that PXR is regulated at the 
transcriptional level, such as the increased levels of PXR mRNA in primary human 
hepatocytes following dexamethasone treatment, which is in part mediated by GRa 
(Pascussi et al. 2000a). Similarly, the role o f the HNF4a in the regulation of PXR is 
probably at the transcriptional level, as deletion of HNF4a in mice repressed expression 
of PXR, and the transcriptional activation was mediated through binding of HNF4a to 
the PXR proximal promoter (Kamiya et al. 2003). Further examples in rodents have
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been reported; in mice treated with the antiglucocorticoid PCN, for example, the level 
o f PXR was significantly increased (Maglich et al. 2002). Also the increased levels of 
PXR mRNA following treatment o f rat hepatocytes with the PPARa ligands PFDA and 
clofibrate, suggests a role for PPARa in the regulation of PXR gene expression (Ma et 
al. 2005).
In silico analyses of the chimpanzee PXR and rat PXR proximal promoter regions 
together with the previously described human PXR promoter region (Aouabdi et al. 
2006) revealed a multitude of putative binding sites for general ti anscription factors and 
for ligand-activated transcription factors that were common to all three gene promoters. 
The identification of putative binding sites for the LETFs was not unexpected as PXR is 
highly expressed in the liver; more fascinating however, was the identification of 
several putative binding sites for LATFs, suggesting that the nature o f the PXR 
promoters reflects the ability of PXR to respond to a diverse range o f chemicals and 
coordinate the expression of genes in many cellular processes. These results suggest 
that the complexity of the regulatory mechanisms governing the transcription o f the 
PXR gene is evolutionally conserved. Furthermore, the interaction with several other 
transcription factors is not surprising, as PXR is able to respond to a diverse range of 
compounds and induce a battery of genes under different physiological conditions; and 
although the response to specific ligands may occur in a species-specific manner, the 
overall regulation of PXR remains fairly evolutionally constant.
Hepatic cell lines are commonly used as in vitro models o f drug metabolism, and as 
such, have been previously used in our lab to investigate the molecular mechanisms 
underlying the regulation of CYP3A4 (El-Sankary et al. 2000; El-Sankary et al. 2002; 
Bombail et al. 2004) and human PXR (Aouabdi et al. 2006). One advantage of using 
cell lines instead of primary hepatocytes is that they are, by definition, ‘stably 
transformed’, and therefore it should be expected that experiments carried out with them 
would show little or no variation. However, the use of cell lines may not be the best 
way to investigate the mechanisms o f gene regulation; their expression of the CYP 
genes is reported to be reduced to less than 0.25 % of normal hepatocytes (Rodriguez- 
Antona et al. 2002), which is in part due to a 15 to 40 % decrease in the expression of
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key LETFs relative to their content in normal hepatocytes (Jover et al. 1998). 
Furthermore, the level o f some transcription factors including PXR, are significantly 
reduced in Huh? cells compared to in primary human hepatocytes (Phillips et al. 2005). 
In the case o f PXR, it was speculated that the reduced expression was due the relatively 
closed chromatin conformation o f the human PXR promoter (Phillips et al. 2005). It is 
well established that cell lines exhibit significant alterations in higher chromatin order 
(Reviewed by Plant 2004); however, these will not affect responses in the non- 
chromosomal reporter genes used extensively in this study, although the lowered 
expression o f necessary nuclear receptors is an acknowledged problem.
Preliminary results o f the reporter gene assay using the construct containing the 1500 
base pairs of the rat PXR proximal promoter showed that basal expression was complex, 
with the deletion constructs showing that the rat PXR proximal promoter contains 
several regions of both positive regulation and negative regulation, which interact to 
produce the net expression level o f PXR. Similar complexity was previously reported 
for the human PXR proximal promoter (Aouabdi et al. 2006; Gibson et al. 2006). 
However, the only comparison which could be made is that the proximal 200 bp of each 
promoter both contained positive regulatory elements.
The reporter gene assay using over-expression o f HNFs showed interesting results, as 
HNFSp and HNF4a up-regulated the expression of the 198 bp rat PXR promoter 
constmct, whereas they resulted in down-regulation of the 1500 bp constmct, which 
further emphasises the complexity o f the regulatory mechanism governing PXR gene 
expression. This phenomenon was observed for the human PXR proximal promoter 
(Gibson et al. 2006), suggesting an evolutionally conserved system, whereby the HNFs 
function as part of a protective mechanism against the over-expression of the 
transcription factor, and hence unwanted effects of induction o f its target genes. 
Moreover, the down-regulation o f PXR by HNF4a shows that the mechanisms 
underlying rat PXR gene expression are probably different from that o f the foetal 
mouse. HNF4a was shown to regulate the mouse foetal PXR by binding to its proximal 
promoter (Kamiya et al. 2003), suggesting that during rodent development, the net 
effect o f HNF4a on PXR expression is modulated by other, as yet, unknown factors.
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The use o f xenobiotics in reporter gene assays with the 1500 bp constructs o f human, 
chimpanzee and rat PXR showed that the regulation of PXR gene expression in each of 
these species is determined by both the abundance/ratio of transcription factors present 
in the cell and the complex nature o f the PXR proximal promoter. Following 
identification o f putative binding sites for LATFs within the proximal promoters, the 
observation o f reporter gene activation following xenobiotic treatment suggests that the 
mediating transcription factor of the response must be at a sufficient level within the 
host cell and have sufficient affinity towards the ligand in order to exert the effects of 
the xenobiotic on PXR gene transcription. In contrast, the lack o f reporter gene 
activation following xenobiotic treatment indicates either the absence o f a response 
element for the mediating LATF within the PXR proximal promoter, or that the LATF 
is weakly/not activated by the exogenous compound. This was exemplified by 
dexamethasone-induced activation of the human PXR reporter constmct; whereby 
greater activation was observed in the rat cell line than in the human cell line, possibly 
due to rat GRa having greater affinity towards dexamethasone than the human GRa, or 
being present to a higher degree in rat cells. This provides further evidence o f the 
complexity o f PXR regulation, and illustrates the ability of LATFs to facilitate the 
expression o f PXR in a species-specific manner.
Generally, species differences in the activation o f PXR transcription were observed for 
each o f the xenobiotic examined; an interesting finding of my studies was the effect of 
rifampicin and PCN on the transcription o f human and rat PXR genes. Both chemicals 
are species-specific PXR ligands; however, they appeared to induce PXR transcription 
in the species in which they are known to only weakly activate the receptor. These 
apparent contradictions may have important consequences for cellular homeostasis in 
both humans and rats, by increasing the pool o f unliganded PXR, and hence potentially 
dismpting expression of PXR target genes. Another interesting finding was the up- 
regulation o f human PXR gene expression by the over-expression o f the glucocorticoid 
receptor following treatment with clotrimazole. The same transcription factor appears 
to mediate clotrimazole-induced increases in rat PXR gene expression, indicating a 
conseiwed mechanism of PXR regulation upon chemical exposure. The increase in 
human PXR expression by over-expression o f GRa was unexpected because
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clotrimazole is not known to be a GRa agonist. However, it probably represents a 
evolutionally conserved protective mechanism against the hepatotoxicity associated 
with the imidazole moiety o f clotrimazole (Cao et al. 2004), whereby GRa up-regulates 
the expression of PXR, which in turn, is then activated by clotrimazole, leading to 
CYP3 A-mediated metabolism of the compound.
In silico examination o f the PXR ligand from diverse species identified critical amino 
acid residues which conferred species-specific activation of PXR by xenobiotics. 
Alignment of the ligand binding domain sequence o f the PXR family members revealed 
that they have diverged through evolution. Furthermore, examination of the geometiy of 
the ligand binding pockets of PXR from diverse species revealed a marked difference 
between rodents and higher mammals, whereby the circumference of rodent PXR ligand 
binding pockets appeared to be considerably larger, which may partly explain the 
rodent-specific PXR activation profile. Hence, the PXR ligand binding pocket has not 
just evolved by mutation o f the DNA encoding individual amino acid residues which 
line the pocket, but there have also been fundamental genetic changes resulting in 
alterations in the tertiary protein structure. Moreover, the ability of PXR to respond to 
different sets of compounds in a species-specific manner almost certainly signifies the 
different evolutionary pressures placed on the species to recognise and respond 
efficiently to endobiotic and xenobiotic stresses. These differences may reflect 
differences in diets or exposure to other chemicals across species (Chrencik et al. 
2005). Alternatively, the PXR activation profiles may be driven by differences in the 
production o f endogenous chemicals such as and bile acids (Kiasowski et al. 2005).
Based on my results, I propose a simplified model which shows the contributory effects 
o f both gene activation and receptor activation in conferring a species-specific 
xenobiotic response (Figure 7.1). I have shown that species-specific PXR gene 
activation is dependent on the nature o f the PXR promoter, the abundance/ratio o f 
transcription factors and the ligand affinity o f LATFs, whereas species-specific PXR 
activation is dependent on both the amino acid residues lining the ligand binding pocket 
and the tertiary protein structure of the ligand binding domain. As PXR gene activation 
is not necessary a prerequisite for PXR activation, there are four possible ‘routes’ o f the
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xenobiotic effect. I f  activation of PXR occurs following xenobiotic exposure, then any 
species-specific effect on downstream PXR targets is due to the ability of the chemical 
to bind to the PXR LBD, irrespective o f whether transcription of PXR genes occurred in 
a species-specific manner. Hence, a species-specific induction of PXR gene expression 
may only be evident if  PXR is not directly activated by the gene-inducing chemical. 
Furthermore, any increase in PXR protein level without the presence o f an exogenous 
PXR ligand, as in this case, may result in activation by endogenous compounds and 
hence peiturbation of cellular homeostasis.
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Figure 7.1: Contribution of genomic activation and receptor activation to 
conferring a species-specific xenobiotic response
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A species-specific xenobiotic response is determined by both genomic PXR activation and PXR ligand 
activation. As ligand activation usually occurs after genomic activation, the differences in the amino acid 
composition o f each species LBD have a greater effect on the response than differences in the 
transcriptional inducibility o f the PXR genes. Hence, species differences in genomic activation can only 
determine the species-specific response when PXR ligand activation does not occur. If the xenobiotic is 
not a ligand for PXR, another endogenous ligand may activate PXR and result in the induction o f target 
genes and disruption o f cellular homeostasis.
7.2 Future directions
The work undertaken in this thesis has mainly focussed on the transcriptional regulation 
of the PXR gene of the human, chimpanzee and rat. As biological function is ultimately 
determined at the protein level and not transcript level, a potential caveat o f this work is 
that the transcriptional changes described herein may be biologically silent. Hence, an 
obvious direction would be to examine whether the rates of transcription correlate with 
levels of PXR protein in each species, which could be achieved by Western blotting.
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Such work would increase further the loiowledge o f how PXR is regulated in diverse 
species, and also provide further clarification o f the molecular pathways governing the 
species differences following chemical exposure. Another potential future direction 
would be the use o f primary hepatocytes, which would overcome the absence o f an 
appropriate primate hepatoma cell line, and would also give an indication as to whether 
the immortalised cell lines used in this study are valid in vitro models. Furthermore, 
primary hepatocytes express transcription factors at greater levels, and hence, would 
give a larger dynamic range for the identification of species differences in PXR gene 
transcription. Moreover, selecting a species in between primates and rodents, such as 
dog or cow, may identify further species difference in PXR regulation and hence, 
provide greater understanding of the evolutionary changes which have occuiTed 
between these species.
In this project I have shown that PXR is under the regulation of hepatocyte nuclear 
factors and the glucocorticoid receptor, which mediate basal and clotrimazole-induced 
PXR gene expression, respectively. However, the involvement of these receptors in 
regulating both the human and rat PXR genes could be confirmed using EMSA or 
siRNA. Moreover, the involvement of other transcription factors in xenobiotic- 
mediated increases o f PXR transcription could be determined using reporter gene assay 
with expression plasmid for each TF, supported by SDM, siRNA or EMSA data. This 
would allow for greater species comparison o f the regulatory networks governing PXR 
expression upon xenobiotic exposiue.
Another area which has been the focus of this thesis has been based on the in silico 
examination of the PXR LBDs from diverse species. A potential future direction o f this 
examination would be through the use o f in silico docking tools, which predict the 
optimal interaction o f ligand molecules with protein targets. Thus, the ability o f each 
species PXR to bind different ligands and the energy associated with such an interaction 
could be calculated. This would strengthen the idea that specific ligand binding pocket 
amino acid residues and the overall tertiaiy PXR structure are key determinants o f the 
species-specific activation profiles.
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9. Appendix
9.1 Plasmid maps
Figure 9.1: SEA? Basic plasmid
Transciiptioii blocker MCS
SEA?
pSEAP2-Basic
4677 bpAmpr
SV40 polyA
Restriction enzyme sites in multiple cloning site
1 Û # 4* SCAT
QOTiBIXBABCTCrraaBCaigCTM CCCaaaC TaBaa/lfnrBOaATCTAABTAAl TAAQCTTOBAATCaCgAATTOa CCCAC C«TQCTQ I ffibi ffWBKirml
MCS: Multiple cloning site; SEAP: secretory alkaline phosphatase; SV40 polyA: SV40 polyadenylation; 
Ampr: lactamase conferring resistance to ampicillin
2 1 1
Figure 9.2: SEAP-hPXR reporter construct
Transcription blocker
Ampr 1
SEAP
hPXR: human PXR 1500 bp proximal promoter; SEAP: secretory alkaline phosphatase; SV40 polyA: 
SV40 polyadenylation; Ampr: lactamase confeiring resistance to ampicillin
Figure 9.3: Expression plasmid for HNF3p in pGEM2
CMV promoter
pGem-2-rat HNF3b
4634 bp
Ampr
SV40 Poly A
CMV: CMV promoter; rHNFSb: cDNA coding for the rat hepatocyte nuclear factor 3 beta; SV40 polyA: 
SV40 polyadenylation; Ampr: lactamase conferring resistance to ampicillin.
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Figure 9.4: Expression plasmids for HNF4a and VDR in pEF6/V5-His
Ampr
EF-la
SV40 polyA
PEF6/V5 His-hHNF4a
5822 bp
hHNF4a
Blasticidin 
EM-7 promoter 
SV40 pomoter
V5
His 
BGH polyA
Amsjr
EF-la
DEFGr/5 His-hVDR 
7124 be
SV40 polyA
Blasticidm 
EM-7 promoter^
S-V40 pomoter
£1 ( His
BGH polyA
EF-la: promoter o f human elongation factor 1 alpha; T7: T7 promoter; hHNF4a: cDNA coding for the 
human hepatocyte nuclear factor 4 alpha; hVDR; cDNA coding for the human vitamin D receptor; V5: 
V5 epitope; His: polyhistidine sequence; BGH polyA: bovine growth hormone polyadenylation; fl: origin 
o f replication o f the filamentous phage fl; EM-7 promoter: promoter for blasticidin; Blasticidin: 
blasticidin resistance gene; SV40 polyA: SV40 polyadenylation; Ampr: lactamase conferring resistance to 
ampicillin..
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Figure 9.5: Expression plasmids for PPARa and GRa in pSG5
SV40
L  T7
f l
SV40
T7
:5G5-#i PPARa
03 1
SV40: SV 40 promoter; p-globin: p-globin intron; T7: T7 promoter, hGRa: cDNA coding for the human 
GR alpha; hPPARa: cDNA coding for the human PPAR alpha; ori: origin o f replication; Ampr: lactamase 
conferring resistance to ampicillin; f l : origin o f  replication o f the filamentous phage f l .
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Figure 9.6: Expression plasmid for RXRa in pSVL
SV40: SV40 promoter; hRXRa: cDNA coding for the human RXR alpha; Ampr: lactamase conferring 
resistance to ampicillin.
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9.2 Genomic DNA standards calculation
The human genome is 3.2 x 10^ bp and the molecular weight of 1 bp is 660 g, so the 
molecular weight o f the human genome is 3.2 x 10* x 660 = 2.11 x 10^  ^g.
The human genome is diploid such that 1 genome contains 2 copies; therefore a molar 
solution o f the haploid genome contains 1.05 x 10^  ^g/1.
One mole contains 6.02 x 10^  ^ molecules according to Avogadro’s number, but DNA 
contains two single strands so each mole o f the human haploid gene contains 1.2 x 10^ "* 
single strands. Therefore, a 1.05 x 10^  ^ g/1 solution contains 1.2 x 10^ "^  single strands, 
and so 1 pg contains 1.14 x 10  ^single strands.
Need a stock solution concentration o f 10  ^ single strands /5 pi, i.e. 2 x lO'^/pl, which 
equates to a DNA concentration o f 17.5 ng/pl.
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